[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 59 of about 59
1. Pertaya N, Marshall CB, Celik Y, Davies PL, Braslavsky I: Direct visualization of spruce budworm antifreeze protein interacting with ice crystals: basal plane affinity confers hyperactivity. Biophys J; 2008 Jul;95(1):333-41
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Direct visualization of spruce budworm antifreeze protein interacting with ice crystals: basal plane affinity confers hyperactivity.
  • It has been proposed that the exceptional activity of these AFPs depends on their ability to prevent ice growth at the basal plane.
  • To test the hypothesis that the hyperactivity of sbwAFP results from direct affinity to the basal plane, we fluorescently tagged sbwAFP and visualized it on the surface of ice crystals using fluorescence microscopy.
  • SbwAFP accumulated at the six prism plane corners and the two basal planes of hexagonal ice crystals.
  • In contrast, fluorescently tagged fish type III AFP did not adhere to the basal planes of a single-crystal ice hemisphere.
  • When ice crystals were grown in the presence of a mixture of type III AFP and sbwAFP, a hybrid crystal shape was produced with sbwAFP bound to the basal planes of truncated bipyramidal crystals.
  • These observations are consistent with the blockage of c-axial growth of ice as a result of direct interaction of sbwAFP with the basal planes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Biotechnol. 1997 Sep;15(9):887-90 [9306405.001]
  • [Cites] Nature. 1997 Aug 21;388(6644):727-8 [9285581.001]
  • [Cites] Biophys J. 1998 May;74(5):2142-51 [9591641.001]
  • [Cites] Science. 1998 Oct 2;282(5386):115-7 [9756474.001]
  • [Cites] Eur J Biochem. 1998 Dec 1;258(2):445-53 [9874210.001]
  • [Cites] Curr Opin Genet Dev. 1998 Dec;8(6):715-20 [9914209.001]
  • [Cites] Cell Mol Life Sci. 1999 Feb;55(2):271-83 [10188586.001]
  • [Cites] Eur J Biochem. 1999 Sep;264(3):653-65 [10491111.001]
  • [Cites] Nat Biotechnol. 2004 Dec;22(12):1567-72 [15558047.001]
  • [Cites] FEMS Microbiol Lett. 2005 Apr 1;245(1):67-72 [15796981.001]
  • [Cites] J Biol Chem. 2005 May 6;280(18):17920-9 [15716269.001]
  • [Cites] FEBS J. 2005 Sep;272(17):4439-49 [16128813.001]
  • [Cites] Science. 2005 Oct 21;310(5747):461 [16239469.001]
  • [Cites] Cryobiology. 2006 Oct;53(2):229-39 [16887111.001]
  • [Cites] Plant Cell Rep. 2006 Dec;25(12):1336-46 [16847628.001]
  • [Cites] Biophys J. 2007 May 15;92(10):3663-73 [17325008.001]
  • [Cites] Biophys J. 2007 Sep 1;93(5):1442-51 [17526572.001]
  • [Cites] Proc Natl Acad Sci U S A. 1977 Jun;74(6):2589-93 [267952.001]
  • [Cites] Biochemistry. 1982 Feb 16;21(4):716-21 [7074035.001]
  • [Cites] Transgenic Res. 1999;8(6):405-14 [10767985.001]
  • [Cites] Nature. 2000 Jul 20;406(6793):249, 251 [10917514.001]
  • [Cites] Nature. 2000 Jul 20;406(6793):322-4 [10917536.001]
  • [Cites] Nature. 2000 Jul 20;406(6793):325-8 [10917537.001]
  • [Cites] Biotechnol Annu Rev. 2000;6:59-101 [11193297.001]
  • [Cites] J Mol Biol. 2001 Jan 26;305(4):875-89 [11162099.001]
  • [Cites] Structure. 2002 May;10(5):619-27 [12015145.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2002 Jul 29;357(1423):927-35 [12171656.001]
  • [Cites] J Biol Chem. 2002 Sep 6;277(36):33349-52 [12105229.001]
  • [Cites] Plant Mol Biol. 2002 Oct;50(3):333-44 [12369611.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Jan 17;300(3):645-8 [12507497.001]
  • [Cites] Microbiology. 2004 Jan;150(Pt 1):171-80 [14702410.001]
  • [Cites] Biochemistry. 2004 Jan 13;43(1):148-54 [14705940.001]
  • [Cites] Nature. 2004 May 13;429(6988):153 [15141201.001]
  • [Cites] Proteins. 2004 Jun 1;55(4):977-91 [15146494.001]
  • [Cites] J Bacteriol. 2004 Sep;186(17):5661-71 [15317770.001]
  • [Cites] Phys Rev Lett. 2004 Sep 17;93(12):128102 [15447309.001]
  • [Cites] Nature. 1984 Mar 15-21;308(5956):295-6 [6700733.001]
  • [Cites] Biophys J. 1991 Feb;59(2):409-18 [2009357.001]
  • [Cites] Biochim Biophys Acta. 1992 May 22;1121(1-2):199-206 [1599942.001]
  • [Cites] Cryobiology. 1992 Feb;29(1):69-79 [1606831.001]
  • [Cites] Biophys J. 1993 Jan;64(1):252-9 [8431545.001]
  • [Cites] Nature. 1995 Feb 23;373(6516):663-4 [7854443.001]
  • [Cites] Biophys J. 1996 Nov;71(5):2346-55 [8913575.001]
  • [Cites] Nature. 1996 Nov 21;384(6606):285-8 [8918883.001]
  • [Cites] Structure. 1996 Nov 15;4(11):1325-37 [8939756.001]
  • [Cites] Biophys J. 1998 Mar;74(3):1502-8 [9512046.001]
  • (PMID = 18339740.001).
  • [ISSN] 1542-0086
  • [Journal-full-title] Biophysical journal
  • [ISO-abbreviation] Biophys. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antifreeze Proteins; 0 / Ice
  • [Other-IDs] NLM/ PMC2426666
  •  go-up   go-down


2. Marzo N, Ortega S, Stratmann T, García A, Ríos M, Giménez A, Gomis R, Mora C: Cyclin-dependent kinase 4 hyperactivity promotes autoreactivity in the immune system but protects pancreatic cell mass from autoimmune destruction in the nonobese diabetic mouse model. J Immunol; 2008 Jan 15;180(2):1189-98
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclin-dependent kinase 4 hyperactivity promotes autoreactivity in the immune system but protects pancreatic cell mass from autoimmune destruction in the nonobese diabetic mouse model.
  • Cyclin-dependent kinase 4 (Cdk4) plays a central role in perinatal pancreatic beta cell replication, thus becoming a potential target for therapeutics in autoimmune diabetes.
  • Its hyperactive form, Cdk4R24C, causes beta cell hyperplasia without promoting hypoglycemia in a nonautoimmune-prone mouse strain.
  • In this study, we explore whether beta cell hyperproliferation induced by the Cdk4R24C mutation balances the autoimmune attack against beta cells inherent to the NOD genetic background.
  • In this study, we show that NOD/Cdk4R24C knockin mice exhibit exacerbated diabetes and insulitis, and that this exacerbated diabetic phenotype is solely due to the hyperactivity of the NOD/Cdk4R24C immune repertoire.
  • Accordingly, NOD/Cdk4R24C splenocytes show increased basal proliferation and higher activation markers expression compared with NOD/WT splenocytes.
  • NOD/SCID/Cdk4R24C knockin mice develop beta cell hyperplasia spontaneously.
  • Thus, the Cdk4R24C mutation opens two avenues in the NOD model: when expressed specifically in beta cells, it provides a new potential strategy for beta cell regeneration in autoimmune diabetes, but its expression in the immune repertoire exacerbates autoimmunity.

  • MedlinePlus Health Information. consumer health - Diabetes Type 1.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18178859.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.11.22 / Cdk4 protein, mouse; EC 2.7.11.22 / Cyclin-Dependent Kinase 4
  •  go-up   go-down


3. Yasoshima Y, Kai N, Yoshida S, Shiosaka S, Koyama Y, Kayama Y, Kobayashi K: Subthalamic neurons coordinate basal ganglia function through differential neural pathways. J Neurosci; 2005 Aug 24;25(34):7743-53
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subthalamic neurons coordinate basal ganglia function through differential neural pathways.
  • The subthalamic nucleus (STN) is a key component of basal ganglia circuitry that mediates a variety of motor functions.
  • The STN neurons send glutamatergic projections to the output structures of basal ganglia, including the substantia nigra pars reticulata (SNr) and the entopeduncular nucleus, and also innervate the globus pallidus (GP).
  • Here we performed conditional ablation of the STN neurons by using immunotoxin-mediated cell targeting.
  • Ablation of the STN neurons increased spontaneous movement and reduced hyperactivity in response to DA stimulation.
  • [MeSH-major] Basal Ganglia / physiology. Neurons / physiology. Subthalamic Nucleus / physiology

  • Hazardous Substances Data Bank. DOPAMINE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16120775.001).
  • [ISSN] 1529-2401
  • [Journal-full-title] The Journal of neuroscience : the official journal of the Society for Neuroscience
  • [ISO-abbreviation] J. Neurosci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] VTD58H1Z2X / Dopamine
  •  go-up   go-down


Advertisement
4. Apicelli AJ, Maggi LB Jr, Hirbe AC, Miceli AP, Olanich ME, Schulte-Winkeler CL, Saporita AJ, Kuchenreuther M, Sanchez J, Weilbaecher K, Weber JD: A non-tumor suppressor role for basal p19ARF in maintaining nucleolar structure and function. Mol Cell Biol; 2008 Feb;28(3):1068-80
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A non-tumor suppressor role for basal p19ARF in maintaining nucleolar structure and function.
  • However, basal NPM and ARF proteins form nucleolar complexes whose functions remain unknown.
  • Nucleoli from Arf(-/)(-) cells displayed increased nucleolar area, suggesting that basal ARF might regulate key nucleolar functions.
  • Concordantly, ribosome biogenesis and protein synthesis were dramatically elevated in the absence of Arf, causing these cells to exhibit tremendous gains in protein amounts and increases in cell volume.
  • Postmitotic osteoclasts from Arf-null mice exhibited hyperactivity in vitro and in vivo, demonstrating a physiological function for basal ARF.
  • Thus, basal ARF proteins act as a monitor of steady-state ribosome biogenesis and growth independent of their ability to prevent unwarranted hyperproliferation.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chromosoma. 1984;90(2):139-48 [6206987.001]
  • [Cites] Micron. 2000 Apr;31(2):127-31 [10588058.001]
  • [Cites] Cancer Res. 2000 Jan 1;60(1):129-33 [10646864.001]
  • [Cites] Mol Cell Biol. 2000 Apr;20(7):2517-28 [10713175.001]
  • [Cites] Genes Dev. 2000 Jul 15;14(14):1797-809 [10898794.001]
  • [Cites] Mol Cell Biol. 2000 Aug;20(16):5930-8 [10913176.001]
  • [Cites] Oncogene. 2000 Oct 12;19(43):4988-99 [11042686.001]
  • [Cites] Cell. 2000 Oct 13;103(2):321-30 [11057904.001]
  • [Cites] Biochem Pharmacol. 1985 Nov 15;34(22):4059-63 [2415133.001]
  • [Cites] Zentralbl Pathol. 1994 Mar;140(1):107-8 [7515667.001]
  • [Cites] Mol Cell Biol. 1997 Aug;17(8):4230-7 [9234680.001]
  • [Cites] Cell. 1997 Nov 28;91(5):649-59 [9393858.001]
  • [Cites] Cell. 1998 Mar 20;92(6):713-23 [9529248.001]
  • [Cites] Genes Dev. 1998 Aug 1;12(15):2424-33 [9694806.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3993-8 [10097151.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6937-41 [10359817.001]
  • [Cites] Biochim Biophys Acta. 1963 Nov 22;76:454-62 [14097407.001]
  • [Cites] Proc Natl Acad Sci U S A. 1965 Apr;53:737-45 [14324529.001]
  • [Cites] Hybrid Hybridomics. 2004 Oct;23(5):293-300 [15672607.001]
  • [Cites] Mol Cell Biol. 2005 Feb;25(4):1258-71 [15684379.001]
  • [Cites] Nat Cell Biol. 2005 Mar;7(3):311-8 [15723054.001]
  • [Cites] Nat Cell Biol. 2005 Mar;7(3):295-302 [15723055.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 24;102(21):7689-94 [15897463.001]
  • [Cites] J Bone Miner Res. 2005 Dec;20(12):2116-23 [16294265.001]
  • [Cites] Cancer Invest. 2005;23(7):599-608 [16305988.001]
  • [Cites] Mol Cell Biol. 2006 May;26(10):3798-809 [16648475.001]
  • [Cites] Nat Cell Biol. 1999 May;1(1):20-6 [10559859.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Sep;7(9):667-77 [16921403.001]
  • [Cites] Nat Rev Cancer. 2006 Sep;6(9):663-73 [16915296.001]
  • [Cites] Oncogene. 2006 Dec 7;25(58):7577-86 [16924243.001]
  • [Cites] Cancer Res. 2007 Feb 15;67(4):1609-17 [17308101.001]
  • [Cites] EMBO J. 2001 Mar 15;20(6):1383-93 [11250904.001]
  • [Cites] Oncogene. 2001 Feb 15;20(7):836-48 [11314011.001]
  • [Cites] Mol Cell Biol. 2001 Sep;21(17):5806-14 [11486020.001]
  • [Cites] Curr Opin Cell Biol. 2001 Dec;13(6):731-7 [11698190.001]
  • [Cites] Nat Rev Cancer. 2003 Mar;3(3):179-92 [12612653.001]
  • [Cites] Mol Cell. 2003 Feb;11(2):415-24 [12620229.001]
  • [Cites] Nat Rev Genet. 2003 Aug;4(8):638-49 [12897775.001]
  • [Cites] Gene. 2003 Aug 14;313:17-42 [12957375.001]
  • [Cites] Prog Cell Cycle Res. 2003;5:301-8 [14593725.001]
  • [Cites] EMBO J. 2003 Nov 17;22(22):6068-77 [14609953.001]
  • [Cites] Mol Cell. 2003 Nov;12(5):1151-64 [14636574.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15930-5 [14665695.001]
  • [Cites] Mol Cell Biol. 2004 Feb;24(3):985-96 [14729947.001]
  • [Cites] Biotechniques. 2004 Jan;36(1):134-8 [14740495.001]
  • [Cites] Oncogene. 2004 Apr 19;23(18):3151-71 [15094765.001]
  • [Cites] Curr Opin Genet Dev. 2004 Apr;14(2):210-7 [15196469.001]
  • [Cites] Nature. 2004 Oct 7;431(7009):712-7 [15361884.001]
  • [Cites] Mol Cell Biol. 2004 Nov;24(21):9327-38 [15485902.001]
  • [Cites] Oncogene. 2004 Oct 21;23(49):8097-104 [15361825.001]
  • [Cites] Micron. 2000 Apr;31(2):133-41 [10588059.001]
  • (PMID = 18070929.001).
  • [ISSN] 1098-5549
  • [Journal-full-title] Molecular and cellular biology
  • [ISO-abbreviation] Mol. Cell. Biol.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM066032; United States / NIGMS NIH HHS / GM / T32 GM007067; United States / NIGMS NIH HHS / GM / GM066032
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cdkn2a protein, mouse; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA, Ribosomal; 0 / Nuclear Proteins; 0 / RNA, Ribosomal; 0 / Tumor Suppressor Proteins; 117896-08-9 / nucleophosmin
  • [Other-IDs] NLM/ PMC2223401
  •  go-up   go-down


5. Sakatani S, Yamada K, Homma C, Munesue S, Yamamoto Y, Yamamoto H, Hirase H: Deletion of RAGE causes hyperactivity and increased sensitivity to auditory stimuli in mice. PLoS One; 2009;4(12):e8309
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deletion of RAGE causes hyperactivity and increased sensitivity to auditory stimuli in mice.
  • The receptor for advanced glycation end-products (RAGE) is a multi-ligand receptor that belongs to the immunoglobulin superfamily of cell surface receptors.
  • However, how RAGE influences gross behavioral activity patterns in basal condition has not been addressed to date.

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain Res. 2003 Mar 21;966(2):167-74 [12618340.001]
  • [Cites] J Neurosci. 2008 Oct 22;28(43):10928-36 [18945900.001]
  • [Cites] J Neurochem. 2004 Sep;90(6):1389-401 [15341523.001]
  • [Cites] Biochem Biophys Res Commun. 1984 May 16;120(3):885-90 [6375662.001]
  • [Cites] J Neurosci Methods. 1984 May;11(1):47-60 [6471907.001]
  • [Cites] J Biol Chem. 1992 Jul 25;267(21):14987-97 [1321822.001]
  • [Cites] J Biol Chem. 1992 Jul 25;267(21):14998-5004 [1378843.001]
  • [Cites] Am J Pathol. 1993 Dec;143(6):1699-712 [8256857.001]
  • [Cites] J Neurochem. 1995 Jul;65(1):228-33 [7790864.001]
  • [Cites] J Biol Chem. 1995 Oct 27;270(43):25752-61 [7592757.001]
  • [Cites] Nature. 1996 Aug 22;382(6593):685-91 [8751438.001]
  • [Cites] J Biol Chem. 1999 Jan 22;274(4):1869-72 [9890936.001]
  • [Cites] Cell. 1999 Jun 25;97(7):889-901 [10399917.001]
  • [Cites] Learn Mem. 1995 Jan-Feb;2(1):26-39 [10467564.001]
  • [Cites] J Pharmacol Sci. 2005 Mar;97(3):305-11 [15750291.001]
  • [Cites] J Neurosci. 2006 Jun 14;26(24):6413-21 [16775128.001]
  • [Cites] Diabetes. 2006 Sep;55(9):2510-22 [16936199.001]
  • [Cites] Eur J Neurosci. 2007 Feb;25(4):1144-54 [17331210.001]
  • [Cites] Crit Care. 2007;11(6):R122 [18042296.001]
  • [Cites] J Neurosci. 2008 Mar 26;28(13):3521-30 [18367618.001]
  • [Cites] Arch Histol Cytol. 2007 Dec;70(5):279-90 [18431028.001]
  • [Cites] Neurosci Res. 2008 Jun;61(2):143-58 [18343518.001]
  • [Cites] J Clin Invest. 2000 Apr;105(8):1117-24 [10772656.001]
  • [Cites] Genesis. 2001 May;30(1):36-44 [11353516.001]
  • [Cites] Exp Neurol. 2001 Sep;171(1):29-45 [11520119.001]
  • [Cites] J Clin Invest. 2001 Oct;108(7):949-55 [11581294.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):4037-42 [11891290.001]
  • [Cites] Genes Immun. 2002 May;3(3):123-35 [12070776.001]
  • [Cites] J Neurosci. 2008 Nov 12;28(46):12023-31 [19005067.001]
  • [Cites] Mol Immunol. 2004 Mar;40(16):1203-11 [15104125.001]
  • (PMID = 20016851.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Advanced Glycosylation End Product-Specific Receptor; 0 / Receptors, Immunologic
  • [Other-IDs] NLM/ PMC2788702
  •  go-up   go-down


6. Nakahara S, Tamura M, Matsuki N, Koyama R: Neuronal hyperactivity sustains the basal dendrites of immature dentate granule cells: time-lapse confocal analysis using hippocampal slice cultures. Hippocampus; 2009 Apr;19(4):379-91
Hazardous Substances Data Bank. TETRODOTOXIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuronal hyperactivity sustains the basal dendrites of immature dentate granule cells: time-lapse confocal analysis using hippocampal slice cultures.
  • In the epileptic hippocampus, mature dentate granule cells (GCs) possess basal dendrites (BDs), which is abnormal and is assumed to contribute to seizure progression.
  • However, there is a lack of direct time-lapse evidence showing that neuronal hyperactivity regulates the dendritic development of GCs.
  • These effects were blocked by coapplying tetrodotoxin, a sodium channel blocker, thus convincing us that neuronal hyperactivity contributes to the maintenance of BDs.
  • These results, for the first time, provide us with direct evidence that neuronal hyperactivity contributes to the stability of pre-existing BDs.
  • [MeSH-minor] Action Potentials. Analysis of Variance. Animals. Calbindins. Cell Shape. Electroporation. Green Fluorescent Proteins. Immunohistochemistry. In Vitro Techniques. Microscopy, Confocal. Picrotoxin. Pseudopodia / ultrastructure. Rats. Rats, Sprague-Dawley. S100 Calcium Binding Protein G / metabolism. Sodium Channel Blockers / pharmacology. Tetrodotoxin / pharmacology

  • MedlinePlus Health Information. consumer health - Epilepsy.
  • Hazardous Substances Data Bank. PICROTOXIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19004014.001).
  • [ISSN] 1098-1063
  • [Journal-full-title] Hippocampus
  • [ISO-abbreviation] Hippocampus
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calbindins; 0 / S100 Calcium Binding Protein G; 0 / Sodium Channel Blockers; 124-87-8 / Picrotoxin; 147336-22-9 / Green Fluorescent Proteins; 4368-28-9 / Tetrodotoxin
  •  go-up   go-down


7. Kintaka Y, Osaka T, Suzuki Y, Hashiguchi T, Niijima A, Kageyama H, Fumiko T, Shioda S, Inoue S: Effects of gastric vagotomy on visceral cell proliferation induced by ventromedial hypothalamic lesions: role of vagal hyperactivity. J Mol Neurosci; 2009 Jul;38(3):243-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of gastric vagotomy on visceral cell proliferation induced by ventromedial hypothalamic lesions: role of vagal hyperactivity.
  • In rats, ventromedial hypothalamic (VMH) lesions induce cell proliferation in the visceral organs (stomach, small intestine, liver, and pancreas) due to hyperactivity of the vagus nerve.
  • To investigate the effects of selective gastric vagotomy on VMH lesion-induced cell proliferation and secretion of gastric acid, we assessed the mitotic index (the number of proliferating cell nuclear antigen (PCNA)-immunopositive cells per 1,000 cells in the gastric mucosal cell layer) and measured the volume of secreted basal gastric acid.
  • VMH lesions resulted in an increased mitotic index and thickness of the gastric mucosal cell layer and gave rise to the hypersecretion of gastric acid.
  • Selective gastric vagotomy restored these parameters to normal without affecting cell proliferation in other visceral organs.
  • These results suggest that VMH lesion-induced vagally mediated cell proliferation in the visceral organs is associated with hyperfunction in these organs, and VMH lesion-induced resistance to ethanol may be due to thickening of the gastric mucosal cell layer resulting from cell proliferation in the gastric mucosa-this in turn is due to hyperactivity of the vagus nerve.
  • [MeSH-major] Cell Proliferation. Gastric Mucosa. Vagotomy. Vagus Nerve / physiology. Ventromedial Hypothalamic Nucleus / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19455436.001).
  • [ISSN] 0895-8696
  • [Journal-full-title] Journal of molecular neuroscience : MN
  • [ISO-abbreviation] J. Mol. Neurosci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Richards AB, Scheel TA, Wang K, Henkemeyer M, Kromer LF: EphB1 null mice exhibit neuronal loss in substantia nigra pars reticulata and spontaneous locomotor hyperactivity. Eur J Neurosci; 2007 May;25(9):2619-28
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EphB1 null mice exhibit neuronal loss in substantia nigra pars reticulata and spontaneous locomotor hyperactivity.
  • The molecular mechanisms that regulate basal ganglia development are largely unknown.
  • Eph receptor tyrosine kinases are potential participants in this process as they regulate development of other CNS regions and are expressed in basal ganglia nuclei, such as the substantia nigra (SN) and striatum.
  • Behavioral evaluation of EphB1 null mice in an open-field environment revealed that these mice exhibited spontaneous locomotor hyperactivity.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GLUTAMIC ACID HYDROCHLORIDE .
  • Hazardous Substances Data Bank. DOPAMINE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17561836.001).
  • [ISSN] 0953-816X
  • [Journal-full-title] The European journal of neuroscience
  • [ISO-abbreviation] Eur. J. Neurosci.
  • [Language] ENG
  • [Grant] United States / NIMH NIH HHS / MH / R01 MH066332; United States / NINDS NIH HHS / NS / NS27054; United States / NINDS NIH HHS / NS / NS38266; United States / NINDS NIH HHS / NS / NS66332
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers; 3KX376GY7L / Glutamic Acid; 56-12-2 / gamma-Aminobutyric Acid; EC 1.14.16.2 / Tyrosine 3-Monooxygenase; EC 2.7.10.1 / Receptor, EphB1; EC 3.2.1.23 / beta-Galactosidase; VTD58H1Z2X / Dopamine
  •  go-up   go-down


9. Müller Smith K, Fagel DM, Stevens HE, Rabenstein RL, Maragnoli ME, Ohkubo Y, Picciotto MR, Schwartz ML, Vaccarino FM: Deficiency in inhibitory cortical interneurons associates with hyperactivity in fibroblast growth factor receptor 1 mutant mice. Biol Psychiatry; 2008 May 15;63(10):953-62
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deficiency in inhibitory cortical interneurons associates with hyperactivity in fibroblast growth factor receptor 1 mutant mice.
  • BACKGROUND: Motor hyperactivity due to hyper-dopaminergic neurotransmission in the basal ganglia is well characterized; much less is known about the role of the neocortex in controlling motor behavior.
  • RESULTS: Fgfr1(f/f;hGfapCre) mice have spontaneous locomotor hyperactivity characterized by longer bouts of locomotion and fewer resting points that is significantly reduced by the D1 and D2 receptor antagonists.
  • The decrease in parvalbumin+ interneurons in cortex correlated with the extent of hyperactivity.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHYLPHENIDATE .
  • Hazardous Substances Data Bank. AMPHETAMINE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17988653.001).
  • [ISSN] 1873-2402
  • [Journal-full-title] Biological psychiatry
  • [ISO-abbreviation] Biol. Psychiatry
  • [Language] ENG
  • [Grant] United States / NIMH NIH HHS / MH / R01 MH067715; United States / NIMH NIH HHS / MH / T32 MH018268; United States / NIMH NIH HHS / MH / 5R01MH067715-03; United States / NIMH NIH HHS / MH / T32MH18268
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biogenic Monoamines; 0 / Central Nervous System Stimulants; 0 / Dopamine Agents; 0 / Nerve Tissue Proteins; 104781-85-3 / Fibroblast Growth Factor 1; 207ZZ9QZ49 / Methylphenidate; CK833KGX7E / Amphetamine; EC 4.1.1.15 / Glutamate Decarboxylase; EC 4.1.1.15 / glutamate decarboxylase 1
  •  go-up   go-down


10. Hirano M, Rakwal R, Shibato J, Sawa H, Nagashima K, Ogawa Y, Yoshida Y, Iwahashi H, Niki E, Masuo Y: Proteomics- and transcriptomics-based screening of differentially expressed proteins and genes in brain of Wig rat: a model for attention deficit hyperactivity disorder (ADHD) research. J Proteome Res; 2008 Jun;7(6):2471-89

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomics- and transcriptomics-based screening of differentially expressed proteins and genes in brain of Wig rat: a model for attention deficit hyperactivity disorder (ADHD) research.
  • Two global omics approaches were applied to develop an inventory of differentially expressed proteins and genes in Wig rat, a promising animal model of attention-deficit hyperactivity disorder (ADHD).
  • Peptide mass fingerprinting/tandem mass spectrometry identified 19 nonredundant proteins, belonging to 7 functional categories, namely, signal transduction, energy metabolism, cellular transport, protein with binding function, protein synthesis, cytoskeleton, and cell rescue.
  • [MeSH-minor] Animals. Attention Deficit Disorder with Hyperactivity / genetics. Attention Deficit Disorder with Hyperactivity / metabolism. Attention Deficit Disorder with Hyperactivity / pathology. Basal Ganglia / metabolism. Disease Models, Animal. Electrophoresis, Gel, Two-Dimensional. Frontal Lobe / metabolism. Male. Mesencephalon / metabolism. Oligonucleotide Array Sequence Analysis. Rats. Rats, Inbred LEC. Rats, Mutant Strains. Rats, Wistar. Spectrometry, Mass, Electrospray Ionization. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization. Tandem Mass Spectrometry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18457438.001).
  • [ISSN] 1535-3893
  • [Journal-full-title] Journal of proteome research
  • [ISO-abbreviation] J. Proteome Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proteins
  •  go-up   go-down


11. Schiffmann SN: [Changes in neural networks by conditional transgenic approach: a key to our comprehension of neuro-psychiatric disorders in the basal ganglia system]. Bull Mem Acad R Med Belg; 2009;164(7-9):171-8; discussion 178-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Changes in neural networks by conditional transgenic approach: a key to our comprehension of neuro-psychiatric disorders in the basal ganglia system].
  • The striatum, the first relay of the basal ganglia system, is critically involved in motor functions and motivational processes.
  • The striatum consists of two populations of neurons projecting at the origin of two distinct paths in the circuit of basal ganglia, and of different populations of interneurons.
  • To identify these specific functions, we have developed new animal models wearing molecular or cell "lesions" by a conditional transgenic approach to target a specific population of neurons.
  • By this approach, we demonstrated the inhibitory role of the population of striatopallidal neurons in the motor control and in the process of drug addiction, identified new genes selectively expressed by striatopallidal neurons that could be the target for future therapies and identified the potential role of this population of neurons disturbances in attention-deficit hyperactivity disorder (ADHD).
  • [MeSH-major] Basal Ganglia / physiopathology. Mental Disorders / physiopathology. Nerve Net / physiopathology. Nervous System Diseases / physiopathology
  • [MeSH-minor] Animals. Attention Deficit Disorder with Hyperactivity / physiopathology. Corpus Striatum / physiopathology. Humans. Huntington Disease / physiopathology. Mice. Mice, Knockout. Models, Animal. Movement Disorders / physiopathology. Neural Pathways / physiopathology. Neurons, Efferent / metabolism. Neuropeptides / metabolism. Nucleus Accumbens / physiopathology. Parkinson Disease / physiopathology. Rats. Rats, Transgenic. Receptors, Dopamine / metabolism. Substance-Related Disorders / physiopathology

  • MedlinePlus Health Information. consumer health - Mental Disorders.
  • MedlinePlus Health Information. consumer health - Neurologic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20218186.001).
  • [ISSN] 0377-8231
  • [Journal-full-title] Bulletin et mémoires de l'Académie royale de médecine de Belgique
  • [ISO-abbreviation] Bull. Mem. Acad. R. Med. Belg.
  • [Language] fre
  • [Publication-type] English Abstract; Lectures
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / Neuropeptides; 0 / Receptors, Dopamine
  •  go-up   go-down


12. Blandini F, Levandis G, Bazzini E, Nappi G, Armentero MT: Time-course of nigrostriatal damage, basal ganglia metabolic changes and behavioural alterations following intrastriatal injection of 6-hydroxydopamine in the rat: new clues from an old model. Eur J Neurosci; 2007 Jan;25(2):397-405
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Time-course of nigrostriatal damage, basal ganglia metabolic changes and behavioural alterations following intrastriatal injection of 6-hydroxydopamine in the rat: new clues from an old model.
  • To gain new information from such a classic model, we studied the time-course of the nigrostriatal damage, metabolic changes in the basal ganglia nuclei (cytochrome oxidase activity) and behavioural modifications (rotational response to apomorphine) following unilateral injection of 6-OHDA into the corpus striatum of rat, over a 4-week period.
  • Striatal infusion of 6-OHDA caused early damage of dopaminergic terminals, followed by a slowly evolving loss of dopaminergic cell bodies in the substantia nigra pars compacta, which became apparent during the second week post-injection and peaked at the 28th day post-infusion; the rotational response to apomorphine was already present at the first time point considered (Day 1), and remained substantially stable throughout the 4-week period of observation.
  • The evolution of the nigrostriatal lesion was accompanied by complex changes in the metabolic activity of the other basal ganglia nuclei investigated (substantia nigra pars reticulata, entopeduncular nucleus, globus pallidus and subthalamic nucleus), which led, ultimately, to a generalized, metabolic hyperactivity, ipsilaterally to the lesion.
  • However, peculiar patterns of metabolic activation, or inhibition, characterized the post-lesional responses of each nucleus, in the early and intermediate phases, with peculiar response profiles that varied closely related to the functional position occupied within the basal ganglia circuitry.
  • [MeSH-major] Basal Ganglia. Behavior, Animal / drug effects. Oxidopamine. Parkinson Disease, Secondary. Substantia Nigra / pathology
  • [MeSH-minor] Animals. Cell Death / drug effects. Cytochromes c / metabolism. Disease Models, Animal. Immunohistochemistry / methods. Male. Rats. Rats, Sprague-Dawley. Time Factors. Tyrosine 3-Monooxygenase / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17284180.001).
  • [ISSN] 0953-816X
  • [Journal-full-title] The European journal of neuroscience
  • [ISO-abbreviation] Eur. J. Neurosci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 8HW4YBZ748 / Oxidopamine; 9007-43-6 / Cytochromes c; EC 1.14.16.2 / Tyrosine 3-Monooxygenase
  •  go-up   go-down


13. Morgan D, Gordon MN: Amyloid, hyperactivity, and metabolism: theoretical comment on Vloeberghs et al. (2008). Behav Neurosci; 2008 Jun;122(3):730-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amyloid, hyperactivity, and metabolism: theoretical comment on Vloeberghs et al. (2008).
  • Potential explanations include increased locomotor activity or increased basal metabolism.

  • MedlinePlus Health Information. consumer health - Alzheimer's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (Copyright) 2008 APA, all rights reserved.
  • [Cites] Neuron. 2004 Jan 8;41(1):27-33 [14715132.001]
  • [Cites] Mitochondrion. 2007 Sep;7(5):297-310 [17625988.001]
  • [Cites] J Am Med Dir Assoc. 2004 Mar-Apr;5(2):89-97 [14984619.001]
  • [Cites] Behav Genet. 1999 May;29(3):177-85 [10547924.001]
  • [Cites] Behav Neurosci. 1999 Oct;113(5):982-90 [10571480.001]
  • [Cites] J Mol Neurosci. 1999 Aug-Oct;13(1-2):159-65 [10691302.001]
  • [Cites] FASEB J. 2000 Jun;14(9):1233-43 [10834945.001]
  • [Cites] Neurobiol Aging. 2002 May-Jun;23(3):335-48 [11959395.001]
  • [Cites] J Nutr. 2002 Nov;132(11 Suppl):3465S-3466S [12421871.001]
  • [Cites] Curr Opin Crit Care. 2003 Aug;9(4):271-8 [12883281.001]
  • [Cites] Proc Nutr Soc. 2003 Nov;62(4):783-91 [15018476.001]
  • [Cites] Neurobiol Aging. 2004 Aug;25(7):893-904 [15212843.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jul 27;101(30):11141-6 [15263077.001]
  • [Cites] Physiol Rev. 1991 Jul;71(3):733-74 [2057526.001]
  • [Cites] J Neurosci. 1995 Sep;15(9):6239-49 [7666206.001]
  • [Cites] Neurology. 1997 Apr;48(4):997-1002 [9109890.001]
  • [Cites] Hum Mol Genet. 1997 Oct;6(11):1951-9 [9302276.001]
  • [Cites] Nat Med. 1998 Jan;4(1):97-100 [9427614.001]
  • [Cites] J Biol Chem. 2004 Nov 5;279(45):46363-6 [15385542.001]
  • [Cites] Eur J Neurosci. 2004 Nov;20(10):2757-66 [15548219.001]
  • [Cites] Arch Neurol. 2005 Jan;62(1):55-60 [15642850.001]
  • [Cites] Physiol Biochem Zool. 2004 Nov-Dec;77(6):869-76 [15674762.001]
  • [Cites] BMC Neurosci. 2005;6:7 [15689237.001]
  • [Cites] Neurobiol Aging. 2005 Jul;26(7):995-1000 [15748777.001]
  • [Cites] Neurology. 2005 Sep 27;65(6):892-7 [16186530.001]
  • [Cites] Adv Surg. 2005;39:245-61 [16250555.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jul;91(7):2569-73 [16636121.001]
  • [Cites] Nat Med. 2006 Jul;12(7):801-8 [16767098.001]
  • [Cites] J Alzheimers Dis. 2006 Jul;9(2):101-10 [16873957.001]
  • [Cites] J Alzheimers Dis. 2006 Jul;9(2):119-26 [16873959.001]
  • [Cites] Behav Pharmacol. 2006 Sep;17(5-6):525-33 [16940774.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 Jan;292(1):C8-23 [16807300.001]
  • [Cites] Behav Brain Res. 2007 Mar 12;178(1):18-28 [17229472.001]
  • [Cites] J Nutr Health Aging. 2007 Jan-Feb;11(1):38-48 [17315079.001]
  • [Cites] Exp Neurol. 2007 Mar;204(1):77-87 [17070803.001]
  • [CommentOn] Behav Neurosci. 2008 Jun;122(3):491-7 [18513119.001]
  • (PMID = 18513144.001).
  • [ISSN] 0735-7044
  • [Journal-full-title] Behavioral neuroscience
  • [ISO-abbreviation] Behav. Neurosci.
  • [Language] ENG
  • [Grant] United States / NIA NIH HHS / AG / AG018478-09; United States / NINDS NIH HHS / NS / NS48335; United States / NIA NIH HHS / AG / AG18478; United States / NIA NIH HHS / AG / AG15490; United States / NIA NIH HHS / AG / AG25509; United States / NIA NIH HHS / AG / AG 04418,; United States / NIA NIH HHS / AG / R01 AG025509-04; United States / NIA NIH HHS / AG / R01 AG018478-09; United States / NIA NIH HHS / AG / P01 AG004418-250018; United States / NIA NIH HHS / AG / R01 AG025509; United States / NIA NIH HHS / AG / R01 AG018478; United States / NINDS NIH HHS / NS / R01 NS048335; United States / NIA NIH HHS / AG / P01 AG004418; United States / NIA NIH HHS / AG / AG25711; United States / NIA NIH HHS / AG / AG025509-04; United States / NIA NIH HHS / AG / P50 AG025711; United States / NIA NIH HHS / AG / R01 AG015490; United States / NIA NIH HHS / AG / AG004418-250018
  • [Publication-type] Comment; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amyloid
  • [Other-IDs] NLM/ NIHMS116685; NLM/ PMC2706527
  •  go-up   go-down


14. Traissard N, Herbeaux K, Cosquer B, Jeltsch H, Ferry B, Galani R, Pernon A, Majchrzak M, Cassel JC: Combined damage to entorhinal cortex and cholinergic basal forebrain neurons, two early neurodegenerative features accompanying Alzheimer's disease: effects on locomotor activity and memory functions in rats. Neuropsychopharmacology; 2007 Apr;32(4):851-71
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined damage to entorhinal cortex and cholinergic basal forebrain neurons, two early neurodegenerative features accompanying Alzheimer's disease: effects on locomotor activity and memory functions in rats.
  • In Alzheimer's disease (AD), cognitive decline is linked to cholinergic dysfunctions in the basal forebrain (BF), although the earliest neuronal damage is described in the entorhinal cortex (EC).
  • Only rats with combined lesions showed diurnal and nocturnal hyperactivity.
  • [MeSH-minor] Analysis of Variance. Animals. Antibodies, Monoclonal. Behavior, Animal. Cell Count / methods. Choline O-Acetyltransferase / metabolism. Male. Maze Learning / physiology. N-Glycosyl Hydrolases. N-Methylaspartate. Psychomotor Performance / drug effects. Rats. Rats, Long-Evans. Ribosome Inactivating Proteins, Type 1

  • MedlinePlus Health Information. consumer health - Memory.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16760925.001).
  • [ISSN] 0893-133X
  • [Journal-full-title] Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
  • [ISO-abbreviation] Neuropsychopharmacology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 192 IgG-saporin; 0 / Antibodies, Monoclonal; 0 / Ribosome Inactivating Proteins, Type 1; 6384-92-5 / N-Methylaspartate; EC 2.3.1.6 / Choline O-Acetyltransferase; EC 3.2.2.- / N-Glycosyl Hydrolases; N9YNS0M02X / Acetylcholine
  •  go-up   go-down


15. Soulage C, Zarrouki B, Soares AF, Lagarde M, Geloen A: Lou/C obesity-resistant rat exhibits hyperactivity, hypermetabolism, alterations in white adipose tissue cellularity, and lipid tissue profiles. Endocrinology; 2008 Feb;149(2):615-25
Hazardous Substances Data Bank. Norepinephrine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lou/C obesity-resistant rat exhibits hyperactivity, hypermetabolism, alterations in white adipose tissue cellularity, and lipid tissue profiles.
  • Basal lipolysis and sensitivity to noradrenaline were similar; however, the responsiveness to noradrenaline was lower in adipocytes from Lou/C compared with that from Wistar rats.
  • [MeSH-minor] Animals. Cell Count. Fatty Acid Synthase, Type I / genetics. Fatty Acids / metabolism. Lipolysis / physiology. Lipoprotein Lipase / genetics. Male. Motor Activity / physiology. Norepinephrine / pharmacology. Rats. Rats, Wistar. Reverse Transcriptase Polymerase Chain Reaction. Species Specificity. Stearoyl-CoA Desaturase / genetics. Stearoyl-CoA Desaturase / metabolism. Sympathetic Nervous System / physiology. Sympathomimetics / pharmacology

  • MedlinePlus Health Information. consumer health - Body Weight.
  • MedlinePlus Health Information. consumer health - Obesity.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18006635.001).
  • [ISSN] 0013-7227
  • [Journal-full-title] Endocrinology
  • [ISO-abbreviation] Endocrinology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fatty Acids; 0 / Sympathomimetics; EC 1.14.19.1 / Scd1 protein, mouse; EC 1.14.19.1 / Stearoyl-CoA Desaturase; EC 2.3.1.85 / Fatty Acid Synthase, Type I; EC 3.1.1.34 / Lipoprotein Lipase; X4W3ENH1CV / Norepinephrine
  •  go-up   go-down


16. Armentero MT, Fancellu R, Nappi G, Bramanti P, Blandini F: Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson's disease. Neurobiol Dis; 2006 Apr;22(1):1-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson's disease.
  • The ionotropic, N-methyl-D-aspartate receptor antagonist MK-801 increased cell survival in the substantia nigra pars compacta (SNc) and corrected the metabolic hyperactivity (increased cytochrome oxidase activity) of the ipsilateral substantia nigra pars reticulata (SNr) associated with the lesion, but showed no effects on the 6-OHDA-induced hyperactivity of the subthalamic nucleus (STN).
  • As opposed to MK-801, MPEP abolished the STN metabolic hyperactivity associated with the nigrostriatal lesion, without affecting SNr activity.
  • Specific modulation of STN hyperactivity obtained with mGluR5 blockade may, therefore, open interesting perspectives for the use of this class of compounds in the treatment of Parkinson's disease.
  • [MeSH-minor] Animals. Cell Survival / drug effects. Cell Survival / physiology. Disease Models, Animal. Dizocilpine Maleate / pharmacology. Dizocilpine Maleate / therapeutic use. Electron Transport Complex IV / drug effects. Electron Transport Complex IV / metabolism. Energy Metabolism / drug effects. Energy Metabolism / physiology. Male. Nerve Degeneration / drug therapy. Nerve Degeneration / physiopathology. Nerve Degeneration / prevention & control. Neuroprotective Agents / pharmacology. Neuroprotective Agents / therapeutic use. Oxidopamine. Pyridines / pharmacology. Pyridines / therapeutic use. Rats. Rats, Sprague-Dawley. Receptor, Metabotropic Glutamate 5. Receptors, Metabotropic Glutamate / antagonists & inhibitors. Receptors, Metabotropic Glutamate / metabolism. Receptors, N-Methyl-D-Aspartate / antagonists & inhibitors. Receptors, N-Methyl-D-Aspartate / metabolism. Subthalamic Nucleus / drug effects. Subthalamic Nucleus / metabolism. Subthalamic Nucleus / physiopathology

  • Hazardous Substances Data Bank. DIZOCILPINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16289868.001).
  • [ISSN] 0969-9961
  • [Journal-full-title] Neurobiology of disease
  • [ISO-abbreviation] Neurobiol. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 6-methyl-2-(phenylethynyl)pyridine; 0 / Excitatory Amino Acid Antagonists; 0 / Grm5 protein, rat; 0 / Neuroprotective Agents; 0 / Pyridines; 0 / Receptor, Metabotropic Glutamate 5; 0 / Receptors, Glutamate; 0 / Receptors, Metabotropic Glutamate; 0 / Receptors, N-Methyl-D-Aspartate; 6LR8C1B66Q / Dizocilpine Maleate; 8HW4YBZ748 / Oxidopamine; EC 1.9.3.1 / Electron Transport Complex IV
  •  go-up   go-down


17. Grigorian A, Torossian S, Demetriou M: T-cell growth, cell surface organization, and the galectin-glycoprotein lattice. Immunol Rev; 2009 Jul;230(1):232-46
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell growth, cell surface organization, and the galectin-glycoprotein lattice.
  • Basal, activation, and arrest signaling in T cells determines survival, coordinates responses to pathogens, and, when dysregulated, leads to loss of self-tolerance and autoimmunity.
  • At the T-cell surface, transmembrane glycoproteins interact with galectins via their N-glycans, forming a molecular lattice that regulates membrane localization, clustering, and endocytosis of surface receptors.
  • Galectin-T-cell receptor (TCR) binding prevents ligand-independent TCR signaling via Lck by blocking spontaneous clustering and CD4-Lck recruitment to TCR, and in turn F-actin transfer of TCR/CD4-Lck complexes to membrane microdomains.
  • Galectin also localizes the tyrosine phosphatase CD45 to microdomains and the immune synapse, suppressing basal and activation signaling by Lck.
  • Genetic and metabolic control of N-glycan branching co-regulate homeostatic set-points for basal, activation, and arrest signaling in T cells and, when disturbed, result in T-cell hyperactivity and autoimmunity.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1984 May 25;259(10):6253-60 [6725252.001]
  • [Cites] Annu Rev Biochem. 1985;54:631-64 [3896128.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Mar;83(6):1852-6 [3081904.001]
  • [Cites] J Neuroimmunol. 1990 Jul;28(2):177-84 [1694534.001]
  • [Cites] Nature. 1992 Apr 16;356(6370):607-9 [1313950.001]
  • [Cites] Nature. 1992 May 14;357(6374):161-4 [1579166.001]
  • [Cites] Glycobiology. 1991 Nov;1(5):453-61 [1840403.001]
  • [Cites] Cell. 1992 Aug 21;70(4):585-93 [1505025.001]
  • [Cites] Glycobiology. 1993 Aug;3(4):297-304 [8400545.001]
  • [Cites] Biochemistry. 1993 Nov 30;32(47):12694-704 [8251489.001]
  • [Cites] Science. 1995 Nov 10;270(5238):985-8 [7481803.001]
  • [Cites] Nature. 1995 Dec 14;378(6558):736-9 [7501023.001]
  • [Cites] Glycobiology. 2008 Oct;18(10):770-8 [18633135.001]
  • [Cites] Eur J Immunol. 2008 Nov;38(11):3015-27 [18991278.001]
  • [Cites] Immunity. 2008 Dec 19;29(6):848-62 [19100699.001]
  • [Cites] J Immunol. 2009 Jan 15;182(2):1167-73 [19124760.001]
  • [Cites] Am J Pathol. 2004 Dec;165(6):2045-53 [15579447.001]
  • [Cites] J Immunol. 2004 Dec 15;173(12):7200-8 [15585841.001]
  • [Cites] Nat Immunol. 2005 Jan;6(1):80-9 [15558067.001]
  • [Cites] J Immunol. 2005 Feb 1;174(3):1479-90 [15661907.001]
  • [Cites] Semin Immunol. 2005 Jun;17(3):231-7 [15826828.001]
  • [Cites] J Exp Med. 2005 Oct 17;202(8):1031-6 [16216891.001]
  • [Cites] J Immunol. 2005 Dec 1;175(11):7202-8 [16301624.001]
  • [Cites] Nat Immunol. 2005 Dec;6(12):1245-52 [16286920.001]
  • [Cites] Cell. 2005 Dec 29;123(7):1307-21 [16377570.001]
  • [Cites] J Immunol. 2006 Jan 15;176(2):778-89 [16393961.001]
  • [Cites] Nature. 2006 Feb 9;439(7077):682-7 [16382236.001]
  • [Cites] Glycobiology. 2006 Apr;16(4):305-17 [16319083.001]
  • [Cites] Nature. 2006 May 11;441(7090):235-8 [16648838.001]
  • [Cites] Am J Pathol. 2006 Jun;168(6):1910-20 [16723706.001]
  • [Cites] Lab Invest. 2006 Jul;86(7):724-37 [16702978.001]
  • [Cites] Immunity. 2006 Jul;25(1):117-27 [16860761.001]
  • [Cites] J Immunol. 2006 Aug 15;177(4):2431-40 [16888005.001]
  • [Cites] J Biol Chem. 2007 Jan 12;282(2):1374-83 [17082191.001]
  • [Cites] Immunity. 2007 Jan;26(1):43-54 [17188005.001]
  • [Cites] Blood. 2007 Mar 1;109(5):2058-65 [17110462.001]
  • [Cites] Cell. 2007 Apr 6;129(1):123-34 [17418791.001]
  • [Cites] Curr Opin Immunol. 2007 Jun;19(3):320-6 [17433869.001]
  • [Cites] Curr Opin Immunol. 2007 Jun;19(3):309-14 [17433872.001]
  • [Cites] J Biol Chem. 2007 Jul 6;282(27):20027-35 [17488719.001]
  • [Cites] Nat Immunol. 2007 Aug;8(8):825-34 [17589510.001]
  • [Cites] J Exp Med. 2009 Feb 16;206(2):463-75 [19171765.001]
  • [Cites] Blood. 1996 May 1;87(9):3783-94 [8611704.001]
  • [Cites] Science. 1996 Jul 5;273(5271):104-6 [8658175.001]
  • [Cites] Immunity. 1996 Sep;5(3):217-28 [8808677.001]
  • [Cites] J Immunol. 1997 May 1;158(9):4237-44 [9126985.001]
  • [Cites] Nature. 1997 Jun 5;387(6633):617-20 [9177351.001]
  • [Cites] Science. 1997 Jun 27;276(5321):2057-62 [9197272.001]
  • [Cites] Blood. 1997 Oct 15;90(8):3089-97 [9376590.001]
  • [Cites] J Immunol. 1997 Dec 15;159(12):5956-63 [9550393.001]
  • [Cites] Nature. 1998 Sep 3;395(6697):82-6 [9738502.001]
  • [Cites] EMBO J. 1998 Sep 15;17(18):5334-48 [9736612.001]
  • [Cites] Science. 1999 Jan 29;283(5402):680-2 [9924026.001]
  • [Cites] J Biol Chem. 1999 Jun 11;274(24):16717-26 [10358011.001]
  • [Cites] Science. 1999 Jul 9;285(5425):221-7 [10398592.001]
  • [Cites] J Immunol. 1999 Oct 1;163(7):3801-11 [10490978.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Nov 30;101(48):16867-72 [15557001.001]
  • [Cites] Nature. 2007 Jul 26;448(7152):484-7 [17581588.001]
  • [Cites] Glycobiology. 2007 Aug;17(8):828-37 [17483135.001]
  • [Cites] Blood. 2007 Sep 1;110(5):1550-8 [17502455.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Oct 2;104(40):15829-34 [17890318.001]
  • [Cites] J Cell Biol. 2007 Oct 22;179(2):341-56 [17938246.001]
  • [Cites] J Biol Chem. 2007 Nov 16;282(46):33725-34 [17855338.001]
  • [Cites] J Biol Chem. 2007 Nov 30;282(48):35361-72 [17897956.001]
  • [Cites] Immunity. 2008 Mar;28(3):414-24 [18342010.001]
  • [Cites] J Biol Chem. 2008 Apr 11;283(15):10109-23 [18216021.001]
  • [Cites] J Biol Chem. 2008 May 2;283(18):12248-58 [18258591.001]
  • [Cites] J Exp Med. 2008 Jul 7;205(7):1517-22 [18591407.001]
  • [Cites] J Biol Chem. 2008 Jul 18;283(29):20547-59 [18456665.001]
  • [Cites] Nature. 2008 Jul 17;454(7202):350-2 [18469800.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jul 15;105(28):9805-10 [18606998.001]
  • [Cites] Nat Med. 2000 Mar;6(3):306-12 [10700233.001]
  • [Cites] Immunity. 2000 Feb;12(2):171-81 [10714683.001]
  • [Cites] J Immunol. 2000 Oct 1;165(7):3722-9 [11034377.001]
  • [Cites] Aliment Pharmacol Ther. 2000 Dec;14(12):1567-79 [11121904.001]
  • [Cites] Nature. 2001 Feb 8;409(6821):733-9 [11217864.001]
  • [Cites] Nat Immunol. 2000 Oct;1(4):329-35 [11017105.001]
  • [Cites] Nat Immunol. 2001 May;2(5):389-96 [11323691.001]
  • [Cites] Glycoconj J. 2000 Jul-Sep;17(7-9):543-51 [11421347.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8744-9 [11447257.001]
  • [Cites] Immunity. 2001 Jul;15(1):71-82 [11485739.001]
  • [Cites] Nature. 2002 Jan 31;415(6871):536-41 [11823861.001]
  • [Cites] Glycobiology. 2002 Feb;12(2):119-27 [11886845.001]
  • [Cites] Nat Rev Immunol. 2001 Dec;1(3):220-8 [11905831.001]
  • [Cites] Immunogenetics. 2002 Apr;54(1):1-8 [11976786.001]
  • [Cites] Cell. 2002 Jun 28;109(7):901-12 [12110186.001]
  • [Cites] Eur J Immunol. 2002 Sep;32(9):2578-87 [12207342.001]
  • [Cites] J Immunol. 2002 Sep 15;169(6):2997-3005 [12218114.001]
  • [Cites] Biochim Biophys Acta. 2002 Sep 19;1572(2-3):232-54 [12223272.001]
  • [Cites] Biochim Biophys Acta. 2002 Sep 19;1572(2-3):263-73 [12223274.001]
  • [Cites] Glycobiology. 2002 Oct;12(10):127R-36R [12244068.001]
  • [Cites] Immunity. 2002 Sep;17(3):303-15 [12354383.001]
  • [Cites] J Biol Chem. 2002 Oct 18;277(42):39343-9 [12176986.001]
  • [Cites] J Immunol. 2002 Nov 1;169(9):5036-42 [12391219.001]
  • [Cites] J Biol Chem. 2002 Nov 29;277(48):46478-86 [12244107.001]
  • [Cites] Curr Opin Struct Biol. 2002 Oct;12(5):616-23 [12464313.001]
  • [Cites] Nat Immunol. 2003 Feb;4(2):189-97 [12496963.001]
  • [Cites] J Biol Chem. 2003 Feb 28;278(9):7469-75 [12499376.001]
  • [Cites] Annu Rev Immunol. 2003;21:107-37 [12414720.001]
  • [Cites] Nat Immunol. 2003 Jul;4(7):670-9 [12796776.001]
  • [Cites] J Exp Med. 2003 Oct 6;198(7):1089-102 [14517277.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8302-11 [14678989.001]
  • [Cites] J Biol Chem. 2004 Mar 19;279(12):10841-7 [14672941.001]
  • [Cites] Annu Rev Immunol. 2004;22:531-62 [15032588.001]
  • [Cites] Science. 2004 Oct 1;306(5693):120-4 [15459394.001]
  • (PMID = 19594640.001).
  • [ISSN] 1600-065X
  • [Journal-full-title] Immunological reviews
  • [ISO-abbreviation] Immunol. Rev.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI082266; United States / NIAID NIH HHS / AI / AI053331-06A1; United States / NIAID NIH HHS / AI / R01 AI053331-06A1; United States / NIAID NIH HHS / AI / R01 AI053331; United States / NIAID NIH HHS / AI / AI082266-01A2; United States / NIAID NIH HHS / AI / R01 AI082266-01A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CTLA-4 Antigen; 0 / CTLA4 protein, human; 0 / Galectins; 0 / Glycoproteins; 0 / Receptors, Antigen, T-Cell; EC 2.- / Transferases; EC 2.7.10.2 / Lymphocyte Specific Protein Tyrosine Kinase p56(lck); EC 3.1.3.48 / Antigens, CD45
  • [Number-of-references] 105
  • [Other-IDs] NLM/ NIHMS265770; NLM/ PMC3059806
  •  go-up   go-down


18. Fukabori R, Kobayashi K: [Functional analysis of the roles of direct and indirect pathways by using immunotoxin-mediated cell targeting approach]. Brain Nerve; 2009 Apr;61(4):412-8
Hazardous Substances Data Bank. DOPAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Functional analysis of the roles of direct and indirect pathways by using immunotoxin-mediated cell targeting approach].
  • The neural circuit connecting the cerebral cortex and the basal ganglia mediates a variety of brain functions including voluntary movement, motor learning, and reinforcement learning.
  • The pathogenesis of certain neurological and neuropsychiatric diseases involves the dysfunction of these dopamin systems; some of these diseases include Parkinson's disease, schizophrenia, and attention deficit hyperactivity disorder.
  • Immunotoxin-mediated cell targeting is an approach employed in transgenic animals to eliminated specific neuronal types from a neuronal circuitry.
  • Here, we describe the use of immunotoxin-mediated cell targeting for studying the neural circuitry that underlies the motor behavior demonstrated in response to systemic dopamine stimulation; further, we propose the potential mechanism that controls direct and indirect striatal pathway-dependent behavior.
  • [MeSH-major] Basal Ganglia / physiology. Cerebral Cortex / physiology. Immunotoxins. Neural Pathways / physiology. Neurons / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19378811.001).
  • [ISSN] 1881-6096
  • [Journal-full-title] Brain and nerve = Shinkei kenkyū no shinpo
  • [ISO-abbreviation] Brain Nerve
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Immunotoxins; VTD58H1Z2X / Dopamine
  • [Number-of-references] 38
  •  go-up   go-down


19. Curatolo P, D'Agati E, Moavero R: The neurobiological basis of ADHD. Ital J Pediatr; 2010;36(1):79
Hazardous Substances Data Bank. ATOMOXETINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Attention-Deficit/Hyperactivity Disorder is not a single pathophysiological entity and appears to have a complex etiology.
  • Structural imaging studies show that brains of children with Attention-Deficit/Hyperactivity Disorder are significantly smaller than unaffected controls.
  • The prefrontal cortex, basal ganglia and cerebellum are differentially affected and evidence indicating reduced connectivity in white matter tracts in key brain areas is emerging.
  • Genetic, pharmacological, imaging, and animal models highlight the important role of dopamine dysregulation in the neurobiology of Attention-Deficit/Hyperactivity Disorder.
  • To date, stimulants are the most effective psychopharmacological treatments available for Attention-Deficit/Hyperactivity Disorder.
  • [MeSH-major] Attention Deficit Disorder with Hyperactivity / physiopathology. Brain / physiopathology
  • [MeSH-minor] Animals. Atomoxetine Hydrochloride. Basal Ganglia / physiopathology. Behavior Therapy. Central Nervous System Stimulants / therapeutic use. Cerebellum / physiopathology. Dopamine / metabolism. Dopamine Agents / metabolism. Dopamine Uptake Inhibitors / therapeutic use. Drug Therapy, Combination. Evidence-Based Medicine. Humans. Italy. Methylphenidate / therapeutic use. Prefrontal Cortex / physiopathology. Propylamines / therapeutic use. Risk Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Attention Deficit Hyperactivity Disorder.
  • Hazardous Substances Data Bank. METHYLPHENIDATE .
  • Hazardous Substances Data Bank. DOPAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuropsychopharmacology. 2010 Feb;35(3):656-64 [19890261.001]
  • [Cites] J Clin Psychiatry. 2010 Jan;71(1):12-3 [20129003.001]
  • [Cites] Psychiatr Clin North Am. 2010 Mar;33(1):159-80 [20159345.001]
  • [Cites] Prog Neuropsychopharmacol Biol Psychiatry. 2010 Apr 16;34(3):441-5 [20100533.001]
  • [Cites] J Child Psychol Psychiatry. 2010 Apr;51(4):368-89 [20015192.001]
  • [Cites] Drug Saf. 2010 Oct 1;33(10):821-42 [20812768.001]
  • [Cites] Lancet. 2010 Oct 23;376(9750):1401-8 [20888040.001]
  • [Cites] Indian Pediatr. 2010 Nov;47(11):955-8 [20453262.001]
  • [Cites] Brain Dev. 2011 Jun;33(6):456-61 [20573461.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 2001 Feb;40(2):168-79 [11211365.001]
  • [Cites] Am J Psychiatry. 2001 Jul;158(7):1067-74 [11431228.001]
  • [Cites] JAMA. 2002 Oct 9;288(14):1740-8 [12365958.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 2003 Jul;42(7):826-33 [12819442.001]
  • [Cites] Neurosci Biobehav Rev. 2003 Nov;27(7):583-92 [14624803.001]
  • [Cites] Paediatr Drugs. 2003;5(12):833-41 [14658924.001]
  • [Cites] Eur Child Adolesc Psychiatry. 2004;13 Suppl 1:I7-30 [15322953.001]
  • [Cites] Am J Hum Genet. 2004 Oct;75(4):661-8 [15297934.001]
  • [Cites] Ann Neurol. 1978 Mar;3(3):231-3 [666263.001]
  • [Cites] Am J Psychiatry. 1996 Sep;153(9):1138-42 [8780415.001]
  • [Cites] Psychol Bull. 1997 Jan;121(1):65-94 [9000892.001]
  • [Cites] Behav Brain Res. 1998 Jul;94(1):127-52 [9708845.001]
  • [Cites] Dev Med Child Neurol. 1999 Mar;41(3):159-65 [10210248.001]
  • [Cites] J Child Psychol Psychiatry. 2005 May;46(5):451-67 [15845126.001]
  • [Cites] Cortex. 2005 Jun;41(3):389-98 [15871603.001]
  • [Cites] Biol Psychiatry. 2005 Jun 1;57(11):1231-8 [15949993.001]
  • [Cites] Biol Psychiatry. 2005 Jun 1;57(11):1293-300 [15950001.001]
  • [Cites] Biol Psychiatry. 2005 Jun 1;57(11):1385-90 [15950012.001]
  • [Cites] Biol Psychiatry. 2005 Jun 1;57(11):1410-5 [15950015.001]
  • [Cites] Lancet. 2005 Jul 16-22;366(9481):237-48 [16023516.001]
  • [Cites] Dev Psychopathol. 2005 Summer;17(3):785-806 [16262992.001]
  • [Cites] Brain Dev. 2005 Dec;27(8):541-3 [16310587.001]
  • [Cites] Trends Cogn Sci. 2006 Mar;10(3):117-23 [16460990.001]
  • [Cites] Neuropharmacology. 2006 May;50(6):755-60 [16427661.001]
  • [Cites] Arch Gen Psychiatry. 2006 May;63(5):540-9 [16651511.001]
  • [Cites] Clin Psychol Rev. 2006 Aug;26(4):433-44 [16480802.001]
  • [Cites] Brain. 2006 Aug;129(Pt 8):2038-46 [16760197.001]
  • [Cites] Behav Brain Res. 2006 Dec 15;175(2):201-11 [17081628.001]
  • [Cites] Cell. 2007 Apr 20;129(2):397-410 [17448997.001]
  • [Cites] Neuropharmacology. 2007 Jun;52(7):1496-508 [17433376.001]
  • [Cites] Brain Dev. 2007 Aug;29(7):400-8 [17207595.001]
  • [Cites] Am J Psychiatry. 2007 Jun;164(6):942-8 [17541055.001]
  • [Cites] Biol Psychiatry. 2007 Jun 15;61(12):1320-8 [17157268.001]
  • [Cites] J Pediatr Psychol. 2007 Jul;32(6):643-54 [17569716.001]
  • [Cites] Arch Gen Psychiatry. 2007 Oct;64(10):1145-52 [17909126.001]
  • [Cites] Biol Psychiatry. 2007 Nov 1;62(9):954-62 [17543895.001]
  • [Cites] Arch Gen Psychiatry. 2007 Nov;64(11):1296-304 [17984398.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 2007 Dec;46(12):1633-41 [18030085.001]
  • [Cites] Neuropsychopharmacology. 2008 Jan;33(1):181-97 [17851542.001]
  • [Cites] Neurosci Biobehav Rev. 2008;32(1):40-55 [17976721.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19649-54 [18024590.001]
  • [Cites] J Ment Health Policy Econ. 2007 Dec;10(4):189-206 [18166830.001]
  • [Cites] Pediatrics. 2008 Jan;121(1):e73-84 [18166547.001]
  • [Cites] Arch Gen Psychiatry. 2008 Jan;65(1):102-14 [18180434.001]
  • [Cites] J Pediatr. 2008 Feb;152(2):263-9 [18206700.001]
  • [Cites] J Cogn Neurosci. 2008 Mar;20(3):478-93 [18004945.001]
  • [Cites] Child Adolesc Psychiatr Clin N Am. 2008 Apr;17(2):439-58, xi [18295155.001]
  • [Cites] J Child Neurol. 2008 Apr;23(4):399-406 [18401033.001]
  • [Cites] Cereb Cortex. 2008 May;18(5):1210-20 [17906338.001]
  • [Cites] J Clin Psychopharmacol. 2008 Jun;28(3 Suppl 2):S46-53 [18480677.001]
  • [Cites] J Neural Transm (Vienna). 2008 May;115(5):777-85 [18196200.001]
  • [Cites] Biol Psychiatry. 2009 Jan 1;65(1):84-8 [18842255.001]
  • [Cites] Encephale. 2009 Apr;35(2):107-14 [19393378.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 2009 May;48(5):484-500 [19318991.001]
  • [Cites] Am J Psychiatry. 2009 Jun;166(6):711-7 [19448185.001]
  • [Cites] J Child Adolesc Psychopharmacol. 2009 Jun;19(3):215-26 [19519256.001]
  • [Cites] Hum Genet. 2009 Jul;126(1):51-90 [19506906.001]
  • [Cites] Dev Med Child Neurol. 2009 Aug;51(8):580-92 [19549202.001]
  • [Cites] Hum Brain Mapp. 2009 Sep;30(9):2757-65 [19107752.001]
  • [Cites] Curr Psychiatry Rep. 2009 Oct;11(5):393-8 [19785981.001]
  • [Cites] Expert Rev Neurother. 2009 Oct;9(10):1547-65 [19831843.001]
  • [Cites] Neuropharmacology. 2009 Dec;57(7-8):590-600 [19715710.001]
  • [Cites] World J Biol Psychiatry. 2009;10(4 Pt 2):495-502 [19337883.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 2009 Feb;48(2):155-65 [19106767.001]
  • (PMID = 21176172.001).
  • [ISSN] 1824-7288
  • [Journal-full-title] Italian journal of pediatrics
  • [ISO-abbreviation] Ital J Pediatr
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Central Nervous System Stimulants; 0 / Dopamine Agents; 0 / Dopamine Uptake Inhibitors; 0 / Propylamines; 207ZZ9QZ49 / Methylphenidate; 57WVB6I2W0 / Atomoxetine Hydrochloride; VTD58H1Z2X / Dopamine
  • [Other-IDs] NLM/ PMC3016271
  •  go-up   go-down


20. Takeuchi Y: [Neurotransmission in developmental disorders]. No To Hattatsu; 2008 Nov;40(6):451-5
Hazardous Substances Data Bank. DOPAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Attention deficit/hyperactivity disorder (AD/HD) is a heterogeneous developmental disorder with an etiology that is not fully understood.
  • The neurotransmission of dopamine in subcortical regions such as the basal ganglia and limbic areas is synaptic; on the other hand, dopamine neurotransmission in the frontal cortex is quite different, because there are very few dopamine transporters (DAT) in the frontal cortex that allow dopamine to diffuse away from the dopamine synapse ("volume transmission").
  • Furthermore, serotonergic neurons exert an inhibitory effect on midbrain dopamine cell bodies, and they have an influence on dopamine release in terminal regions.
  • In addition to abnormal circuitry in specific limbic and neocortical areas of the cerebral cortex, impairments in brainstem, cerebellar, thalamic, and basal ganglia connections have been reported.
  • The first is cell migration, the second is unbalanced excitatory-inhibitory networks, and the third is synapse formation and pruning, the key factors being reelin, neurexin, and neuroligin.
  • [MeSH-major] Attention Deficit Disorder with Hyperactivity / physiopathology. Autistic Disorder / physiopathology. Dopamine / physiology. Neurons / physiology. Synaptic Transmission
  • [MeSH-minor] Animals. Brain / physiology. Cell Adhesion Molecules, Neuronal. Glutamic Acid / physiology. Humans. Membrane Proteins / physiology. Nerve Tissue Proteins / physiology. Norepinephrine / physiology. Serotonin / physiology

  • MedlinePlus Health Information. consumer health - Attention Deficit Hyperactivity Disorder.
  • Hazardous Substances Data Bank. GLUTAMIC ACID HYDROCHLORIDE .
  • Hazardous Substances Data Bank. Norepinephrine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19039985.001).
  • [ISSN] 0029-0831
  • [Journal-full-title] No to hattatsu. Brain and development
  • [ISO-abbreviation] No To Hattatsu
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Cell Adhesion Molecules, Neuronal; 0 / Membrane Proteins; 0 / Nerve Tissue Proteins; 0 / neuroligin 3; 333DO1RDJY / Serotonin; 3KX376GY7L / Glutamic Acid; VTD58H1Z2X / Dopamine; X4W3ENH1CV / Norepinephrine
  • [Number-of-references] 20
  •  go-up   go-down


21. Hill M, Anney RJ, Gill M, Hawi Z: Functional analysis of intron 8 and 3' UTR variable number of tandem repeats of SLC6A3: differential activity of intron 8 variants. Pharmacogenomics J; 2010 Oct;10(5):442-7
Hazardous Substances Data Bank. METHYLPHENIDATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Association studies have found that variation in the dopamine transporter gene (SLC6A3) is important in the susceptibility to attention-deficit hyperactivity disorder (ADHD) and response to methylphenidate treatment.
  • We assessed the relative activity of variable number tandem repeat (VNTR) alleles of SLC6A3 under basal and stimulated cellular conditions, as well as in the presence of pharmacological blockade of the dopamine transporter using gene-reporter constructs.
  • The lack of enhanced allele-specific activity in response to treatment regimes suggests that differential activity under basal conditions is the primary mode of action.
  • [MeSH-minor] Alleles. Attention Deficit Disorder with Hyperactivity / drug therapy. Attention Deficit Disorder with Hyperactivity / genetics. Cell Culture Techniques. Cell Line, Tumor. Colforsin / pharmacology. Dopamine Uptake Inhibitors / therapeutic use. Genes, Reporter. Genetic Vectors. Humans. Luciferases / genetics. Methylphenidate / therapeutic use. Piperazines / pharmacology. Transfection

  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827857453 for PMID:20029387 [PharmGKB] .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20029387.001).
  • [ISSN] 1473-1150
  • [Journal-full-title] The pharmacogenomics journal
  • [ISO-abbreviation] Pharmacogenomics J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 3' Untranslated Regions; 0 / Dopamine Plasma Membrane Transport Proteins; 0 / Dopamine Uptake Inhibitors; 0 / Piperazines; 0 / SLC6A3 protein, human; 1F7A44V6OU / Colforsin; 207ZZ9QZ49 / Methylphenidate; 76778-22-8 / GBR 12935; EC 1.13.12.- / Luciferases
  •  go-up   go-down


22. Zhou M, Rebholz H, Brocia C, Warner-Schmidt JL, Fienberg AA, Nairn AC, Greengard P, Flajolet M: Forebrain overexpression of CK1delta leads to down-regulation of dopamine receptors and altered locomotor activity reminiscent of ADHD. Proc Natl Acad Sci U S A; 2010 Mar 2;107(9):4401-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Dopamine neurotransmission controls motor and perseverative behavior, is mediated by protein phosphorylation, and may be perturbed in disorders of attention and hyperactivity.
  • Under basal conditions, CK1delta OE mice exhibited horizontal and vertical hyperactivity, reduced anxiety, and nesting behavior deficiencies.
  • All together, under basal conditions and in response to drug stimulation, the behavioral phenotype of CK1delta OE mice is reminiscent of the symptoms and drug responses observed in attention-deficit/hyperactivity disorder and therefore the CK1delta OE mice appear to be a model for this disorder.

  • MedlinePlus Health Information. consumer health - Attention Deficit Hyperactivity Disorder.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHYLPHENIDATE .
  • Hazardous Substances Data Bank. AMPHETAMINE .
  • Hazardous Substances Data Bank. DIZOCILPINE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • SciCrunch. Marmoset Gene list: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1982-7 [11172062.001]
  • [Cites] Oncogene. 2000 Nov 9;19(47):5303-13 [11103931.001]
  • [Cites] Science. 2001 Nov 2;294(5544):1024-30 [11691979.001]
  • [Cites] Cell. 2001 Dec 28;107(7):855-67 [11779462.001]
  • [Cites] J Neurosci. 2002 Jun 1;22(11):4372-80 [12040043.001]
  • [Cites] Biol Psychiatry. 2003 Nov 15;54(10):960-71 [14625138.001]
  • [Cites] J Biol Chem. 2004 Apr 16;279(16):15938-45 [14761950.001]
  • [Cites] Science. 2004 Oct 29;306(5697):879-81 [15514160.001]
  • [Cites] Science. 1991 Aug 30;253(5023):1031-4 [1887218.001]
  • [Cites] J Neurosci. 1992 Jul;12(7):2865-74 [1613559.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Oct 15;89(20):9454-8 [1409656.001]
  • [Cites] Science. 1993 Feb 5;259(5096):780-5 [8430330.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2682-5 [7708705.001]
  • [Cites] Mol Cell Biol. 1996 Oct;16(10):5375-85 [8816449.001]
  • [Cites] Science. 1996 Dec 6;274(5293):1678-83 [8939850.001]
  • [Cites] EMBO J. 1997 Jul 16;16(14):4194-204 [9250663.001]
  • [Cites] J Biol Chem. 1998 Jun 26;273(26):15980-4 [9632646.001]
  • [Cites] Curr Opin Neurobiol. 1998 Apr;8(2):263-71 [9635212.001]
  • [Cites] Brain Res Brain Res Rev. 1998 May;26(2-3):274-84 [9651542.001]
  • [Cites] Cell. 1998 Jul 10;94(1):97-107 [9674431.001]
  • [Cites] Science. 1999 Jan 15;283(5400):397-401 [9888856.001]
  • [Cites] J Biol Chem. 1999 Feb 5;274(6):3804-10 [9920934.001]
  • [Cites] Nature. 2005 Mar 31;434(7033):640-4 [15800623.001]
  • [Cites] Appl Psychophysiol Biofeedback. 2005 Dec;30(4):365-73 [16385424.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4159-64 [17360493.001]
  • [Cites] J Child Psychol Psychiatry. 2008 Jul;49(7):691-704 [18081766.001]
  • [Cites] J Med Chem. 2008 Sep 11;51(17):5229-42 [18698753.001]
  • [Cites] Neuropsychopharmacology. 2009 Apr;34(5):1311-21 [19005464.001]
  • [Cites] Neurobiol Dis. 2010 Jan;37(1):228-36 [19840852.001]
  • [Cites] Neuropsychopharmacology. 2010 Jan;35(1):278-300 [19759528.001]
  • [Cites] Brain Cogn. 2010 Feb;72(1):146-59 [19944514.001]
  • [Cites] Exp Brain Res. 2010 Jan;200(3-4):307-17 [19904530.001]
  • [Cites] Neurosci Biobehav Rev. 2010 Apr;34(5):744-54 [19944715.001]
  • [Cites] J Biol Chem. 1999 Nov 5;274(45):32063-70 [10542239.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 1999 Dec;38(12):1474-7 [10596245.001]
  • [Cites] Neurosci Biobehav Rev. 2000 Jan;24(1):51-7 [10654661.001]
  • [Cites] Science. 2000 Apr 21;288(5465):483-92 [10775102.001]
  • [Cites] Brain Res. 2000 May 19;865(1):116-20 [10814741.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11062-8 [11572969.001]
  • (PMID = 20145109.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NIDA NIH HHS / DA / P01 DA010044; United States / NIMH NIH HHS / MH / P01 MH040899; United States / NIDA NIH HHS / DA / DA10044
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Excitatory Amino Acid Antagonists; 0 / Receptors, Dopamine D1; 0 / Receptors, Dopamine D2; 207ZZ9QZ49 / Methylphenidate; 6LR8C1B66Q / Dizocilpine Maleate; CK833KGX7E / Amphetamine; EC 2.7.11.1 / Casein Kinase Idelta
  • [Other-IDs] NLM/ PMC2840146
  •  go-up   go-down


23. Drgon T, Lin Z, Wang GJ, Fowler J, Pablo J, Mash DC, Volkow N, Uhl GR: Common human 5' dopamine transporter (SLC6A3) haplotypes yield varying expression levels in vivo. Cell Mol Neurobiol; 2006 Jul-Aug;26(4-6):875-89
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] 5' Flanking Region. Adult. Attention Deficit Disorder with Hyperactivity / metabolism. Basal Ganglia / metabolism. Base Sequence. Female. Gene Expression. Gene Frequency. Humans. Male. Molecular Sequence Data. Sequence Analysis, DNA. Sequence Homology, Nucleic Acid

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16710758.001).
  • [ISSN] 0272-4340
  • [Journal-full-title] Cellular and molecular neurobiology
  • [ISO-abbreviation] Cell. Mol. Neurobiol.
  • [Language] eng
  • [Grant] United States / NIDA NIH HHS / DA / DA 06227; United States / NIDA NIH HHS / DA / DA 7092-01; United States / NIDA NIH HHS / DA / DA00280; United States / NIDA NIH HHS / DA / DA09490-01
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dopamine Plasma Membrane Transport Proteins; 0 / SLC6A3 protein, human
  •  go-up   go-down


24. Beaulieu JM, Sotnikova TD, Gainetdinov RR, Caron MG: Paradoxical striatal cellular signaling responses to psychostimulants in hyperactive mice. J Biol Chem; 2006 Oct 27;281(43):32072-80
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we used dopamine transporter knock-out mice to examine which particular changes in the regulation of these cell signaling mechanisms are associated with distinct behavioral responses to psychostimulants.
  • However, in dopamine transporter knock-out mice that display a hyperactivity phenotype resulting from a persistent hyperdopaminergic state, these drugs antagonize hyperactivity.
  • Under basal conditions, dopamine transporter knock-out mice show enhanced striatal DARPP-32 phosphorylation, activation of ERK, and inactivation of Akt as compared with wild-type littermates.
  • However, administration of amphetamine or methylphenidate to these mice reveals that inhibition of ERK signaling is a common determinant for the ability of these drugs to antagonize hyperactivity.
  • In contrast, psychostimulants activate ERK and induce hyperactivity in normal animals.
  • These data suggest that the inhibitory action of psychostimulants on dopamine-dependent hyperactivity results from altered regulation of striatal ERK signaling.
  • In addition, these results illustrate how altered homeostatic state of neurotransmission can influence in vivo signaling responses and biological actions of pharmacological agents used to manage psychiatric conditions such as Attention Deficit Hyperactivity Disorder (ADHD).

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHYLPHENIDATE .
  • Hazardous Substances Data Bank. AMPHETAMINE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16954211.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Grant] United States / NIDA NIH HHS / DA / DA 13511; United States / NIMH NIH HHS / MH / MH 40159; United States / NIMH NIH HHS / MH / MH 73853; United States / NINDS NIH HHS / NS / NS 19576
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Central Nervous System Stimulants; 0 / Phosphoproteins; 0 / Psychotropic Drugs; 0 / Serotonin Receptor Agonists; 207ZZ9QZ49 / Methylphenidate; 333DO1RDJY / Serotonin; 74885-09-9 / 5-carboxamidotryptamine; CK833KGX7E / Amphetamine
  •  go-up   go-down


25. Sagi Y, Driguès N, Youdim MB: The neurochemical and behavioral effects of the novel cholinesterase-monoamine oxidase inhibitor, ladostigil, in response to L-dopa and L-tryptophan, in rats. Br J Pharmacol; 2005 Oct;146(4):553-60
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In sharp contrast to the inductive effect of the MAO A/B inhibitor, tranylcypromine (TCP), on stereotyped hyperactivity in response to L-dopa (50 mg kg(-1)) or L-tryptophan (100 mg kg(-1)), ladostigil completely inhibited these behavioral hyperactivity syndromes.
  • Accordingly, acute rivastigmine (2 mg kg(-1)) and chronic TV3279 abolished the ability of TCP to initiate L-dopa-induced hyperactivity, while scopolamine (0.5 mg kg(-1)) reversed the inhibitory effect of chronic ladostigil on L-dopa-induced hyperactivity, suggesting that ladostigil may attenuate successive locomotion by activating central cholinergic muscarinic receptors.Finally, while chronic ladostigil administration to naïve rats resulted in preserved spontaneous motor behavior, acute treatment with ladostigil decreased motor performance, compared to control animals.
  • [MeSH-major] Basal Ganglia / drug effects. Behavior, Animal / drug effects. Cholinesterase Inhibitors / pharmacology. Hippocampus / drug effects. Hyperkinesis / prevention & control. Indans / pharmacology. Monoamine Oxidase Inhibitors / pharmacology. Motor Activity / drug effects

  • Hazardous Substances Data Bank. TRANYLCYPROMINE .
  • Hazardous Substances Data Bank. SCOPOLAMINE .
  • Hazardous Substances Data Bank. Norepinephrine .
  • Hazardous Substances Data Bank. DOPAMINE .
  • Hazardous Substances Data Bank. (L)-Tryptophan .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Psychopharmacology (Berl). 1999 Dec;147(3):250-6 [10639682.001]
  • [Cites] Neuroscience. 1983 Dec;10(4):1105-20 [6320043.001]
  • [Cites] J Neural Transm Suppl. 2000;(60):157-69 [11205137.001]
  • [Cites] Life Sci. 2001 Feb 16;68(13):1545-55 [11253171.001]
  • [Cites] Ann N Y Acad Sci. 2001 Jun;939:450-8 [11462801.001]
  • [Cites] Int Psychogeriatr. 2001 Jun;13(2):199-205 [11495394.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15312-7 [11752469.001]
  • [Cites] Pharmacol Toxicol. 2001 Nov;89(5):249-54 [11881978.001]
  • [Cites] Cell Mol Neurobiol. 2001 Dec;21(6):555-73 [12043833.001]
  • [Cites] J Neural Transm (Vienna). 2002 Jul;109(7-8):1067-80 [12111444.001]
  • [Cites] Int J Clin Pract Suppl. 2002 Jun;(127):45-63 [12139367.001]
  • [Cites] J Med Chem. 2002 Nov 21;45(24):5260-79 [12431053.001]
  • [Cites] J Chem Neuroanat. 2003 Mar;25(3):161-73 [12706204.001]
  • [Cites] Swiss Med Wkly. 2003 Mar 8;133(9-10):131-42 [12707840.001]
  • [Cites] Neurochem Res. 1992 Aug;17(8):785-90 [1641060.001]
  • [Cites] J Neurochem. 1996 Oct;67(4):1532-9 [8858937.001]
  • [Cites] Pharmacol Biochem Behav. 1984 Mar;20(3):397-403 [6143326.001]
  • [Cites] Fundam Appl Toxicol. 1984 Apr;4(2 Pt 2):S195-208 [6724212.001]
  • [Cites] J Comp Neurol. 1988 Mar 8;269(2):219-34 [3281983.001]
  • [Cites] J Neural Transm Suppl. 1990;29:251-8 [2193109.001]
  • [Cites] J Pharmacol Exp Ther. 1990 Nov;255(2):549-53 [2243341.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Mar 15;88(6):2608-11 [1672454.001]
  • [Cites] Neurosci Res. 1997 Jan;27(1):1-8 [9089693.001]
  • [Cites] Life Sci. 1997;60(22):PL 317-23 [9180344.001]
  • [Cites] Pharmacol Biochem Behav. 1997 Dec;58(4):851-8 [9408186.001]
  • [Cites] Neuropharmacology. 1999 Feb;38(2):323-6 [10218876.001]
  • [Cites] Brain. 1999 Aug;122 ( Pt 8):1449-68 [10430831.001]
  • [Cites] Biochem Pharmacol. 1961 Jul;7:88-95 [13726518.001]
  • [Cites] Prog Neuropsychopharmacol Biol Psychiatry. 2003 Jun;27(4):555-61 [12787840.001]
  • [Cites] J Neurochem. 2003 Jul;86(2):290-7 [12871570.001]
  • [Cites] Acta Biol Hung. 2003;54(2):183-9 [14535624.001]
  • [Cites] Dement Geriatr Cogn Disord. 2004;17 Suppl 1:32-9 [14676467.001]
  • [Cites] Arch Neurol. 2004 Apr;61(4):561-6 [15096406.001]
  • [Cites] J Neurochem. 1971 Jun;18(6):1053-66 [4254940.001]
  • [Cites] Br J Pharmacol. 1975 Nov;55(3):415-22 [1203627.001]
  • [Cites] Life Sci. 1976 Oct 1;19(7):995-1003 [994718.001]
  • [Cites] Br J Pharmacol. 1977 Jul;60(3):343-9 [890205.001]
  • [Cites] Psychopharmacology (Berl). 1981;73(1):31-3 [6785786.001]
  • [Cites] Life Sci. 1981 Apr 27;28(17):1953-9 [7253803.001]
  • [Cites] Psychopharmacology (Berl). 1981;73(4):311-3 [6789349.001]
  • [Cites] Pharmacology. 1982;24(4):222-9 [7201143.001]
  • [Cites] Biol Psychiatry. 1982 Aug;17(8):937-46 [6288127.001]
  • [Cites] J Neurochem. 1983 Nov;41(5):1364-9 [6619871.001]
  • [Cites] Trends Neurosci. 2000 Mar;23(3):120-6 [10675916.001]
  • (PMID = 16086033.001).
  • [ISSN] 0007-1188
  • [Journal-full-title] British journal of pharmacology
  • [ISO-abbreviation] Br. J. Pharmacol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / (N-propargyl-(3R) aminoindan-5-yl)-ethyl methyl carbamate; 0 / (N-propargyl-(3R) and (3S) aminoindan-5-yl)-ethyl methyl carbamate; 0 / Carbamates; 0 / Cholinesterase Inhibitors; 0 / Indans; 0 / Monoamine Oxidase Inhibitors; 0 / Muscarinic Antagonists; 0 / Phenylcarbamates; 333DO1RDJY / Serotonin; 3E3V44J4Z9 / Tranylcypromine; 451IFR0GXB / Scopolamine Hydrobromide; 46627O600J / Levodopa; 8DUH1N11BX / Tryptophan; PKI06M3IW0 / Rivastigmine; VTD58H1Z2X / Dopamine; X4W3ENH1CV / Norepinephrine
  • [Other-IDs] NLM/ PMC1751181
  •  go-up   go-down


26. Szucs RP, Frankel PS, McMahon LR, Cunningham KA: Relationship of cocaine-induced c-Fos expression to behaviors and the role of serotonin 5-HT2A receptors in cocaine-induced c-Fos expression. Behav Neurosci; 2005 Oct;119(5):1173-83
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Significant correlations were observed between cocaine-induced hyperactivity and c-Fos expression in the nucleus accumbens core (NAcC), caudate-putamen (CPu), and subthalamic nucleus.
  • [MeSH-minor] Analysis of Variance. Animals. Basal Ganglia / drug effects. Basal Ganglia / metabolism. Cell Count / methods. Dose-Response Relationship, Drug. Drug Interactions. Fluorobenzenes / pharmacology. Immunohistochemistry / methods. Male. Motor Activity / drug effects. Piperidines / pharmacology. Rats. Rats, Sprague-Dawley. Serotonin Antagonists / pharmacology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. COCAINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16300424.001).
  • [ISSN] 0735-7044
  • [Journal-full-title] Behavioral neuroscience
  • [ISO-abbreviation] Behav. Neurosci.
  • [Language] eng
  • [Grant] United States / NIDA NIH HHS / DA / DA 00260; United States / NIDA NIH HHS / DA / DA 06057; United States / NIDA NIH HHS / DA / DA 06511; United States / NIDA NIH HHS / DA / DA 07287; United States / NIDA NIH HHS / DA / DA06059
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dopamine Uptake Inhibitors; 0 / Fluorobenzenes; 0 / Piperidines; 0 / Proto-Oncogene Proteins c-fos; 0 / Receptor, Serotonin, 5-HT2A; 0 / Serotonin Antagonists; 139290-65-6 / MDL 100907; I5Y540LHVR / Cocaine
  •  go-up   go-down


27. Kraus KS, Ding D, Zhou Y, Salvi RJ: Central auditory plasticity after carboplatin-induced unilateral inner ear damage in the chinchilla: up-regulation of GAP-43 in the ventral cochlear nucleus. Hear Res; 2009 Sep;255(1-2):33-43
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we documented the relationship between carboplatin-induced hair cell degeneration and VCN plasticity in the chinchilla.
  • Unilateral application of carboplatin (5mg/ml) on the round window membrane resulted in massive hair cell loss.
  • Outer hair cell degeneration showed a pronounced basal-to-apical gradient while inner hair cell loss was more equally distributed throughout the cochlea.
  • In VCN, the high-frequency area dorsally showed slightly yet significantly stronger GAP-43 up-regulation than the low-frequency area ventrally, possibly reflecting the high-to-low frequency gradient of hair cell degeneration.
  • Alternatively, massive fiber growth may represent a deleterious process causing central hyperactivity that leads to loudness recruitment or tinnitus.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Exp Neurol. 2002 Sep;177(1):202-21 [12429223.001]
  • [Cites] Hear Res. 2003 Jul;181(1-2):65-72 [12855364.001]
  • [Cites] J Laryngol Otol. 1993 Jul;107(7):585-9 [15125271.001]
  • [Cites] J Comp Neurol. 2004 Jul 26;475(3):374-90 [15221952.001]
  • [Cites] J Neurosci Res. 2004 Sep 15;77(6):829-42 [15334601.001]
  • [Cites] J Am Audiol Soc. 1976 May-Jun;1(6):243-51 [931759.001]
  • [Cites] Brain Res. 1977 Dec 9;138(1):111-23 [589462.001]
  • [Cites] J Cell Biol. 1981 Apr;89(1):86-95 [6164682.001]
  • [Cites] Neurosci Lett. 1985 Nov 11;61(3):235-41 [2934647.001]
  • [Cites] Brain Res. 1988 May 24;449(1-2):104-15 [3395841.001]
  • [Cites] Annu Rev Neurosci. 1989;12:127-56 [2648946.001]
  • [Cites] J Neurosci. 1990 Feb;10(2):588-602 [2137532.001]
  • [Cites] Neuroscience. 1990;34(2):465-78 [2139720.001]
  • [Cites] J Comp Neurol. 1990 May 1;295(1):52-70 [2341636.001]
  • [Cites] Neuron. 1991 Jan;6(1):21-30 [1824753.001]
  • [Cites] J Neurosci. 1991 Dec;11(12):3738-51 [1836017.001]
  • [Cites] Prog Brain Res. 1991;89:69-87 [1839072.001]
  • [Cites] Brain Res Dev Brain Res. 1992 May 22;67(1):75-83 [1386294.001]
  • [Cites] Exp Brain Res. 1992;91(2):284-95 [1333987.001]
  • [Cites] J Neurosci Res. 1993 Jun 1;35(2):162-9 [8320748.001]
  • [Cites] J Am Acad Audiol. 1993 Sep;4(5):277-83; discussion 283-4 [8219294.001]
  • [Cites] Laryngoscope. 1994 Apr;104(4):488-93 [8164491.001]
  • [Cites] Hear Res. 1994 May;75(1-2):93-102 [8071158.001]
  • [Cites] Brain Res Mol Brain Res. 1994 Jul;24(1-4):107-17 [7968347.001]
  • [Cites] Scanning Microsc. 1994 Mar;8(1):97-106 [7973504.001]
  • [Cites] J Neurobiol. 1994 Dec;25(12):1570-8 [7861120.001]
  • [Cites] Science. 1995 Mar 31;267(5206):2006-9 [7701325.001]
  • [Cites] Exp Neurol. 1995 Sep;135(1):28-35 [7556551.001]
  • [Cites] Hear Res. 1996 Jul;96(1-2):71-82 [8817308.001]
  • [Cites] Trends Neurosci. 1997 Feb;20(2):84-91 [9023877.001]
  • [Cites] Synapse. 1997 Mar;25(3):243-57 [9068122.001]
  • [Cites] J Comp Neurol. 1997 May 26;382(1):116-38 [9136815.001]
  • [Cites] Brain Res. 1997 May 2;755(2):221-8 [9175890.001]
  • [Cites] Exp Neurol. 1997 Oct;147(2):256-68 [9344551.001]
  • [Cites] Hear Res. 1997 Oct;112(1-2):199-215 [9367242.001]
  • [Cites] Audiology. 1997 Nov-Dec;36(6):301-11 [9406619.001]
  • [Cites] J Comp Neurol. 1998 Jul 27;397(2):163-80 [9658282.001]
  • [Cites] J Neurosci. 1998 Dec 15;18(24):10429-37 [9852580.001]
  • [Cites] Hear Res. 1999 Feb;128(1-2):97-102 [10082289.001]
  • [Cites] J Comp Neurol. 1999 Sep 20;412(2):353-72 [10441761.001]
  • [Cites] J Neurosci Res. 2005 Jul 1;81(1):91-101 [15931674.001]
  • [Cites] Hear Res. 2005 Aug;206(1-2):64-73 [16080999.001]
  • [Cites] Hear Res. 2005 Aug;206(1-2):185-99 [16081008.001]
  • [Cites] Neuroscience. 2005;134(2):467-81 [15964701.001]
  • [Cites] J Neurosci Res. 2006 Jan;83(1):157-66 [16307447.001]
  • [Cites] Hear Res. 2006 Jun-Jul;216-217:168-75 [16549284.001]
  • [Cites] Eur J Neurosci. 2006 Jun;23(12):3187-99 [16820009.001]
  • [Cites] Hear Res. 2000 Jan;139(1-2):153-71 [10601720.001]
  • [Cites] Ann N Y Acad Sci. 1999 Nov 28;884:152-70 [10842592.001]
  • [Cites] Hear Res. 2000 Sep;147(1-2):261-74 [10962190.001]
  • [Cites] Hear Res. 2001 Aug;158(1-2):139-50 [11506946.001]
  • [Cites] J Neurosci. 2001 Sep 15;21(18):7372-83 [11549747.001]
  • [Cites] Audiol Neurootol. 2001 Jul-Aug;6(4):182-6 [11694724.001]
  • [Cites] Hear Res. 2002 Mar;165(1-2):19-29 [12031511.001]
  • [Cites] J Comp Neurol. 2002 Sep 23;451(3):250-66 [12210137.001]
  • (PMID = 19435600.001).
  • [ISSN] 1878-5891
  • [Journal-full-title] Hearing research
  • [ISO-abbreviation] Hear. Res.
  • [Language] ENG
  • [Grant] United States / NIDCD NIH HHS / DC / R01 DC006630; United States / NIDCD NIH HHS / DC / R01 DC006630-05; United States / NIDCD NIH HHS / DC / R01 DC06630
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / GAP-43 Protein; BG3F62OND5 / Carboplatin
  • [Other-IDs] NLM/ NIHMS139908; NLM/ PMC2777517
  •  go-up   go-down


28. Coulaud J, Durant S, Homo-Delarche F: Glucose homeostasis in pre-diabetic NOD and lymphocyte-deficient NOD/SCID mice during gestation. Rev Diabet Stud; 2010;7(1):36-46
Hazardous Substances Data Bank. GLUCAGON .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: Given that beta-cell stimulation is a natural feature of gestation, we hypothesized that glucose homeostasis is disturbed in gestate pre-diabetic NOD and non-diabetic NOD/SCID mice, which may accelerate the onset of diabetes and increase diabetes prevalence.
  • METHODS: During gestation and postpartum, mice were analyzed under basal feed conditions followed by glucose injection (1 g/kg, i.p.) after overnight fast, using glucose tolerance test (GTT).
  • RESULTS: 1. Basal glucagonemia rose markedly in first-gestation fed NOD mice.
  • 2. beta-cell hyperactivity was present earlier in first-gestation non-diabetic fasted NOD and NOD/SCID mice than in age-matched C57BL/6 mice, assessed by increased insulin/glucose ratio after GTT.
  • CONCLUSIONS: First-gestation pre-diabetic NOD and non-diabetic NOD/SCID mice exhibited beta-cell hyperactivity and deregulation of glucagon and/or corticosterone secretion.

  • MedlinePlus Health Information. consumer health - Blood Sugar.
  • MedlinePlus Health Information. consumer health - Diabetes and Pregnancy.
  • MedlinePlus Health Information. consumer health - Diabetes Type 1.
  • MedlinePlus Health Information. consumer health - Prediabetes.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diabetes. 1990 Jun;39(6):697-701 [2189761.001]
  • [Cites] Diabetes. 2005 Jul;54(7):2026-31 [15983203.001]
  • [Cites] Diabetes Metab Rev. 1990 Dec;6(3):147-67 [2091909.001]
  • [Cites] Autoimmunity. 1991;10(1):65-9 [1742424.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Dec;75(6):1574-6 [1464667.001]
  • [Cites] Diabetologia. 1993 Aug;36(8):759-66 [8405744.001]
  • [Cites] Physiol Behav. 1994 Aug;56(2):241-6 [7938233.001]
  • [Cites] Metabolism. 1994 Nov;43(11):1410-8 [7968596.001]
  • [Cites] Diabetologia. 1995 Mar;38(3):274-6 [7758872.001]
  • [Cites] Endocr Rev. 2005 Oct;26(6):775-99 [15827110.001]
  • [Cites] Diabetologia. 2006 Feb;49(2):261-70 [16404554.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12475-80 [16895987.001]
  • [Cites] J Autoimmun. 2007 Feb;28(1):19-23 [17207966.001]
  • [Cites] Diabetes Care. 2007 Sep;30(9):2314-20 [17536068.001]
  • [Cites] J Neuroimmunol. 2007 Sep;189(1-2):59-68 [17658621.001]
  • [Cites] Exp Neurol. 2008 Apr;210(2):359-67 [18190910.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13163-8 [18719127.001]
  • [Cites] Diabetes. 2008 Dec;57(12):3281-8 [18835930.001]
  • [Cites] Can J Physiol Pharmacol. 2009 Mar;87(3):161-79 [19295658.001]
  • [Cites] Mol Endocrinol. 2009 Jul;23(7):947-54 [19282364.001]
  • [Cites] Nat Med. 2009 Aug;15(8):930-9 [19633656.001]
  • [Cites] Nat Med. 2009 Aug;15(8):921-9 [19633657.001]
  • [Cites] Med Hypotheses. 2009 Nov;73(5):670-81 [19515499.001]
  • [Cites] J Cardiovasc Transl Res. 2009 Sep;2(3):277-85 [19655024.001]
  • [Cites] Diabetologia. 2010 Oct;53(10):2167-76 [20523966.001]
  • [Cites] Lab Invest. 2001 Feb;81(2):231-9 [11232645.001]
  • [Cites] Mol Med. 2001 May;7(5):311-9 [11474577.001]
  • [Cites] Diabetologia. 2001 Jul;44(7):914-22 [11508279.001]
  • [Cites] Histol Histopathol. 2002 Apr;17(2):393-401 [11962743.001]
  • [Cites] Diabetes. 2002 May;51(5):1499-506 [11978648.001]
  • [Cites] Metabolism. 2002 Jun;51(6):765-8 [12037732.001]
  • [Cites] Diabetes Metab Res Rev. 2002 May-Jun;18(3):192-200 [12112937.001]
  • [Cites] Trends Endocrinol Metab. 2002 Jul;13(5):209-14 [12185667.001]
  • [Cites] Nat Med. 2003 Feb;9(2):198-205 [12539039.001]
  • [Cites] Lab Invest. 2003 Feb;83(2):227-39 [12594237.001]
  • [Cites] Trends Immunol. 2003 Nov;24(11):574-9 [14596878.001]
  • [Cites] Ann N Y Acad Sci. 2003 Nov;997:136-49 [14644820.001]
  • [Cites] Diabetes Care. 2004 May;27(5):1194-9 [15111544.001]
  • [Cites] ILAR J. 2004;45(3):237-58 [15229372.001]
  • [Cites] Metabolism. 1966 Jul;15(7):577-81 [5918358.001]
  • [Cites] In Vitro. 1979 Jul;15(7):507-21 [393618.001]
  • [Cites] Am J Physiol. 1984 Jan;246(1 Pt 1):E25-31 [6364830.001]
  • [Cites] Diabete Metab. 1985 Oct;11(5):310-5 [3908179.001]
  • [Cites] Endocrinology. 1996 Aug;137(8):3497-506 [8754779.001]
  • [Cites] Immunol Today. 1996 Oct;17(10):456-60 [8908809.001]
  • [Cites] Autoimmunity. 1996;24(2):113-21 [8986323.001]
  • [Cites] Diabetes. 1997 Apr;46(4):599-606 [9075799.001]
  • [Cites] Diabet Med. 1997 Apr;14(4):327-31 [9113489.001]
  • [Cites] Acta Physiol Scand. 1997 Apr;159(4):303-12 [9146751.001]
  • [Cites] Diabetes Res Clin Pract. 1997 Oct;38(1):9-19 [9347241.001]
  • [Cites] J Autoimmun. 1997 Oct;10(5):461-72 [9376074.001]
  • [Cites] Pediatr Res. 1997 Oct;42(4):489-91 [9380441.001]
  • [Cites] Endocrinology. 1998 Mar;139(3):1115-24 [9492045.001]
  • [Cites] Ann N Y Acad Sci. 1998 May 1;840:480-90 [9629274.001]
  • [Cites] Endocrinology. 1998 Nov;139(11):4540-6 [9794463.001]
  • [Cites] Nat Med. 1999 Jun;5(6):601-4 [10371488.001]
  • [Cites] Diabetes Res Clin Pract. 1999 May;44(2):83-92 [10414926.001]
  • [Cites] Diabetologia. 2004 Oct;47(10):1661-7 [15480539.001]
  • [Cites] Cell Tissue Res. 2004 Dec;318(3):579-89 [15480796.001]
  • [Cites] Diabetes Care. 2005 May;28(5):1207-8 [15855591.001]
  • [Cites] Acta Diabetol. 2005 Mar;42(1):31-5 [15868111.001]
  • [Cites] Proc Soc Exp Biol Med. 1991 Apr;196(4):457-60 [2008443.001]
  • (PMID = 20703437.001).
  • [ISSN] 1614-0575
  • [Journal-full-title] The review of diabetic studies : RDS
  • [ISO-abbreviation] Rev Diabet Stud
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / Insulin; 9007-92-5 / Glucagon; W980KJ009P / Corticosterone
  • [Other-IDs] NLM/ PMC2923379
  •  go-up   go-down


29. Imamov O, Yakimchuk K, Morani A, Schwend T, Wada-Hiraike O, Razumov S, Warner M, Gustafsson JA: Estrogen receptor beta-deficient female mice develop a bladder phenotype resembling human interstitial cystitis. Proc Natl Acad Sci U S A; 2007 Jun 5;104(23):9806-9
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We found that, in the bladders of WT mice, ERbeta is expressed in the basal cell layer of the urothelium.
  • The hyperactivity of T cells may be because of an imbalance between ERalpha and ERbeta signaling in female ERbeta(-/-) mice.

  • Genetic Alliance. consumer health - Interstitial cystitis.
  • MedlinePlus Health Information. consumer health - Interstitial Cystitis.
  • Jackson Laboratory JAX®Mice Database. culture/stock collections - B6.129P2-Esr2<tm1Unc>/J (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Exp Immunol. 1992 Mar;87(3):450-4 [1544229.001]
  • [Cites] J Urol. 1991 Apr;145(4):732-5 [2005689.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11162-6 [8248223.001]
  • [Cites] Br J Urol. 1994 May;73(5):508-15 [8012772.001]
  • [Cites] Urology. 1995 Apr;45(4):587-90 [7716839.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5925-30 [8650195.001]
  • [Cites] Urology. 1996 Nov;48(5):817-21 [8911536.001]
  • [Cites] Urol Res. 1996;24(6):367-73 [9008331.001]
  • [Cites] Immunol Cell Biol. 1997 Feb;75(1):102-6 [9046440.001]
  • [Cites] Int J Immunopharmacol. 1996 Dec;18(12):693-700 [9172012.001]
  • [Cites] J Endocrinol. 1997 Sep;154(3):R13-6 [9379111.001]
  • [Cites] J Urol. 1998 Jan;159(1):83-5 [9400442.001]
  • [Cites] Urology. 1998 Jun;51(6):939-44 [9609630.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15677-82 [9861029.001]
  • [Cites] J Urol. 2005 Apr;173(4):1182-5 [15758737.001]
  • [Cites] Curr Opin Immunol. 2006 Feb;18(1):31-8 [16337364.001]
  • [Cites] J Pathol. 2006 Feb;208(3):408-14 [16294372.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2959-64 [16477031.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 2;103(18):7165-9 [16636272.001]
  • [Cites] Eur J Immunol. 2006 Jul;36(7):1729-38 [16783854.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 Jan;292(1):C106-14 [16837648.001]
  • [Cites] Neurourol Urodyn. 2007;26(2):309-16 [16894621.001]
  • [Cites] Urology. 1999 Dec;54(6):960-3 [10604689.001]
  • [Cites] J Mol Endocrinol. 2000 Feb;24(1):145-55 [10657006.001]
  • [Cites] Int J Urol. 2000 Aug;7(8):292-7 [10976817.001]
  • [Cites] J Immunol. 2002 Feb 15;168(4):1566-71 [11823483.001]
  • [Cites] J Virol. 2002 Jul;76(13):6487-94 [12050361.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15578-83 [12438700.001]
  • [Cites] Eur J Immunol. 2003 Feb;33(2):512-21 [12645950.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 May 27;100(11):6694-9 [12740446.001]
  • [Cites] Bioorg Med Chem Lett. 2003 Jul 21;13(14):2399-403 [12824043.001]
  • [Cites] Int J Urol. 2003 Oct;10 Suppl:S35-8 [14641413.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9375-80 [15187231.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12628-33 [15314222.001]
  • [Cites] Anal Biochem. 1967 Oct;21(1):98-106 [4228891.001]
  • [Cites] Clin Chim Acta. 1972 Oct;41:19-27 [4264813.001]
  • [Cites] Acta Paediatr Scand. 1973 Sep;62(5):481-91 [4271022.001]
  • [Cites] Clin Chem. 1986 Nov;32(11):2073-6 [3096595.001]
  • [Cites] Int Immunol. 1992 Sep;4(9):1049-54 [1356428.001]
  • (PMID = 17522255.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogen Receptor beta; 0 / Glycosaminoglycans; 0 / glucosaminoglycans
  • [Other-IDs] NLM/ PMC1887607
  •  go-up   go-down


30. Babovic D, Jiang L, Gantois I, Lawrence AJ, Ferreri V, Schütz G, Waddington JL, Drago J: Age-related behavioural phenotype and cellular characterisation of mice with progressive ablation of D1 dopamine receptor-expressing cells. Behav Brain Res; 2010 Jan 5;206(1):78-87
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • While MUT mice evidenced hyperactivity over initial exploration at both time points, the topography of hyperactivity shifted.
  • Moreover, initial hyperactivity was sustained over habituation at 12 weeks, but not at 22 weeks.
  • Quantitative autoradiography at 20 weeks revealed loss of D1-like dopamine receptor binding in the entire basal ganglia, with upregulated D2-like binding.
  • Understanding the mechanistic bases of mitigation vs persistence of individual phenotypes in relation to neural adaptation consequent to cell loss may lead to novel therapeutic strategies for basal ganglia disorders.

  • MedlinePlus Health Information. consumer health - Huntington's Disease.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19733597.001).
  • [ISSN] 1872-7549
  • [Journal-full-title] Behavioural brain research
  • [ISO-abbreviation] Behav. Brain Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Receptors, Dopamine D1; 0 / Receptors, Dopamine D2
  •  go-up   go-down


31. Briot A, Deraison C, Lacroix M, Bonnart C, Robin A, Besson C, Dubus P, Hovnanian A: Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome. J Exp Med; 2009 May 11;206(5):1135-47
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lack of LEKTI causes stratum corneum detachment secondary to epidermal proteases hyperactivity.
  • This proinflammatory and proallergic pathway is independent of the primary epithelial failure and is activated under basal conditions in NS keratinocytes.
  • This cell-autonomous process is already established in the epidermis of Spink5(-/-) embryos, and the resulting proinflammatory microenvironment leads to eosinophilic and mast cell infiltration in a skin graft model in nude mice.


32. Palomero-Gallagher N, Schleicher A, Lindemann S, Lessenich A, Zilles K, Löscher W: Receptor fingerprinting the circling ci2 rat mutant: insights into brain asymmetry and motor control. Exp Neurol; 2008 Apr;210(2):624-37

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since it is more likely that imbalances in several neurotransmitter systems result in the cascade of neurochemical disturbances underlying disorders involving motor dysfunctions, we measured the densities of 12 neurotransmitter receptors in the basal ganglia and vestibular nuclei of adult circling mutants (ci2/ci2), non-circling littermates (ci2/+) and controls from the background strain (LEW/Ztm).
  • Hyperactivity level of mutants was positively correlated with the adenosine A2A receptor densities in the ipsilateral Acb, but negatively correlated with those of the ipsilateral thalamus.
  • [MeSH-major] Behavior, Animal / physiology. Brain / pathology. Hyperkinesis. Peptide Mapping / methods. Rats, Mutant Strains / abnormalities. Receptors, Cell Surface / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18255063.001).
  • [ISSN] 0014-4886
  • [Journal-full-title] Experimental neurology
  • [ISO-abbreviation] Exp. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Cell Surface
  •  go-up   go-down


33. Zhang J, Guan Z: Pathways involved in somatosensory electrical modulation of dorsal cochlear nucleus activity. Brain Res; 2007 Dec 12;1184:121-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our recent study has shown that somatosensory electrical stimulation may be useful to modulate sound-induced hyperactivity in the dorsal cochlear nucleus (DCN), a neural correlate of certain forms of tinnitus.
  • To address this issue, we conducted c-fos immunocytochemistry using hamsters and mapped neural activation in both auditory and non-auditory structures following transcutaneous electrical stimulation of the basal part of the pinna.
  • [MeSH-minor] Animals. Cell Count / methods. Cricetinae. Electric Stimulation / methods. Male. Mesocricetus. Neurons / metabolism. Proto-Oncogene Proteins c-fos / metabolism. Stilbamidines / metabolism. Trigeminal Nuclei / metabolism. Trigeminal Nuclei / radiation effects. Wheat Germ Agglutinin-Horseradish Peroxidase Conjugate / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17964553.001).
  • [ISSN] 0006-8993
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / 2-hydroxy-4,4'-diamidinostilbene, methanesulfonate salt; 0 / Proto-Oncogene Proteins c-fos; 0 / Stilbamidines; 0 / Wheat Germ Agglutinin-Horseradish Peroxidase Conjugate
  •  go-up   go-down


34. Surucu B, Bozulic L, Hynx D, Parcellier A, Hemmings BA: In vivo analysis of protein kinase B (PKB)/Akt regulation in DNA-PKcs-null mice reveals a role for PKB/Akt in DNA damage response and tumorigenesis. J Biol Chem; 2008 Oct 31;283(44):30025-33
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To address this, we analyzed basal, insulin-induced, and DNA damage-induced PKB Ser-473 phosphorylation in DNA-PK catalytic subunit-null DNA-PKcs(-/-) mice.
  • Moreover, DNA-PKcs(-/-) mice showed a tissue-specific increase in basal PKB phosphorylation.
  • In particular, persistent PKB hyperactivity in the thymus apparently contributed to spontaneous lymphomagenesis in DNA-PKcs(-/-) mice.


35. Borchhardt KA, Hörl WH, Sunder-Plassmann G: Reversibility of 'secondary hypercalcitoninemia' after kidney transplantation. Am J Transplant; 2005 Jul;5(7):1757-63
Hazardous Substances Data Bank. Calcitonin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We examined the effect of kidney transplantation on basal and pentagastrin-stimulated CT in CKD patients with elevated screening CT levels.
  • Before transplantation, the median basal CT concentration of 17 patients was 31 pg/mL (13-76), and decreased to 8 pg/mL (4-28) at 23 months (2-34) after kidney transplantation (p < 0.00005).
  • Therefore, the increase of CT concentration in patients with impaired kidney function presumably reflects 'secondary hypercalcitoninemia' due to C-cell hyperactivity.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • Hazardous Substances Data Bank. PENTAGASTRIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15943636.001).
  • [ISSN] 1600-6135
  • [Journal-full-title] American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • [ISO-abbreviation] Am. J. Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 9007-12-9 / Calcitonin; AYI8EX34EU / Creatinine; EF0NX91490 / Pentagastrin
  •  go-up   go-down


36. Braunstein KE, Eschbach J, Ròna-Vörös K, Soylu R, Mikrouli E, Larmet Y, René F, Gonzalez De Aguilar JL, Loeffler JP, Müller HP, Bucher S, Kaulisch T, Niessen HG, Tillmanns J, Fischer K, Schwalenstöcker B, Kassubek J, Pichler B, Stiller D, Petersen A, Ludolph AC, Dupuis L: A point mutation in the dynein heavy chain gene leads to striatal atrophy and compromises neurite outgrowth of striatal neurons. Hum Mol Genet; 2010 Nov 15;19(22):4385-98
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The molecular motor dynein and its associated regulatory subunit dynactin have been implicated in several neurodegenerative conditions of the basal ganglia, such as Huntington's disease (HD) and Perry syndrome, an atypical Parkinson-like disease.
  • However, dynactin is also able to act independently of dynein, and there is currently no direct evidence linking dynein to basal ganglia degeneration.
  • These mice exhibited motor and behavioural abnormalities including hindlimb clasping, early muscle weakness, incoordination and hyperactivity.
  • Our study supports a role for dynein dysfunction in the pathogenesis of neurodegenerative disorders of the basal ganglia, such as Perry syndrome and HD.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOPAMINE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Cell Biol. 2000 Jan;2(1):20-4 [10620802.001]
  • [Cites] Neuroimage. 2009 Jan 1;44(1):43-50 [18691659.001]
  • [Cites] J Neurosci. 2000 Apr 1;20(7):2439-50 [10729324.001]
  • [Cites] Nat Cell Biol. 2000 Nov;2(11):776-83 [11056531.001]
  • [Cites] Behav Brain Res. 2001 Nov 29;126(1-2):185-95 [11704263.001]
  • [Cites] Neuron. 2002 May 30;34(5):715-27 [12062019.001]
  • [Cites] Mov Disord. 2002 Jul;17(4):748-57 [12210870.001]
  • [Cites] J Neurosci. 2002 Sep 15;22(18):8266-76 [12223581.001]
  • [Cites] Nat Genet. 2003 Apr;33(4):455-6 [12627231.001]
  • [Cites] Science. 2003 May 2;300(5620):808-12 [12730604.001]
  • [Cites] Adv Drug Deliv Rev. 2003 Nov 14;55(11):1385-403 [14597137.001]
  • [Cites] Brain Res. 2004 Apr 16;1005(1-2):29-35 [15044061.001]
  • [Cites] J Neurosci. 2004 Apr 28;24(17):4250-8 [15115821.001]
  • [Cites] Cell. 2004 Jul 9;118(1):127-38 [15242649.001]
  • [Cites] Neurology. 2004 Aug 24;63(4):724-6 [15326253.001]
  • [Cites] Cell. 2004 Oct 1;119(1):121-35 [15454086.001]
  • [Cites] Anat Rec. 1991 Dec;231(4):482-97 [1793176.001]
  • [Cites] J Cell Biol. 1993 Dec;123(6 Pt 1):1373-87 [8253838.001]
  • [Cites] Nature. 1995 Nov 23;378(6555):398-402 [7477378.001]
  • [Cites] Neuroimage. 1996 Dec;4(3 Pt 1):153-8 [9345505.001]
  • [Cites] J Neurosci. 1998 Feb 15;18(4):1261-9 [9454836.001]
  • [Cites] Nat Genet. 1998 Oct;20(2):198-202 [9771716.001]
  • [Cites] Ann Neurol. 2005 May;57(5):687-94 [15852399.001]
  • [Cites] J Cell Biol. 2005 May 23;169(4):561-7 [15911875.001]
  • [Cites] J Nucl Med. 2005 Jun;46(6):964-72 [15937307.001]
  • [Cites] Nat Genet. 2005 Jul;37(7):771-6 [15980862.001]
  • [Cites] Exp Neurol. 2009 Jan;215(1):146-52 [18952079.001]
  • [Cites] Exp Neurol. 2006 Mar;198(1):271-4 [16427626.001]
  • [Cites] Nat Genet. 2009 Feb;41(2):163-5 [19136952.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2647-52 [19196984.001]
  • [Cites] PLoS One. 2009;4(4):e5292 [19390590.001]
  • [Cites] Mol Endocrinol. 2009 May;23(5):620-9 [19228793.001]
  • [Cites] Nat Neurosci. 2009 Jul;12(7):864-71 [19525941.001]
  • [Cites] J Neurosci. 2009 Aug 5;29(31):9903-17 [19657041.001]
  • [Cites] J Neurosci. 2009 Oct 14;29(41):12776-86 [19828789.001]
  • [Cites] J Neurosci. 2009 Nov 25;29(47):14752-63 [19940170.001]
  • [Cites] J Biol Chem. 2009 Dec 4;284(49):34103-15 [19815545.001]
  • [Cites] J Neurol Sci. 2010 Feb 15;289(1-2):149-54 [19732908.001]
  • [Cites] J Neurosci. 2010 Feb 3;30(5):1739-49 [20130183.001]
  • [Cites] Nat Rev Neurosci. 2010 May;11(5):316-28 [20404840.001]
  • [Cites] Int J Dev Neurosci. 2006 Apr-May;24(2-3):103-11 [16406469.001]
  • [Cites] J Cell Biol. 2006 Feb 27;172(5):733-45 [16505168.001]
  • [Cites] EMBO J. 2006 Sep 20;25(18):4372-80 [16957779.001]
  • [Cites] Cell Metab. 2006 Nov;4(5):349-62 [17055784.001]
  • [Cites] Biochim Biophys Acta. 2006 Nov-Dec;1762(11-12):1094-108 [16730956.001]
  • [Cites] Traffic. 2007 Feb;8(2):124-9 [17181772.001]
  • [Cites] J Biol Chem. 2007 Mar 9;282(10):7352-9 [17209049.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4182-7 [17360497.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10045-50 [17548833.001]
  • [Cites] Neuron. 2007 Jul 5;55(1):53-68 [17610817.001]
  • [Cites] J Neurosci. 2007 Dec 19;27(51):13982-90 [18094236.001]
  • [Cites] J Neurosci. 2007 Dec 26;27(52):14515-24 [18160659.001]
  • [Cites] J Neurosci. 2008 Feb 27;28(9):1997-2005 [18305234.001]
  • [Cites] Orphanet J Rare Dis. 2008;3:7 [18348718.001]
  • [Cites] Hum Mol Genet. 2008 Jul 1;17(13):1946-55 [18364389.001]
  • [Cites] J Neurochem. 2008 Jul;106(1):83-95 [18346199.001]
  • [Cites] Cell Cycle. 2008 Jul 15;7(14):2241-8 [18635969.001]
  • [Cites] Hum Mol Genet. 2008 Sep 1;17(17):2595-609 [18502785.001]
  • [Cites] Hum Mol Genet. 2008 Sep 15;17(18):2849-62 [18579581.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Aug 26;105(34):12599-604 [18719118.001]
  • [Cites] Nat Cell Biol. 2008 Oct;10(10):1172-80 [18758451.001]
  • [Cites] Nat Cell Biol. 2008 Oct;10(10):1164-71 [18758452.001]
  • [Cites] J Neurosci. 2008 Oct 22;28(43):10814-24 [18945889.001]
  • [Cites] J Cereb Blood Flow Metab. 2000 Mar;20(3):423-51 [10724107.001]
  • (PMID = 20807776.001).
  • [ISSN] 1460-2083
  • [Journal-full-title] Human molecular genetics
  • [ISO-abbreviation] Hum. Mol. Genet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Microtubule-Associated Proteins; 0 / Receptors, Dopamine D2; 144198-36-7 / dynactin; EC 3.6.4.2 / Dyneins; VTD58H1Z2X / Dopamine
  • [Other-IDs] NLM/ PMC3298848
  •  go-up   go-down


37. Le Masurier M, Oldenzeil W, Lehman C, Cowen P, Sharp T: Effect of acute tyrosine depletion in using a branched chain amino-acid mixture on dopamine neurotransmission in the rat brain. Neuropsychopharmacology; 2006 Feb;31(2):310-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In microdialysis experiments this amino-acid mixture reduced basal and amphetamine-evoked striatal dopamine release, as well as amphetamine-induced hyperactivity.
  • [MeSH-minor] 3,4-Dihydroxyphenylacetic Acid / metabolism. 5-Hydroxytryptophan / metabolism. Amphetamine / pharmacology. Analysis of Variance. Animals. Behavior, Animal / drug effects. Catecholamines / metabolism. Cell Count / methods. Dopamine Agents / pharmacology. Dose-Response Relationship, Drug. Drug Interactions. Immunohistochemistry / methods. Male. Microdialysis / methods. Motor Activity / drug effects. Oncogene Proteins v-fos / metabolism. Rats. Rats, Sprague-Dawley. Serotonin / metabolism. Time Factors

  • Hazardous Substances Data Bank. AMPHETAMINE .
  • Hazardous Substances Data Bank. DOPAMINE .
  • Hazardous Substances Data Bank. 5-HYDROXYTRYPTOPHAN .
  • Hazardous Substances Data Bank. L-TYROSINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16034439.001).
  • [ISSN] 0893-133X
  • [Journal-full-title] Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
  • [ISO-abbreviation] Neuropsychopharmacology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amino Acids, Branched-Chain; 0 / Catecholamines; 0 / Dopamine Agents; 0 / Oncogene Proteins v-fos; 102-32-9 / 3,4-Dihydroxyphenylacetic Acid; 333DO1RDJY / Serotonin; 42HK56048U / Tyrosine; C1LJO185Q9 / 5-Hydroxytryptophan; CK833KGX7E / Amphetamine; VTD58H1Z2X / Dopamine
  •  go-up   go-down


38. Windels F, Carcenac C, Poupard A, Savasta M: Pallidal origin of GABA release within the substantia nigra pars reticulata during high-frequency stimulation of the subthalamic nucleus. J Neurosci; 2005 May 18;25(20):5079-86
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Basal levels of Glu and GABA in the GP and SNr were significantly higher in hemiparkinsonian than in intact rats.
  • These results provide neurochemical confirmation of the hyperactivity of the STN after dopaminergic denervation and suggest that the therapeutic effects of HFS-STN may result partly from the stimulation of pallidonigral fibers, thereby revealing a potential role for pallidal GABA in the inhibition of basal ganglial output structures during HFS-STN.
  • [MeSH-minor] Animals. Cell Count / methods. Chromatography, High Pressure Liquid / methods. Dose-Response Relationship, Radiation. Electrochemistry / methods. Electrodes. Functional Laterality. Glutamic Acid / metabolism. Immunohistochemistry / methods. Male. Microdialysis / methods. Oxidopamine / toxicity. Rats. Rats, Sprague-Dawley. Tyrosine 3-Monooxygenase / metabolism

  • Hazardous Substances Data Bank. GLUTAMIC ACID HYDROCHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15901790.001).
  • [ISSN] 1529-2401
  • [Journal-full-title] The Journal of neuroscience : the official journal of the Society for Neuroscience
  • [ISO-abbreviation] J. Neurosci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 3KX376GY7L / Glutamic Acid; 56-12-2 / gamma-Aminobutyric Acid; 8HW4YBZ748 / Oxidopamine; EC 1.14.16.2 / Tyrosine 3-Monooxygenase
  •  go-up   go-down


39. Steiner MA, Marsicano G, Nestler EJ, Holsboer F, Lutz B, Wotjak CT: Antidepressant-like behavioral effects of impaired cannabinoid receptor type 1 signaling coincide with exaggerated corticosterone secretion in mice. Psychoneuroendocrinology; 2008 Jan;33(1):54-67
Hazardous Substances Data Bank. DESIPRAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hypothalamic-pituitary-adrenocortical (HPA) axis hyperactivity is associated with major depressive disorders, and treatment with classical antidepressants ameliorates not only psychopathological symptoms, but also the dysregulation of the HPA axis.
  • We demonstrate that the genetic inactivation of CB1 is accompanied by increased plasma corticosterone levels both under basal conditions and at different time points following exposure to the FST.

  • MedlinePlus Health Information. consumer health - Depression.
  • MedlinePlus Health Information. consumer health - Stress.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuropsychopharmacology. 2000 Nov;23(5):477-501 [11027914.001]
  • [Cites] Pharmacogenomics J. 2008 Jun;8(3):196-208 [17684478.001]
  • [Cites] Mol Psychiatry. 2002;7(3):254-75 [11920153.001]
  • [Cites] J Neurosci. 2002 Apr 15;22(8):3262-8 [11943827.001]
  • [Cites] Nature. 2002 Aug 1;418(6897):530-4 [12152079.001]
  • [Cites] Eur J Neurosci. 2002 Oct;16(7):1395-8 [12405999.001]
  • [Cites] Br J Pharmacol. 2003 Feb;138(4):544-53 [12598408.001]
  • [Cites] Int J Obes Relat Metab Disord. 2003 Mar;27(3):289-301 [12629555.001]
  • [Cites] Behav Pharmacol. 2003 Dec;14(8):573-82 [14665974.001]
  • [Cites] Neuroendocrinology. 2003 Dec;78(6):294-300 [14688442.001]
  • [Cites] Eur J Neurosci. 1999 Dec;11(12):4213-25 [10594647.001]
  • [Cites] Eur J Neurosci. 2004 Apr;19(7):1906-12 [15078564.001]
  • [Cites] Neuropharmacology. 2004 Jun;46(7):966-73 [15081793.001]
  • [Cites] Cell Mol Life Sci. 2004 Apr;61(7-8):945-50 [15095014.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11851-6 [15280545.001]
  • [Cites] Life Sci. 2004 Oct 29;75(24):2959-70 [15454346.001]
  • [Cites] Eur J Biochem. 1995 Aug 15;232(1):54-61 [7556170.001]
  • [Cites] Endocrinology. 1997 Aug;138(8):3476-85 [9231802.001]
  • [Cites] Neuroscience. 1998 Feb;82(4):1131-49 [9466436.001]
  • [Cites] Brain Res. 1999 Aug 21;839(1):173-9 [10482810.001]
  • [Cites] J Neuroendocrinol. 1999 Nov;11(11):873-8 [10520138.001]
  • [Cites] Endocrinology. 2004 Dec;145(12):5431-8 [15331569.001]
  • [Cites] Biol Psychiatry. 2005 Feb 1;57(3):261-7 [15691527.001]
  • [Cites] Nat Rev Neurosci. 2005 Jun;6(6):463-75 [15891777.001]
  • [Cites] Nat Rev Drug Discov. 2005 Sep;4(9):775-90 [16138108.001]
  • [Cites] Behav Pharmacol. 2005 Sep;16(5-6):333-52 [16148438.001]
  • [Cites] Behav Pharmacol. 2005 Sep;16(5-6):431-40 [16148448.001]
  • [Cites] Eur Neuropsychopharmacol. 2005 Dec;15(6):593-9 [15916883.001]
  • [Cites] Trends Pharmacol Sci. 2005 Dec;26(12):609-17 [16260047.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18620-5 [16352709.001]
  • [Cites] Endocr Rev. 2006 Feb;27(1):73-100 [16306385.001]
  • [Cites] Handb Exp Pharmacol. 2005;(168):299-325 [16596779.001]
  • [Cites] J Endocrinol Invest. 2006;29(3 Suppl):27-46 [16751707.001]
  • [Cites] Annu Rev Neurosci. 2006;29:37-76 [16776579.001]
  • [Cites] Eur J Pharmacol. 2006 Dec 3;551(1-3):162-7 [17030030.001]
  • [Cites] Neuropsychopharmacology. 2006 Dec;31(12):2591-9 [16710317.001]
  • [Cites] Eur J Pharmacol. 2007 Jan 12;554(2-3):155-63 [17116301.001]
  • [Cites] Endocrinology. 2007 Apr;148(4):1574-81 [17194743.001]
  • [Cites] Biol Psychiatry. 2007 Jul 1;62(1):47-54 [17123470.001]
  • [Cites] Biol Psychiatry. 2007 Nov 15;62(10):1103-10 [17511970.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jun;86(6):2687-96 [11397872.001]
  • (PMID = 17976922.001).
  • [ISSN] 0306-4530
  • [Journal-full-title] Psychoneuroendocrinology
  • [ISO-abbreviation] Psychoneuroendocrinology
  • [Language] ENG
  • [Grant] United States / NIMH NIH HHS / MH / MH066172-01; United States / NIMH NIH HHS / MH / P50 MH066172; United States / NIMH NIH HHS / MH / P50 MH066172-01
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antidepressive Agents, Tricyclic; 0 / Piperidines; 0 / Pyrazoles; 0 / Receptor, Cannabinoid, CB1; 158681-13-1 / rimonabant; TG537D343B / Desipramine; W980KJ009P / Corticosterone
  • [Other-IDs] NLM/ NIHMS38680; NLM/ PMC2267923
  •  go-up   go-down


40. O'Mahony A, Raber J, Montano M, Foehr E, Han V, Lu SM, Kwon H, LeFevour A, Chakraborty-Sett S, Greene WC: NF-kappaB/Rel regulates inhibitory and excitatory neuronal function and synaptic plasticity. Mol Cell Biol; 2006 Oct;26(19):7283-98
SciCrunch. Marmoset Gene list: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • IkappaBalpha-SR expression also results in diminished basal GluR1 levels and impaired synaptic strength (input/output function), both of which are fully restored following activity-based task learning.
  • Consistent with diminished GAD65-derived inhibitory tone and enhanced excitatory firing, IkappaBalpha-SR+ mice exhibit increased late-phase long-term potentiation, hyperactivity, seizures, increased exploratory activity, and enhanced spatial learning and memory.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GLUTAMIC ACID HYDROCHLORIDE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Neurosci. 1987;10:131-61 [3032063.001]
  • [Cites] Behav Neurosci. 1988 Jun;102(3):356-62 [3395447.001]
  • [Cites] Neuron. 1991 Jul;7(1):91-100 [2069816.001]
  • [Cites] Neurochem Res. 1991 Mar;16(3):215-26 [1780024.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5547-51 [1319065.001]
  • [Cites] Science. 1993 Mar 26;259(5103):1912-5 [8096091.001]
  • [Cites] J Neurosci Res. 1993 Apr 15;34(6):689-706 [8315667.001]
  • [Cites] Mech Dev. 1993 Oct;43(2-3):135-47 [8297787.001]
  • [Cites] Science. 1995 Mar 10;267(5203):1485-8 [7878466.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Oct 10;92(21):9618-22 [7568184.001]
  • [Cites] Mol Cell Biol. 1995 Oct;15(10):5339-45 [7565683.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9077-81 [7568076.001]
  • [Cites] Curr Opin Neurobiol. 1996 Apr;6(2):264-8 [8725970.001]
  • [Cites] Brain Res Mol Brain Res. 1996 Jun;38(2):179-90 [8793106.001]
  • [Cites] Cereb Cortex. 2005 Mar;15(3):291-8 [15238431.001]
  • [Cites] Curr Opin Neurobiol. 2005 Feb;15(1):21-8 [15721740.001]
  • [Cites] Nat Neurosci. 2005 Jun;8(6):759-67 [15880109.001]
  • [Cites] Brain Res. 2005 Jun 21;1047(2):233-44 [15907811.001]
  • [Cites] Trends Neurosci. 2005 Aug;28(8):436-45 [15982754.001]
  • [Cites] Mol Cell Biol. 2006 Apr;26(8):2936-46 [16581769.001]
  • [Cites] Nat Neurosci. 2006 Jul;9(7):887-95 [16732277.001]
  • [Cites] Biochem Biophys Res Commun. 1996 Dec 24;229(3):891-5 [8954991.001]
  • [Cites] Trends Neurosci. 1997 Jun;20(6):252-8 [9185306.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12911-6 [10536022.001]
  • [Cites] Synapse. 2000 Feb;35(2):151-9 [10611641.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 1999 Dec 29;354(1392):2027-52 [10670023.001]
  • [Cites] Brain Res. 2000 Feb 14;855(2):274-81 [10677600.001]
  • [Cites] Nat Neurosci. 2000 Mar;3(3):238-44 [10700255.001]
  • [Cites] Nature. 2000 Mar 23;404(6776):352-4 [10746713.001]
  • [Cites] Nat Med. 2000 May;6(5):573-7 [10802715.001]
  • [Cites] J Neurosci. 2000 Jun 1;20(11):3993-4001 [10818134.001]
  • [Cites] J Neurophysiol. 2000 Jul;84(1):390-400 [10899213.001]
  • [Cites] J Clin Invest. 2001 Feb;107(3):247-54 [11160145.001]
  • [Cites] Nat Rev Neurosci. 2001 Jan;2(1):11-23 [11253355.001]
  • [Cites] Nat Rev Neurosci. 2001 Mar;2(3):185-93 [11256079.001]
  • [Cites] Epilepsia. 2001;42 Suppl 3:8-12 [11520315.001]
  • [Cites] Neuroscience. 2002;111(4):853-62 [12031408.001]
  • [Cites] Neuroscience. 2002;112(1):161-72 [12044481.001]
  • [Cites] Neuron. 2002 May 30;34(5):807-20 [12062026.001]
  • [Cites] Biosci Rep. 2001 Oct;21(5):565-611 [12168768.001]
  • [Cites] J Mol Neurosci. 2002 Aug-Oct;19(1-2):171-7 [12212777.001]
  • [Cites] Brain Behav Immun. 1996 Jun;10(2):126-38 [8811936.001]
  • [Cites] Hippocampus. 1996;6(4):347-470 [8915675.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11451-5 [9326630.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):14060-5 [9391152.001]
  • [Cites] Genes Dev. 1998 Apr 1;12(7):968-81 [9531535.001]
  • [Cites] J Neurochem. 1998 May;70(5):1876-86 [9572271.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):7097-102 [9618545.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12580-5 [9770528.001]
  • [Cites] Science. 1998 Nov 20;282(5393):1504-8 [9822384.001]
  • [Cites] Trends Pharmacol Sci. 1998 Dec;19(12):500-5 [9871412.001]
  • [Cites] Exp Brain Res. 1999 Jan;124(2):215-22 [9928844.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1698-703 [9990087.001]
  • [Cites] Cancer Res. 1999 Jul 15;59(14):3299-303 [10416581.001]
  • [Cites] Nature. 1999 Sep 2;401(6748):63-9 [10485705.001]
  • [Cites] Exp Neurol. 2002 Aug;176(2):277-88 [12359170.001]
  • [Cites] Science. 2002 Oct 18;298(5593):556-62 [12386325.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14500-5 [12391294.001]
  • [Cites] Nat Rev Neurosci. 2002 Dec;3(12):921-31 [12461549.001]
  • [Cites] Neurobiol Dis. 2002 Oct;11(1):199-213 [12460558.001]
  • [Cites] Neuroscientist. 2002 Dec;8(6):562-73 [12467378.001]
  • [Cites] Neurobiol Learn Mem. 2002 Nov;78(3):508-27 [12559831.001]
  • [Cites] Mol Cell Biol. 2003 Apr;23(8):2680-98 [12665571.001]
  • [Cites] Mol Neurobiol. 2003 Feb;27(1):99-106 [12668903.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2003 Apr 29;358(1432):721-6 [12740118.001]
  • [Cites] J Neurosci. 2003 Aug 6;23(18):7183-93 [12904479.001]
  • [Cites] CNS Spectr. 2003 Aug;8(8):597-610 [12907923.001]
  • [Cites] Nat Neurosci. 2003 Oct;6(10):1072-8 [12947408.001]
  • [Cites] J Neurosci. 2003 Oct 15;23(28):9403-8 [14561868.001]
  • [Cites] Sci Am. 2004 Apr;290(4):54-61 [15045754.001]
  • [Cites] Neuroscience. 2004;126(1):163-71 [15145082.001]
  • [Cites] Neurobiol Dis. 2004 Aug;16(3):527-37 [15262264.001]
  • [Cites] Restor Neurol Neurosci. 2004;22(2):121-30 [15272146.001]
  • [Cites] Behav Brain Res. 2004 Oct 5;154(2):577-84 [15313047.001]
  • [Cites] Hippocampus. 2004;14(6):677-83 [15318326.001]
  • [Cites] Neuron. 2004 Sep 30;44(1):59-73 [15450160.001]
  • [Cites] EMBO J. 2004 Oct 13;23(20):4096-105 [15457210.001]
  • [Cites] Dev Biol. 1980 Mar 15;75(2):454-9 [6989691.001]
  • (PMID = 16980629.001).
  • [ISSN] 0270-7306
  • [Journal-full-title] Molecular and cellular biology
  • [ISO-abbreviation] Mol. Cell. Biol.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / C06 RR018928; United States / NIA NIH HHS / AG / R01 AG020904; United States / NIA NIH HHS / AG / AG 20904
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / I-kappa B Proteins; 0 / Isoenzymes; 0 / RNA, Messenger; 0 / Receptors, AMPA; 0 / Transcription Factor RelA; 0 / glutamate receptor ionotropic, AMPA 1; 139874-52-5 / NF-kappaB inhibitor alpha; 3KX376GY7L / Glutamic Acid; 56-12-2 / gamma-Aminobutyric Acid; EC 4.1.1.15 / Glutamate Decarboxylase; EC 4.1.1.15 / glutamate decarboxylase 2
  • [Other-IDs] NLM/ PMC1592877
  •  go-up   go-down


41. Barlow PW, Kurczyńska EU: The anatomy of the chi-chi of Ginkgo biloba suggests a mode of elongation growth that is an alternative to growth driven by an apical meristem. J Plant Res; 2007 Mar;120(2):269-80

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Towards the base of the chi-chi, the fusiform cells and young tracheids were aligned parallel to the axis, indicating that the orientation of the cambial cells in basal regions of the chi-chi gradually became normalised as the tip of the chi-chi extended forwards.
  • Nevertheless, in such basal sites, tracheids near the centre of the chi-chi showed variable orientations in accordance with their mode of formation during the early stages of chi-chi development.
  • The initiation of a chi-chi is proposed to derive from a localised hyperactivity of vascular cambial-cell production in the supporting stem.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17171395.001).
  • [ISSN] 0918-9440
  • [Journal-full-title] Journal of plant research
  • [ISO-abbreviation] J. Plant Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


42. Demura M, Bulun SE: CpG dinucleotide methylation of the CYP19 I.3/II promoter modulates cAMP-stimulated aromatase activity. Mol Cell Endocrinol; 2008 Feb 13;283(1-2):127-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aromatase promoter I.3/II, regulated by a cAMP response element (CRE), is normally quiescent in human skin fibroblasts, whereas its hyperactivity may cause local or systemic estrogen excess.
  • Basal and cAMP-stimulated aromatase activity and promoter I.3/II activation were significantly higher in the presence of unmethylated DNA.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18201819.001).
  • [ISSN] 0303-7207
  • [Journal-full-title] Molecular and cellular endocrinology
  • [ISO-abbreviation] Mol. Cell. Endocrinol.
  • [Language] eng
  • [Grant] United States / PHS HHS / / C67167
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Cyclic AMP Response Element-Binding Protein; 0 / RNA, Messenger; E0399OZS9N / Cyclic AMP; EC 1.14.14.1 / Aromatase
  •  go-up   go-down


43. Zhou L, Gall D, Qu Y, Prigogine C, Cheron G, Tissir F, Schiffmann SN, Goffinet AM: Maturation of "neocortex isole" in vivo in mice. J Neurosci; 2010 Jun 9;30(23):7928-39
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we show that Celsr3|Dlx mutant mice have no extrinsic neocortical connections yet survive to postnatal day 20, acquire a basic behavioral repertoire, and display spontaneous hyperactivity, with abnormal light/dark activity cycling.
  • Deep layer neurons were reduced in number, and their apical and basal dendritic arbors were blunted, with reduced synapse density.
  • [MeSH-minor] Animals. Cadherins / genetics. Cadherins / metabolism. Electrophysiology. Homeodomain Proteins / genetics. Homeodomain Proteins / metabolism. Immunohistochemistry. In Situ Hybridization. Interneurons / physiology. Locomotion / physiology. Mice. Mice, Transgenic. Mutation. Patch-Clamp Techniques. Receptors, Cell Surface / genetics. Receptors, Cell Surface / metabolism. Transcription Factors / genetics. Transcription Factors / metabolism

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20534841.001).
  • [ISSN] 1529-2401
  • [Journal-full-title] The Journal of neuroscience : the official journal of the Society for Neuroscience
  • [ISO-abbreviation] J. Neurosci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cadherins; 0 / Celsr3 protein, mouse; 0 / Distal-less homeobox proteins; 0 / Homeodomain Proteins; 0 / Receptors, Cell Surface; 0 / Transcription Factors
  •  go-up   go-down


44. Rondou P, Haegeman G, Vanhoenacker P, Van Craenenbroeck K: BTB Protein KLHL12 targets the dopamine D4 receptor for ubiquitination by a Cul3-based E3 ligase. J Biol Chem; 2008 Apr 25;283(17):11083-96
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The D4 receptor has a remarkable polymorphism in its third intracellular loop, which is under intensive investigation and which has been associated with, among other conditions, attention deficit hyperactivity disorder.
  • In addition, we show that also other dopamine receptor subtypes undergo basal ubiquitination, but this is not affected by KLHL12.

  • SciCrunch. OMIM: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Biophys Res Commun. 1997 Sep 18;238(2):590-4 [9299557.001]
  • [Cites] Nature. 1992 Jul 9;358(6382):149-52 [1319557.001]
  • [Cites] Biochemistry. 1998 Nov 10;37(45):15726-36 [9843378.001]
  • [Cites] J Comp Neurol. 1998 Dec 21;402(3):353-71 [9853904.001]
  • [Cites] Neuropsychopharmacology. 1999 Jul;21(1):3-16 [10379515.001]
  • [Cites] Trends Biochem Sci. 2004 Dec;29(12):634-7 [15544948.001]
  • [Cites] Mol Cell Biol. 2004 Dec;24(24):10941-53 [15572695.001]
  • [Cites] Mol Cell Biol. 2005 Jan;25(1):162-71 [15601839.001]
  • [Cites] J Biol Chem. 2005 Apr 22;280(16):16076-87 [15708858.001]
  • [Cites] J Biol Chem. 2005 May 13;280(19):19350-7 [15755724.001]
  • [Cites] J Biol Chem. 2005 Aug 26;280(34):30091-9 [15983046.001]
  • [Cites] Nat Cell Biol. 2006 Apr;8(4):348-57 [16547521.001]
  • [Cites] Mol Psychiatry. 2006 Aug;11(8):782-6 [16619053.001]
  • [Cites] Cell Signal. 2007 Feb;19(2):278-88 [16935469.001]
  • [Cites] J Cell Biol. 2007 Jun 4;177(5):905-16 [17535965.001]
  • [Cites] Neurosci Biobehav Rev. 2000 Jan;24(1):125-32 [10654668.001]
  • [Cites] Jpn J Pharmacol. 2000 Jan;82(1):1-14 [10874582.001]
  • [Cites] Eur J Pharmacol. 2000 Sep 29;405(1-3):303-27 [11033337.001]
  • [Cites] Eur J Pharmacol. 2000 Dec 27;410(2-3):183-203 [11134669.001]
  • [Cites] J Biol Chem. 2001 Apr 13;276(15):12345-55 [11152677.001]
  • [Cites] J Biol Chem. 2001 Feb 9;276(6):4416-23 [11054417.001]
  • [Cites] Science. 2001 Nov 9;294(5545):1307-13 [11588219.001]
  • [Cites] J Biol Chem. 2001 Dec 7;276(49):45509-12 [11641392.001]
  • [Cites] Physiol Rev. 2002 Apr;82(2):373-428 [11917093.001]
  • [Cites] Mol Endocrinol. 2003 Sep;17(9):1777-91 [12805411.001]
  • [Cites] Nature. 2003 Sep 18;425(6955):311-6 [13679921.001]
  • [Cites] Nature. 2003 Sep 18;425(6955):316-21 [13679922.001]
  • [Cites] Endocrinology. 2003 Oct;144(10):4393-402 [12960054.001]
  • [Cites] Mol Cell. 2003 Sep;12(3):783-90 [14527422.001]
  • [Cites] Nat Cell Biol. 2003 Nov;5(11):1001-7 [14528312.001]
  • [Cites] Nat Cell Biol. 2003 Nov;5(11):950-1 [14593416.001]
  • [Cites] Dev Cell. 2003 Nov;5(5):709-22 [14602072.001]
  • [Cites] J Biol Chem. 2003 Nov 14;278(46):45954-9 [12960162.001]
  • [Cites] EMBO J. 2004 Apr 21;23(8):1681-7 [15071497.001]
  • [Cites] Annu Rev Neurosci. 2004;27:223-46 [15217332.001]
  • [Cites] Mol Cell Biol. 2004 Aug;24(16):7130-9 [15282312.001]
  • [Cites] Mol Cell Biol. 2004 Oct;24(19):8477-86 [15367669.001]
  • [Cites] Exp Cell Res. 2004 Oct 15;300(1):72-83 [15383316.001]
  • [Cites] Physiol Rev. 1998 Jan;78(1):189-225 [9457173.001]
  • (PMID = 18303015.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / CUL3 protein, human; 0 / Cullin Proteins; 0 / KLHL12 protein, human; 0 / KLHL12 protein, mouse; 0 / Microfilament Proteins; 0 / Receptors, Dopamine; 137750-34-6 / Receptors, Dopamine D4; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  • [Other-IDs] NLM/ PMC2431063
  •  go-up   go-down


45. Zhu J, Reith ME: Role of the dopamine transporter in the action of psychostimulants, nicotine, and other drugs of abuse. CNS Neurol Disord Drug Targets; 2008 Nov;7(5):393-409
Hazardous Substances Data Bank. NICOTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The DA transporter (DAT) is a major target for drugs of abuse in the category of psychostimulants, and for methylphenidate (MPH), a drug used for treating attention deficit hyperactivity disorder (ADHD), which can also be a psychostimulant drug of abuse.
  • In addition, DAT expression is regulated through the removal (internalization) and recycling of the protein from the cell surface.
  • Furthermore, recent studies have demonstrated that individual differences in response to novel environments and psychostimulants can be predicted based on individual basal functional DAT expression.

  • MedlinePlus Health Information. consumer health - Drug Abuse.
  • MedlinePlus Health Information. consumer health - Opioid Abuse and Addiction.
  • Hazardous Substances Data Bank. DOPAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trends Pharmacol Sci. 2006 Jul;27(7):375-83 [16762425.001]
  • [Cites] Synapse. 2006 Sep 1;60(3):251-5 [16752364.001]
  • [Cites] Synapse. 2006 Sep 15;60(4):288-94 [16786536.001]
  • [Cites] Mol Pharmacol. 2006 Aug;70(2):542-8 [16684900.001]
  • [Cites] Exp Clin Psychopharmacol. 2006 Aug;14(3):389-401 [16893281.001]
  • [Cites] Eur J Nucl Med. 2000 Oct;27(10):1518-24 [11083541.001]
  • [Cites] Prog Brain Res. 2000;125:291-302 [11098665.001]
  • [Cites] Eur J Pharmacol. 2000 Dec 15;409(3):265-71 [11108820.001]
  • [Cites] Alcohol. 2000 Oct;22(2):107-15 [11113625.001]
  • [Cites] Neuroscience. 2000;101(3):619-27 [11113311.001]
  • [Cites] J Neurochem. 1992 Jul;59(1):259-66 [1613502.001]
  • [Cites] J Neurochem. 1992 Sep;59(3):848-56 [1494911.001]
  • [Cites] J Neurochem. 1993 Jan;60(1):376-9 [8417161.001]
  • [Cites] J Pharmacol Exp Ther. 1993 Apr;265(1):53-9 [8386244.001]
  • [Cites] Synapse. 1998 Nov;30(3):255-62 [9776129.001]
  • [Cites] J Neurosci Res. 2006 Aug 1;84(2):450-9 [16676328.001]
  • [Cites] Behav Brain Res. 2006 Oct 2;173(1):85-93 [16846651.001]
  • [Cites] Psychiatr Genet. 2007 Feb;17(1):23-7 [17167341.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2007;47:681-98 [17209801.001]
  • [Cites] Synapse. 2007 Mar;61(3):157-65 [17146768.001]
  • [Cites] Mol Pharmacol. 2007 Mar;71(3):835-42 [17164407.001]
  • [Cites] Pharmacol Biochem Behav. 2007 Jan;86(1):45-54 [17258302.001]
  • [Cites] J Biol Chem. 2007 Mar 23;282(12):8915-25 [17255098.001]
  • [Cites] Int J Neurosci. 2007 Jun;117(6):757-94 [17454243.001]
  • [Cites] J Pharmacol Exp Ther. 1994 Dec;271(3):1678-85 [7996484.001]
  • [Cites] J Exp Biol. 1994 Nov;196:229-36 [7823024.001]
  • [Cites] J Exp Biol. 1994 Nov;196:263-81 [7823027.001]
  • [Cites] Neurosci Lett. 1994 Aug 1;176(2):259-63 [7830960.001]
  • [Cites] Biochem Pharmacol. 1995 Mar 1;49(5):742-5 [7887991.001]
  • [Cites] J Biol Chem. 2005 Dec 9;280(49):40442-9 [16204245.001]
  • [Cites] AAPS J. 2005;7(3):E592-9 [16353938.001]
  • [Cites] Neuropsychopharmacology. 2006 Feb;31(2):351-62 [15957006.001]
  • [Cites] Brain Res Bull. 2006 Feb 15;68(6):393-405 [16459193.001]
  • [Cites] Brain Res Brain Res Rev. 1993 Sep-Dec;18(3):247-91 [8401595.001]
  • [Cites] Neuropharmacology. 1993 Sep;32(9):885-93 [8232791.001]
  • [Cites] Brain Res. 1993 Nov 19;628(1-2):17-25 [8313144.001]
  • [Cites] J Subst Abuse. 1994;6(1):1-20 [8081104.001]
  • [Cites] J Neurosci. 1994 Oct;14(10):6144-52 [7931568.001]
  • [Cites] J Pharmacol Exp Ther. 2004 Jan;308(1):367-77 [14563785.001]
  • [Cites] Pharmacol Biochem Behav. 2002 Aug;73(1):193-207 [12076739.001]
  • [Cites] Pharmacol Biochem Behav. 2002 Aug;73(1):209-24 [12076740.001]
  • [Cites] Psychopharmacology (Berl). 2002 Jul;162(2):102-18 [12110988.001]
  • [Cites] Synapse. 2002 Jul;45(1):52-65 [12112414.001]
  • [Cites] Eur J Pharmacol. 1994 Nov 3;264(3):391-8 [7698180.001]
  • [Cites] Neuroscience. 1995 Feb;64(3):587-97 [7715773.001]
  • [Cites] Psychopharmacology (Berl). 1995 Jan;117(1):2-10; discussion 14-20 [7724697.001]
  • [Cites] J Neurosci. 1995 May;15(5 Pt 2):4102-8 [7751968.001]
  • [Cites] Synapse. 1998 Nov;30(3):275-83 [9776131.001]
  • [Cites] J Neurochem. 1998 Nov;71(5):1785-803 [9798903.001]
  • [Cites] Arch Gen Psychiatry. 1998 Nov;55(11):973-9 [9819065.001]
  • [Cites] J Neurosci. 1998 Dec 15;18(24):10304-9 [9852568.001]
  • [Cites] Eur J Pharmacol. 1998 Nov 20;361(2-3):269-75 [9865517.001]
  • [Cites] J Neurosci. 1999 Jan 15;19(2):630-6 [9880583.001]
  • [Cites] J Neurochem. 1999 Jan;72(1):148-56 [9886065.001]
  • [Cites] J Neurochem. 1999 Mar;72(3):1266-74 [10037500.001]
  • [Cites] J Pharmacol Exp Ther. 1999 Apr;289(1):266-77 [10087014.001]
  • [Cites] Nat Neurosci. 1998 Jun;1(2):132-7 [10195128.001]
  • [Cites] J Membr Biol. 1999 May 1;169(1):1-12 [10227847.001]
  • [Cites] Pharmacol Biochem Behav. 1999 Jun;63(2):245-52 [10371653.001]
  • [Cites] Life Sci. 1999;65(1):PL7-12 [10403500.001]
  • [Cites] Biol Psychiatry. 1999 Aug 1;46(3):303-11 [10435196.001]
  • [Cites] J Pharmacol Exp Ther. 1999 Sep;290(3):940-9 [10454463.001]
  • [Cites] J Neurochem. 1999 Sep;73(3):1066-74 [10461896.001]
  • [Cites] J Neurosci. 1999 Sep 15;19(18):7699-710 [10479674.001]
  • [Cites] Neuropsychopharmacology. 2004 Dec;29(12):2168-79 [15292903.001]
  • [Cites] J Pharmacol Exp Ther. 2005 Jan;312(1):231-7 [15316087.001]
  • [Cites] Mol Pharmacol. 2005 Jan;67(1):140-51 [15615700.001]
  • [Cites] Neuropharmacology. 2005 Jan;48(1):72-9 [15617729.001]
  • [Cites] Traffic. 2005 Feb;6(2):157-70 [15634215.001]
  • [Cites] J Pharmacol Exp Ther. 2005 Mar;312(3):1298-304 [15542623.001]
  • [Cites] J Neurosci. 2005 Feb 23;25(8):1889-93 [15728828.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 1;102(9):3495-500 [15728379.001]
  • [Cites] J Biol Chem. 2005 Mar 25;280(12):10914-9 [15647254.001]
  • [Cites] Brain Res Mol Brain Res. 2005 Mar 24;134(1):170-9 [15790541.001]
  • [Cites] Alcohol Clin Exp Res. 2005 May;29(5):746-55 [15897718.001]
  • [Cites] J Neurosci. 2005 May 18;25(20):5029-37 [15901784.001]
  • [Cites] J Neurochem. 2005 Jun;93(6):1434-43 [15935059.001]
  • [Cites] Synapse. 2005 Sep 1;57(3):175-8 [15945061.001]
  • [Cites] Mol Pharmacol. 2005 Jul;68(1):102-9 [15795321.001]
  • [Cites] Psychopharmacology (Berl). 2005 Jul;180(3):408-13 [15719221.001]
  • [Cites] Prog Neurobiol. 2005 Apr;75(6):406-33 [15955613.001]
  • [Cites] Synapse. 2005 Nov;58(2):72-94 [16088952.001]
  • [Cites] Nat Neurosci. 2005 Jul;8(7):881-8 [15924135.001]
  • [Cites] Nature. 2005 Sep 8;437(7056):215-23 [16041361.001]
  • [Cites] Pharmacol Ther. 2005 Oct;108(1):94-108 [16083966.001]
  • [Cites] Neuropharmacology. 2005 Nov;49(6):759-68 [16181646.001]
  • [Cites] Neuropharmacology. 2005 Nov;49(6):750-8 [16212991.001]
  • [Cites] Mol Pharmacol. 2005 Nov;68(5):1376-86 [16077034.001]
  • [Cites] Lancet. 1999 Dec 18-25;354(9196):2132-3 [10609822.001]
  • [Cites] Neuroscience. 2000;96(1):91-9 [10683414.001]
  • [Cites] Eur J Pharmacol. 2000 Feb 11;389(1):59-65 [10686296.001]
  • [Cites] Cereb Cortex. 2000 Mar;10(3):272-84 [10731222.001]
  • [Cites] Brain Res. 2006 Feb 16;1073-1074:175-82 [16457790.001]
  • [Cites] J Neurochem. 2006 Apr;97 Suppl 1:3-10 [16635244.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9333-8 [16754872.001]
  • [Cites] AAPS J. 2006;8(2):E337-47 [16796384.001]
  • [Cites] Biol Psychiatry. 2006 Jun 15;59(12):1151-9 [16566899.001]
  • [Cites] Synapse. 2000 Oct;38(1):10-6 [10941136.001]
  • [Cites] Eur J Neurosci. 2000 Aug;12(8):2985-92 [10971639.001]
  • [Cites] Addiction. 2000 Aug;95 Suppl 2:S119-28 [11002907.001]
  • [Cites] Eur J Pharmacol. 2000 Oct 6;406(1):1-13 [11011026.001]
  • [Cites] Am J Med Genet. 2000 Oct 9;96(5):590-1 [11054764.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1982-7 [11172062.001]
  • [Cites] J Neurosci. 2001 Mar 1;21(5):1452-63 [11222635.001]
  • [Cites] J Pharmacol Exp Ther. 2001 Apr;297(1):27-34 [11259524.001]
  • [Cites] Behav Brain Res. 2001 Jun;121(1-2):11-20 [11275280.001]
  • [Cites] J Neurosci. 2001 May 1;21(9):RC141: 1-4 [11312315.001]
  • [Cites] Mol Pharmacol. 2001 Jan;59(1):113-21 [11125031.001]
  • [Cites] J Neurosci. 2000 Dec 15;20(24):9333-40 [11125013.001]
  • [Cites] J Pharmacol Exp Ther. 2001 Mar;296(3):931-8 [11181926.001]
  • [Cites] J Neurosci. 2001 Feb 15;21(4):1413-9 [11160413.001]
  • [Cites] Mol Pharmacol. 2007 May;71(5):1222-32 [17267664.001]
  • [Cites] J Neurochem. 2007 Jun;101(5):1258-71 [17419806.001]
  • [Cites] Mol Pharmacol. 2007 Jun;71(6):1563-71 [17341654.001]
  • [Cites] Br J Pharmacol. 2007 Jun;151(3):414-22 [17401441.001]
  • [Cites] Neuropharmacology. 2007 Jun;52(8):1596-605 [17459426.001]
  • [Cites] Synapse. 2007 Sep;61(9):771-7 [17568430.001]
  • [Cites] Psychopharmacology (Berl). 2007 Sep;193(4):495-501 [17492432.001]
  • [Cites] Eur J Neurosci. 2007 Aug;26(3):717-28 [17651428.001]
  • [Cites] J Pharmacol Exp Ther. 2007 Nov;323(2):738-45 [17693585.001]
  • [Cites] J Biol Chem. 2007 Dec 7;282(49):35842-54 [17923483.001]
  • [Cites] Biochem Pharmacol. 2008 Jan 1;75(1):196-217 [17825265.001]
  • [Cites] Neuropharmacology. 2008 Mar;54(3):605-12 [18164041.001]
  • [Cites] Mol Pharmacol. 2008 Mar;73(3):813-23 [17978168.001]
  • [Cites] Mol Pharmacol. 2008 Apr;73(4):1141-50 [18216182.001]
  • [Cites] Neuroimage. 2008 Apr 15;40(3):1195-201 [18282769.001]
  • [Cites] J Neurochem. 2008 May;105(3):910-20 [18088380.001]
  • [Cites] J Neurochem. 2008 Jun;105(5):1683-99 [18248623.001]
  • [Cites] J Neurochem. 1998 Sep;71(3):1289-97 [9721755.001]
  • [Cites] Psychol Rev. 1987 Oct;94(4):469-92 [3317472.001]
  • [Cites] Psychopharmacol Bull. 1987;23(3):417-24 [2893420.001]
  • [Cites] J Neurochem. 1988 Apr;50(4):1123-30 [3346670.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Jul;85(14):5274-8 [2899326.001]
  • [Cites] Science. 1988 Nov 4;242(4879):715-23 [2903550.001]
  • [Cites] J Neurosci Methods. 1989 Jan;26(3):217-27 [2521916.001]
  • [Cites] Neurochem Res. 1989 Jun;14(6):511-5 [2569677.001]
  • [Cites] Science. 1989 Sep 29;245(4925):1511-3 [2781295.001]
  • [Cites] Pharmacol Rev. 1989 Mar;41(1):3-52 [2682679.001]
  • [Cites] Brain Res. 1990 Jan 29;508(1):65-9 [2337793.001]
  • [Cites] FASEB J. 1990 Jul;4(10):2737-44 [2197154.001]
  • [Cites] J Neurochem. 1990 Nov;55(5):1734-40 [1976759.001]
  • [Cites] Neuroendocrinology. 1990 Sep;52(3):256-61 [2170853.001]
  • [Cites] Psychopharmacology (Berl). 1990;102(3):364-72 [2251333.001]
  • [Cites] Nature. 1991 Mar 21;350(6315):230-2 [2005978.001]
  • [Cites] J Neurochem. 1991 May;56(5):1485-92 [2013751.001]
  • [Cites] J Biol Chem. 1991 Jun 15;266(17):11192-8 [2040627.001]
  • [Cites] Pharmacol Biochem Behav. 1991 Feb;38(2):467-70 [2057515.001]
  • [Cites] Trends Neurosci. 1991 Jul;14(7):299-302 [1719677.001]
  • [Cites] J Neurosci. 1992 Feb;12(2):483-8 [1346804.001]
  • [Cites] Pharmacol Biochem Behav. 1992 Jan;41(1):203-10 [1539070.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Mar 15;89(6):2046-50 [1347943.001]
  • [Cites] Biochem Pharmacol. 1992 May 28;43(10):2189-99 [1599505.001]
  • [Cites] J Neurosci. 2003 Dec 3;23(35):10999-1007 [14657156.001]
  • [Cites] Arch Gen Psychiatry. 2003 Dec;60(12):1256-64 [14662558.001]
  • [Cites] Behav Brain Res. 2004 Jan 5;148(1-2):107-17 [14684252.001]
  • [Cites] Behav Brain Res. 2004 Jan 5;148(1-2):185-98 [14684259.001]
  • [Cites] Trends Pharmacol Sci. 1993 Feb;14(2):43-9 [8480373.001]
  • [Cites] J Neurochem. 1993 Jul;61(1):273-83 [8515274.001]
  • [Cites] J Neurochem. 1993 Aug;61(2):764-7 [8336153.001]
  • [Cites] Behav Brain Res. 1993 Jun 30;55(2):131-41 [7689319.001]
  • [Cites] Curr Opin Neurobiol. 1993 Jun;3(3):337-44 [8103691.001]
  • [Cites] J Pharmacol Exp Ther. 2003 Nov;307(2):729-36 [12975490.001]
  • [Cites] Am J Psychiatry. 2003 Nov;160(11):1909-18 [14594733.001]
  • [Cites] J Biol Chem. 2003 Nov 14;278(46):45045-8 [14519759.001]
  • [Cites] Eur J Pharmacol. 2003 Oct 31;479(1-3):139-52 [14612145.001]
  • [Cites] Eur J Pharmacol. 2003 Oct 31;479(1-3):153-8 [14612146.001]
  • [Cites] Eur J Pharmacol. 2003 Oct 31;479(1-3):159-70 [14612147.001]
  • [Cites] Psychopharmacology (Berl). 2003 Nov;170(3):235-41 [12845407.001]
  • [Cites] Schizophr Res. 2003 Dec 1;65(1):47-55 [14623374.001]
  • [Cites] Neurosci Biobehav Rev. 2003 Nov;27(7):615-21 [14624806.001]
  • [Cites] Neuropsychopharmacology. 2003 Dec;28(12):2089-101 [12902997.001]
  • [Cites] J Neurosci. 2002 Jul 15;22(14):6272-81 [12122086.001]
  • [Cites] J Pharmacol Exp Ther. 2002 Sep;302(3):1201-11 [12183681.001]
  • [Cites] J Biol Chem. 2002 Aug 23;277(34):30724-9 [12070173.001]
  • [Cites] Med Res Rev. 2002 Sep;22(5):429-64 [12210554.001]
  • [Cites] Annu Rev Neurosci. 1995;18:463-95 [7605071.001]
  • [Cites] Biochemistry. 1995 Aug 1;34(30):9734-47 [7626644.001]
  • [Cites] N Engl J Med. 1995 Oct 5;333(14):944 [7666894.001]
  • [Cites] Pharmacol Biochem Behav. 1995 Jun-Jul;51(2-3):397-405 [7667360.001]
  • [Cites] Nat Med. 1995 Jul;1(7):654-7 [7585146.001]
  • [Cites] J Neurochem. 1996 Jan;66(1):216-21 [8522957.001]
  • [Cites] Pharmacol Biochem Behav. 1995 Sep;52(1):29-34 [7501675.001]
  • [Cites] Nat Genet. 1996 Jan;12(1):81-4 [8528258.001]
  • [Cites] Mol Neurobiol. 1995 Aug-Dec;11(1-3):1-19 [8561954.001]
  • [Cites] Brain Res. 1995 Oct 23;696(1-2):15-20 [8574663.001]
  • [Cites] J Med Chem. 1996 Jan 19;39(2):371-9 [8558504.001]
  • [Cites] Nature. 1996 Feb 15;379(6566):606-12 [8628395.001]
  • [Cites] J Pharmacol Exp Ther. 1996 Jun;277(3):1527-32 [8667219.001]
  • [Cites] Neuroreport. 1996 Jan 31;7(2):457-62 [8730805.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1996;36:359-78 [8725394.001]
  • [Cites] J Biol Chem. 1996 Aug 30;271(35):21672-80 [8702957.001]
  • [Cites] Eur J Pharmacol. 1996 Mar 28;299(1-3):33-9 [8901005.001]
  • [Cites] Synapse. 1996 Mar;22(3):217-25 [9132989.001]
  • [Cites] J Med Chem. 1996 Nov 22;39(24):4689-91 [8941381.001]
  • [Cites] Neurosci Lett. 1997 Mar 21;224(3):201-5 [9131671.001]
  • [Cites] Psychopharmacology (Berl). 1997 May;131(1):23-33 [9181632.001]
  • [Cites] J Neuropsychiatry Clin Neurosci. 1997 Summer;9(3):482-97 [9276849.001]
  • [Cites] J Pharmacol Exp Ther. 1997 Sep;282(3):1358-65 [9316847.001]
  • [Cites] J Pharmacol Exp Ther. 1987 Sep;242(3):917-26 [3656119.001]
  • [Cites] Alcohol. 1997 Nov-Dec;14(6):593-601 [9401676.001]
  • [Cites] Brain Res Brain Res Rev. 1997 Oct;25(2):192-216 [9403138.001]
  • [Cites] Nature. 1998 Jan 8;391(6663):173-7 [9428762.001]
  • [Cites] J Pharmacol Exp Ther. 1998 Feb;284(2):592-8 [9454802.001]
  • [Cites] J Neurosci. 1998 Mar 15;18(6):1979-86 [9482784.001]
  • [Cites] Am J Psychiatry. 1998 Apr;155(4):474-8 [9545991.001]
  • [Cites] J Neurochem. 1998 May;70(5):1941-9 [9572278.001]
  • [Cites] Alcohol Clin Exp Res. 1998 Apr;22(2):367-74 [9581642.001]
  • [Cites] J Biol Chem. 1998 Jun 5;273(23):14231-7 [9603927.001]
  • [Cites] Brain Res Brain Res Rev. 1998 May;26(2-3):148-53 [9651511.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9238-43 [9689064.001]
  • [Cites] Synapse. 1998 Sep;30(1):79-87 [9704884.001]
  • [Cites] Behav Brain Res. 1998 Jul;94(1):127-52 [9708845.001]
  • [Cites] Eur J Pharmacol. 1999 Oct 1;382(1):45-9 [10556503.001]
  • [Cites] J Neurochem. 1999 Dec;73(6):2406-14 [10582600.001]
  • [Cites] J Biol Chem. 1999 Dec 10;274(50):35794-801 [10585462.001]
  • [Cites] J Biol Chem. 1999 Dec 24;274(52):36928-34 [10601246.001]
  • [Cites] Brain Res. 1985 Dec 23;360(1-2):325-30 [3000533.001]
  • [Cites] Dev Psychobiol. 1986 Jul;19(4):303-13 [3732621.001]
  • [Cites] J Pharmacol Exp Ther. 2003 Apr;305(1):180-90 [12649367.001]
  • [Cites] Science. 1987 Sep 4;237(4819):1219-23 [2820058.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3106-11 [10716733.001]
  • [Cites] Ann Nucl Med. 2000 Feb;14(1):1-9 [10770574.001]
  • [Cites] Eur J Pharmacol. 2000 Mar 30;393(1-3):295-314 [10771025.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6850-5 [10823899.001]
  • [Cites] Ann N Y Acad Sci. 2000;909:104-32 [10911926.001]
  • [Cites] Nat Rev Neurosci. 2004 Jan;5(1):55-65 [14708004.001]
  • [Cites] J Neurosci. 2002 Oct 1;22(19):8705-10 [12351745.001]
  • [Cites] Trends Pharmacol Sci. 2002 Aug;23(8):367-73 [12377578.001]
  • [Cites] Eur Neuropsychopharmacol. 2002 Dec;12(6):557-66 [12468018.001]
  • [Cites] J Biol Chem. 2003 Jan 24;278(4):2731-9 [12429746.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2003;43:261-84 [12359863.001]
  • [Cites] J Biol Chem. 2003 Feb 14;278(7):4990-5000 [12464618.001]
  • [Cites] J Pharmacol Exp Ther. 2003 Mar;304(3):1181-7 [12604695.001]
  • [Cites] Curr Med Chem. 2004 Feb;11(3):267-77 [14965231.001]
  • [Cites] J Biol Chem. 2004 Mar 5;279(10):8966-75 [14699142.001]
  • [Cites] J Neurosci. 2004 Mar 31;24(13):3436-43 [15056723.001]
  • [Cites] Trends Neurosci. 2004 May;27(5):270-7 [15111009.001]
  • [Cites] Psychopharmacology (Berl). 2004 May;173(3-4):310-7 [14747902.001]
  • [Cites] J Neurochem. 2004 May;89(4):853-64 [15140185.001]
  • [Cites] Mol Pharmacol. 2004 Jun;65(6):1526-35 [15155845.001]
  • [Cites] Neuron. 2004 May 27;42(4):522-4 [15157413.001]
  • [Cites] J Pharmacol Exp Ther. 2004 Jul;310(1):1-7 [15064332.001]
  • [Cites] Neurochem Int. 2004 Oct;45(5):627-32 [15234104.001]
  • [Cites] Pharmacol Ther. 2004 Aug;103(2):121-46 [15369680.001]
  • [Cites] Neuropharmacology. 2004;47 Suppl 1:80-91 [15464127.001]
  • [Cites] Neuropharmacology. 2004;47 Suppl 1:92-100 [15464128.001]
  • [Cites] Pharmacol Ther. 2004 Oct;104(1):17-27 [15500906.001]
  • [Cites] Psychopharmacology (Berl). 2004 Nov;176(2):129-38 [15502935.001]
  • [Cites] J Pharmacol Exp Ther. 1979 Feb;208(2):195-202 [216794.001]
  • [Cites] J Pharmacol Exp Ther. 1979 Feb;208(2):203-9 [762652.001]
  • [Cites] Biochem Pharmacol. 1982 Mar 15;31(6):983-92 [7082379.001]
  • [Cites] Psychoneuroendocrinology. 1982;7(2-3):217-21 [7178375.001]
  • [Cites] Mol Pharmacol. 1985 Aug;28(2):128-37 [2410768.001]
  • [Cites] Brain Res. 1985 Dec 2;348(2):355-8 [4075093.001]
  • [Cites] J Neurochem. 2001 May;77(4):1116-27 [11359877.001]
  • [Cites] Brain Res Bull. 2001 Apr;54(6):631-8 [11403989.001]
  • [Cites] EMBO J. 2001 Jun 15;20(12):3056-62 [11406582.001]
  • [Cites] Psychopharmacology (Berl). 2001 May;155(3):278-84 [11432690.001]
  • [Cites] J Pharmacol Exp Ther. 2001 Aug;298(2):395-402 [11454899.001]
  • [Cites] J Biol Chem. 2001 Aug 3;276(31):29012-8 [11395483.001]
  • [Cites] J Neurosci. 2001 Aug 15;21(16):6338-47 [11487657.001]
  • [Cites] Alcohol Clin Exp Res. 2001 Aug;25(8):1087-97 [11505038.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10055-60 [11526230.001]
  • [Cites] Behav Pharmacol. 2001 Jul;12(4):267-75 [11548112.001]
  • [Cites] J Neurosci. 2001 Oct 1;21(19):7561-7 [11567046.001]
  • [Cites] Neurosci Lett. 2001 Oct 26;312(3):169-72 [11602337.001]
  • [Cites] Eur J Neurosci. 2001 Nov;14(9):1533-8 [11722615.001]
  • [Cites] J Neurochem. 2001 Dec;79(5):1070-9 [11739621.001]
  • [Cites] Synapse. 2001 Dec 1;42(3):185-92 [11746715.001]
  • [Cites] Pharmacol Ther. 2001 Oct;92(1):21-55 [11750035.001]
  • [Cites] J Neurochem. 2002 Jan;80(1):1-11 [11796738.001]
  • [Cites] Psychopharmacology (Berl). 2001 Dec;158(4):388-98 [11797060.001]
  • [Cites] Mol Pharmacol. 2002 Feb;61(2):436-45 [11809869.001]
  • [Cites] Nat Neurosci. 2002 Feb;5(2):169-74 [11802171.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Feb 8;290(5):1545-50 [11820798.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1683-8 [11818545.001]
  • [Cites] Respiration. 2002;69(1):7-11 [11844955.001]
  • [Cites] J Neurochem. 2002 Apr;81(2):292-300 [12064476.001]
  • [Cites] J Neurochem. 2002 May;81(4):859-69 [12065645.001]
  • [Cites] Alcohol Clin Exp Res. 2002 Jun;26(6):758-64 [12068242.001]
  • [Cites] J Neurosci. 2003 Apr 1;23(7):3076-84 [12684494.001]
  • [Cites] J Atten Disord. 2002;6 Suppl 1:S31-43 [12685517.001]
  • [Cites] Neurosci Lett. 2003 May 29;343(1):9-12 [12749985.001]
  • [Cites] Curr Drug Targets CNS Neurol Disord. 2002 Aug;1(4):413-21 [12769613.001]
  • [Cites] J Biol Chem. 2003 Jun 13;278(24):22168-74 [12682063.001]
  • [Cites] J Biol Chem. 2003 Jul 25;278(30):28274-83 [12746456.001]
  • [Cites] Arch Gen Psychiatry. 2003 Sep;60(9):929-37 [12963675.001]
  • [Cites] J Neurosci. 2003 Sep 17;23(24):8480-8 [13679416.001]
  • [Cites] Synapse. 2003 Dec 1;50(3):266-8 [14515345.001]
  • (PMID = 19128199.001).
  • [ISSN] 1996-3181
  • [Journal-full-title] CNS & neurological disorders drug targets
  • [ISO-abbreviation] CNS Neurol Disord Drug Targets
  • [Language] ENG
  • [Grant] United States / NIDA NIH HHS / DA / R01 DA012964; United States / NIDA NIH HHS / DA / DA013261-08; United States / NIDA NIH HHS / DA / DA13261; United States / NIDA NIH HHS / DA / R01 DA013261; United States / NIDA NIH HHS / DA / P50 DA005312; United States / NIDA NIH HHS / DA / R01 DA019676; United States / NIDA NIH HHS / DA / DA19676; United States / NIDA NIH HHS / DA / R01 DA013261-08; United States / NIDA NIH HHS / DA / R21 DA018372; United States / NIDA NIH HHS / DA / R21 DA018372-02; United States / NIDA NIH HHS / DA / R01 DA012964-08; United States / NIDA NIH HHS / DA / DA018372-02; United States / NIDA NIH HHS / DA / R01 DA019676-04; United States / NIDA NIH HHS / DA / P50 DA005312-18; United States / NIDA NIH HHS / DA / DA05312; United States / NIDA NIH HHS / DA / DA018372; United States / NIDA NIH HHS / DA / DA12964
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United Arab Emirates
  • [Chemical-registry-number] 0 / Central Nervous System Stimulants; 0 / Dopamine Plasma Membrane Transport Proteins; 6M3C89ZY6R / Nicotine; VTD58H1Z2X / Dopamine
  • [Number-of-references] 296
  • [Other-IDs] NLM/ NIHMS306957; NLM/ PMC3133725
  •  go-up   go-down


46. Moreno G, Perelló M, Camihort G, Luna G, Console G, Gaillard RC, Spinedi E: Impact of transient correction of increased adrenocortical activity in hypothalamo-damaged, hyperadipose female rats. Int J Obes (Lond); 2006 Jan;30(1):73-82
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Circulating levels of several hormones, in basal and after i.v. high-glucose load conditions, and RP adiposity morphology and function were then evaluated.
  • These characteristics were fully reversed after transient correction of corticoadrenal hyperactivity induced by AE.

  • Hazardous Substances Data Bank. MONOSODIUM GLUTAMATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16231033.001).
  • [ISSN] 0307-0565
  • [Journal-full-title] International journal of obesity (2005)
  • [ISO-abbreviation] Int J Obes (Lond)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / Glucocorticoids; 0 / Insulin; 0 / Leptin; 7S5I7G3JQL / Dexamethasone; W81N5U6R6U / Sodium Glutamate; W980KJ009P / Corticosterone
  •  go-up   go-down


47. Huleihel R, Yanai J: Disruption of the development of cholinergic-induced translocation/activation of PKC isoforms after prenatal heroin exposure. Brain Res Bull; 2006 Mar 31;69(2):174-81
Hazardous Substances Data Bank. HEROIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Prenatal exposure of mice to heroin resulted in behavioral deficits present at adulthood, and related to septohippocampal cholinergic innervation accompanied by both pre- and postsynaptic cholinergic hyperactivity; including an increase in membrane PKC activity, and a desensitization of PKC to cholinergic input, which correlated highly with the behavioral performance, and was reversed by cholinergic grafting.
  • Prenatal heroin exposure increased basal PKCgamma, beta and alpha levels.

  • MedlinePlus Health Information. consumer health - Heroin.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16533667.001).
  • [ISSN] 0361-9230
  • [Journal-full-title] Brain research bulletin
  • [ISO-abbreviation] Brain Res. Bull.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / HD 40820
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 0 / Cholinergic Agonists; 0 / Protein Isoforms; 0 / Receptors, Cholinergic; 70D95007SX / Heroin; EC 2.7.11.13 / Protein Kinase C; N9YNS0M02X / Acetylcholine
  •  go-up   go-down


48. Budziszewska B, Lasoń W, Steczkowska M, Gergont A: [Value of the experiment for developmental neurology]. Przegl Lek; 2009;66(11):958-62
MedlinePlus Health Information. consumer health - Neurologic Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The etiology of autism is not known and there is no drug for ameliorating basal symptoms of this disease.
  • Therapeutic action of psychostimulant drugs in the attention deficit hyperactivity disorder (ADHD) are known for years, but because of their addictive properties, decision about their clinical use in a child is not easy.
  • The introduction of efficient neuroprotective drugs, which may ameliorate secondary neuronal cell damage in various brain regions to the therapy is the main aim of numerous experimental works.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20297638.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Neuroprotective Agents
  • [Number-of-references] 37
  •  go-up   go-down


49. Karlsson RM, Hefner KR, Sibley DR, Holmes A: Comparison of dopamine D1 and D5 receptor knockout mice for cocaine locomotor sensitization. Psychopharmacology (Berl); 2008 Sep;200(1):117-27
Hazardous Substances Data Bank. COCAINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: D1R KO showed modest basal hyperactivity and increased center exploration relative to WT.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7491-5 [1831904.001]
  • [Cites] Arch Gen Psychiatry. 1999 Dec;56(12):1101-6 [10591286.001]
  • [Cites] Brain Res. 2000 Jan 3;852(1):198-207 [10661513.001]
  • [Cites] Synapse. 2000 Aug;37(2):125-45 [10881034.001]
  • [Cites] Neuroscience. 2000;100(4):689-99 [11036203.001]
  • [Cites] Behav Neurosci. 2001 Oct;115(5):1129-44 [11584926.001]
  • [Cites] Psychopharmacology (Berl). 2002 Feb;159(4):407-14 [11823893.001]
  • [Cites] J Neurosci. 2002 May 1;22(9):3312-20 [11978805.001]
  • [Cites] Trends Neurosci. 2002 Jul;25(7):336-40 [12079755.001]
  • [Cites] J Neurosci. 2002 Jul 15;22(14):5817-22 [12122043.001]
  • [Cites] J Neurosci. 2002 Dec 15;22(24):10801-10 [12486173.001]
  • [Cites] Annu Rev Psychol. 2003;54:25-53 [12185211.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):9175-9 [1833775.001]
  • [Cites] Brain Res Brain Res Rev. 1991 Sep-Dec;16(3):223-44 [1665095.001]
  • [Cites] Psychopharmacology (Berl). 1991;105(3):335-9 [1839178.001]
  • [Cites] Neuropharmacology. 1993 Apr;32(4):387-91 [8497339.001]
  • [Cites] Cell. 1994 Dec 16;79(6):945-55 [8001143.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Dec 20;91(26):12564-8 [7809078.001]
  • [Cites] Synapse. 1994 Sep;18(1):35-45 [7825122.001]
  • [Cites] Brain Res. 1995 Mar 6;673(2):242-50 [7606438.001]
  • [Cites] J Neurosci. 1995 Sep;15(9):6287-99 [7666211.001]
  • [Cites] Eur J Pharmacol. 1995 Sep 5;283(1-3):125-31 [7498301.001]
  • [Cites] J Neurosci. 1995 Dec;15(12):7821-36 [8613722.001]
  • [Cites] Neuroreport. 1995 Nov 27;6(17):2314-6 [8747144.001]
  • [Cites] J Neurosci. 1996 Oct 15;16(20):6579-91 [8815934.001]
  • [Cites] Pharmacol Biochem Behav. 1996 Mar;53(3):481-6 [8866944.001]
  • [Cites] Neuroscience. 1996 Oct;74(3):813-23 [8884777.001]
  • [Cites] Crit Rev Neurobiol. 1997;11(1):21-33 [9093812.001]
  • [Cites] Neuroreport. 1997 Jul 28;8(11):2523-7 [9261820.001]
  • [Cites] Pharmacol Toxicol. 1997 Sep;81(3):105-13 [9335067.001]
  • [Cites] Neuropsychopharmacology. 1998 Jan;18(1):26-40 [9408916.001]
  • [Cites] J Neurosci. 1998 May 1;18(9):3470-9 [9547254.001]
  • [Cites] Synapse. 1998 Oct;30(2):181-93 [9723788.001]
  • [Cites] Behav Pharmacol. 1998 Feb;9(1):69-76 [9832950.001]
  • [Cites] J Pharmacol Exp Ther. 1991 Sep;258(3):882-90 [1890623.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1999;39:313-41 [10331087.001]
  • [Cites] Neuropharmacology. 2004 Dec;47(8):1117-34 [15567422.001]
  • [Cites] Synapse. 2005 Mar 15;55(4):201-11 [15668951.001]
  • [Cites] J Comp Neurol. 2005 Jul 4;487(3):270-82 [15892099.001]
  • [Cites] J Neurosci. 2005 Jul 13;25(28):6651-7 [16014726.001]
  • [Cites] Neuropsychopharmacology. 2005 Aug;30(8):1443-54 [15770241.001]
  • [Cites] Eur J Neurosci. 2005 Oct;22(7):1741-50 [16197514.001]
  • [Cites] Psychopharmacology (Berl). 2005 Oct;181(4):611-38 [16041535.001]
  • [Cites] Psychopharmacology (Berl). 2005 Nov;183(1):20-30 [16136298.001]
  • [Cites] Neurosci Biobehav Rev. 2006;30(2):215-38 [16099045.001]
  • [Cites] Psychopharmacology (Berl). 2006 Sep;187(4):455-66 [16835771.001]
  • [Cites] J Neurosci. 2006 Aug 16;26(33):8549-58 [16914681.001]
  • [Cites] Eur J Neurosci. 2006 Aug;24(3):806-18 [16930410.001]
  • [Cites] Alcohol Clin Exp Res. 2006 Dec;30(12):1957-65 [17117959.001]
  • [Cites] Neurosci Biobehav Rev. 2007;31(1):3-17 [16950513.001]
  • [Cites] J Neurosci. 2006 Dec 20;26(51):13287-96 [17182779.001]
  • [Cites] Psychopharmacology (Berl). 2007 Apr;191(2):311-22 [17206494.001]
  • [Cites] Neuropsychopharmacology. 2007 May;32(5):1109-21 [17063155.001]
  • [Cites] Pharmacol Biochem Behav. 2007 May;87(1):158-63 [17524461.001]
  • [Cites] Addict Biol. 2007 Sep;12(3-4):227-462 [17678505.001]
  • [Cites] J Neurosci. 2007 Nov 14;27(46):12484-8 [18003826.001]
  • [Cites] Pharmacol Biochem Behav. 2003 Apr;75(1):123-31 [12759120.001]
  • [Cites] Psychopharmacology (Berl). 2003 Sep;169(2):161-8 [12768268.001]
  • [Cites] J Neurosci. 2003 Sep 17;23(24):8506-12 [13679419.001]
  • [Cites] Science. 2003 Nov 21;302(5649):1412-5 [14631045.001]
  • [Cites] Genes Brain Behav. 2003 Dec;2(6):365-80 [14653308.001]
  • [Cites] Neuropharmacology. 2004;47 Suppl 1:242-55 [15464141.001]
  • [Cites] Neuropharmacology. 2004;47 Suppl 1:256-73 [15464142.001]
  • [Cites] Psychopharmacologia. 1974;39(4):345-57 [4615333.001]
  • [Cites] Nature. 1976 Apr 22;260(5553):731-2 [944382.001]
  • (PMID = 18600316.001).
  • [ISSN] 0033-3158
  • [Journal-full-title] Psychopharmacology
  • [ISO-abbreviation] Psychopharmacology (Berl.)
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 AA000411-04
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Receptors, Dopamine D1; 137750-35-7 / Receptors, Dopamine D5; I5Y540LHVR / Cocaine
  • [Other-IDs] NLM/ NIHMS56410; NLM/ PMC2586326
  •  go-up   go-down


50. Schirmer M, Kaiser A, Lessenich A, Lindemann S, Fedrowitz M, Gernert M, Löscher W: Auditory and vestibular defects and behavioral alterations after neonatal administration of streptomycin to Lewis rats: Similarities and differences to the circling (ci2/ci2) Lewis rat mutant. Brain Res; 2007 Jun 25;1155:179-95
MedlinePlus Health Information. consumer health - Hearing Disorders and Deafness.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In rodents, damage to the inner ear is often associated with rotational behavior and locomotor hyperactivity reminiscent of such behaviors resulting from an imbalance of forebrain dopamine systems.
  • Based on previous observations in the circling (ci2/ci2) Lewis (LEW) rat mutant, a spontaneous mutation leading to hair cell loss, deafness, impairment of vestibular functions, lateralized circling, hyperactivity and alterations in the nigrostriatal dopamine system, we have recently hypothesized that vestibular defects during postnatal development, independent of whether induced or inherited, lead to secondary changes in the dopaminergic system within the basal ganglia, which would be a likely explanation for the typical behavioral phenotype seen in such models.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17493596.001).
  • [ISSN] 0006-8993
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


51. Adriani W, Canese R, Podo F, Laviola G: 1H MRS-detectable metabolic brain changes and reduced impulsive behavior in adult rats exposed to methylphenidate during adolescence. Neurotoxicol Teratol; 2007 Jan-Feb;29(1):116-25
Hazardous Substances Data Bank. METHYLPHENIDATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Administration of methylphenidate (MPH, Ritalin) to children affected by attention deficit hyperactivity disorder (ADHD) is an elective therapy, which however raises concerns for public health, due to possible persistent neuro-behavioral alterations.
  • MPH-exposed animals showed a less marked shifting profile from the large/late to the small/soon reward, suggesting reduced basal levels of impulsivity, compared to controls.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17196789.001).
  • [ISSN] 0892-0362
  • [Journal-full-title] Neurotoxicology and teratology
  • [ISO-abbreviation] Neurotoxicol Teratol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Central Nervous System Stimulants; 207ZZ9QZ49 / Methylphenidate
  •  go-up   go-down


52. Xu ZZ, Zhang L, Liu T, Park JY, Berta T, Yang R, Serhan CN, Ji RR: Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions. Nat Med; 2010 May;16(5):592-7, 1p following 597
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we report that peripheral (intraplantar) or spinal (intrathecal) administration of RvE1 or RvD1 in mice potently reduces inflammatory pain behaviors induced by intraplantar injection of formalin, carrageenan or complete Freund's adjuvant (CFA), without affecting basal pain perception.
  • RvE1 also abolishes transient receptor potential vanilloid subtype-1 (TRPV1)- and TNF-alpha-induced excitatory postsynaptic current increases and TNF-alpha-evoked N-methyl-D-aspartic acid (NMDA) receptor hyperactivity in spinal dorsal horn neurons via inhibition of the extracellular signal-regulated kinase (ERK) signaling pathway.

  • MedlinePlus Health Information. consumer health - Pain.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Neurosci. 1999 Dec;2(12):1114-9 [10570489.001]
  • [Cites] Pain. 2000 Mar;85(1-2):145-51 [10692613.001]
  • [Cites] Pain Med. 2009 May-Jun;10(4):654-62 [19302436.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Jun 16;106(24):9872-7 [19487674.001]
  • [Cites] Cell. 2009 Jun 12;137(6):987-8 [19524498.001]
  • [Cites] Science. 2000 Apr 14;288(5464):306-13 [10764638.001]
  • [Cites] Science. 2000 Jun 9;288(5472):1765-9 [10846153.001]
  • [Cites] Nature. 2001 Mar 22;410(6827):471-5 [11260714.001]
  • [Cites] J Neurosci. 2001 Jun 1;21(11):3771-9 [11356865.001]
  • [Cites] Nature. 2001 Sep 13;413(6852):203-10 [11557989.001]
  • [Cites] J Neurosci. 2003 Apr 1;23(7):2517-21 [12684435.001]
  • [Cites] J Exp Med. 2003 Oct 6;198(7):977-85 [14530373.001]
  • [Cites] Trends Neurosci. 2003 Dec;26(12):696-705 [14624855.001]
  • [Cites] J Neurosci. 2004 Sep 22;24(38):8300-9 [15385613.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1980;20:441-62 [7387124.001]
  • [Cites] Eur J Pharmacol. 1980 Oct 17;67(2-3):313-6 [6893963.001]
  • [Cites] Anesthesiology. 1992 Oct;77(4):757-63 [1416174.001]
  • [Cites] Pain. 1992 Sep;50(3):355-63 [1333581.001]
  • [Cites] Pain. 1996 Mar;64(3):493-501 [8783314.001]
  • [Cites] J Neurosci. 1997 Feb 1;17(3):975-82 [8994052.001]
  • [Cites] Nat Med. 1999 Jun;5(6):698-701 [10371510.001]
  • [Cites] Trends Pharmacol Sci. 1999 Aug;20(8):329-37 [10431212.001]
  • [Cites] J Exp Med. 2005 Mar 7;201(5):713-22 [15753205.001]
  • [Cites] J Neurosci. 2006 Jan 4;26(1):246-55 [16399694.001]
  • [Cites] Clin Rheumatol. 2006;25 Suppl 1:S22-9 [16741783.001]
  • [Cites] J Biol Chem. 2006 Aug 11;281(32):22847-54 [16757471.001]
  • [Cites] Pain. 2007 May;129(1-2):210-23 [17335973.001]
  • [Cites] Nature. 2007 Jun 14;447(7146):869-74 [17568749.001]
  • [Cites] Nat Med. 2007 Jul;13(7):868-73 [17589522.001]
  • [Cites] Neuron. 2007 Aug 2;55(3):365-76 [17678851.001]
  • [Cites] J Cardiovasc Pharmacol. 2007 Nov;50(5):470-9 [18030055.001]
  • [Cites] Nat Med. 2008 Mar;14(3):331-6 [18264108.001]
  • [Cites] PLoS One. 2008;3(4):e1879 [18382663.001]
  • [Cites] J Exp Med. 2008 Apr 14;205(4):767-75 [18391062.001]
  • [Cites] Nat Rev Immunol. 2008 May;8(5):349-61 [18437155.001]
  • [Cites] J Neurosci. 2008 May 14;28(20):5189-94 [18480275.001]
  • [Cites] Nat Immunol. 2008 Aug;9(8):873-9 [18568027.001]
  • [Cites] Nat Med. 2008 Dec;14(12):1325-32 [19011637.001]
  • [Cites] Trends Pharmacol Sci. 2008 Nov;29(11):550-7 [18805596.001]
  • [Cites] J Neurosci. 2009 Apr 1;29(13):4096-108 [19339605.001]
  • [CommentIn] Nat Rev Rheumatol. 2010 Jul;6(7):379 [20614500.001]
  • [CommentIn] Nat Rev Drug Discov. 2010 Jun;9(6):432 [20514067.001]
  • [CommentIn] Nat Med. 2010 May;16(5):518-20 [20448572.001]
  • [CommentIn] Expert Opin Investig Drugs. 2010 Nov;19(11):1461-4 [20942774.001]
  • (PMID = 20383154.001).
  • [ISSN] 1546-170X
  • [Journal-full-title] Nature medicine
  • [ISO-abbreviation] Nat. Med.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK074448; United States / NIDCR NIH HHS / DE / DE019938-01; United States / NINDS NIH HHS / NS / R01 NS054932-03; United States / NINDS NIH HHS / NS / R01 NS054932; United States / NINDS NIH HHS / NS / NS054932-03; United States / NINDS NIH HHS / NS / NS067686-01; United States / NINDS NIH HHS / NS / NS67686; United States / NIDCR NIH HHS / DE / R01-DE17794; United States / NIGMS NIH HHS / GM / R01 GM038765; United States / NINDS NIH HHS / NS / F30 NS054362; United States / NIDDK NIH HHS / DK / R01 DK074448-05; United States / NIDCR NIH HHS / DE / DE017794-04; United States / NIDCR NIH HHS / DE / R01 DE017794; United States / NIGMS NIH HHS / GM / GM038765-23; United States / NIDCR NIH HHS / DE / R01 DE019938-01; United States / NINDS NIH HHS / NS / R01 NS054932-04; United States / NIGMS NIH HHS / GM / R37 GM038765-23; United States / NINDS NIH HHS / NS / R01 NS067686; United States / NIDDK NIH HHS / DK / DK074448-05; United States / NIDCR NIH HHS / DE / R01 DE017794-04; United States / NIGMS NIH HHS / GM / R37 GM038765; United States / NIDCR NIH HHS / DE / R01-DE019938; United States / NINDS NIH HHS / NS / R01-NS54362; United States / NINDS NIH HHS / NS / R01 NS067686-01; United States / NIDCR NIH HHS / DE / R01 DE019938; United States / NIGMS NIH HHS / GM / R37 GM38765; United States / NIDDK NIH HHS / DK / R01-DK074448
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid; 0 / Analgesics; 0 / resolvin D1; 25167-62-8 / Docosahexaenoic Acids; AAN7QOV9EA / Eicosapentaenoic Acid
  • [Other-IDs] NLM/ NIHMS196352; NLM/ PMC2866054
  •  go-up   go-down


53. Tunc E, Erdogan D, Gozil R, Bahcelioglu M, Calguner E, Take G, Caglar G, Oktem H: Dose-dependent immunohistochemical changes in rat cornea and retina after oral methylphenidate administration. Anat Histol Embryol; 2009 Apr;38(2):128-32
Hazardous Substances Data Bank. METHYLPHENIDATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Methylphenidate hydrochloride (MPH), more commonly known as Ritalin, is a piperidine derivative and is the drug most often used to treat attention deficit/hyperactivity disorder, one of the most common behavioural disorders of children and young adults.
  • In our study, we observed that the cornea D2 receptor reactivity showed a dose-related increase after MPH treatment, especially in basal cells of the epithelium and a dose-dependent decrease in the retinal ganglion cell which was statistically meaningful.
  • Apoptotic cell number showed a meaningful increase in the high dose treated group compared to the other groups of the study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19007354.001).
  • [ISSN] 1439-0264
  • [Journal-full-title] Anatomia, histologia, embryologia
  • [ISO-abbreviation] Anat Histol Embryol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Central Nervous System Stimulants; 0 / Receptors, Dopamine; 207ZZ9QZ49 / Methylphenidate
  •  go-up   go-down


54. Aydin C, Aytan N, Mahon MJ, Tawfeek HA, Kowall NW, Dedeoglu A, Bastepe M: Extralarge XL(alpha)s (XXL(alpha)s), a variant of stimulatory G protein alpha-subunit (Gs(alpha)), is a distinct, membrane-anchored GNAS product that can mimic Gs(alpha). Endocrinology; 2009 Aug;150(8):3567-75
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • XXL(alpha)s-R844H, which bears a mutation analogous to that in the constitutively active Gs(alpha) mutant Gs(alpha)-R201H (gsp oncogene), displayed elevated basal signaling.
  • Our findings suggest that XXL(alpha)s deficiency or hyperactivity may contribute to the pathogenesis of diseases caused by GNAS mutations.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 2003 Aug;23(16):5475-88 [12897124.001]
  • [Cites] Am J Med Genet A. 2003 Apr 1;118A(1):71-5 [12605446.001]
  • [Cites] Annu Rev Med. 2004;55:27-39 [14746508.001]
  • [Cites] Hum Mol Genet. 2004 Apr 1;13(7):741-50 [14962976.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8366-71 [15148396.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jun;89(6):3007-9 [15181091.001]
  • [Cites] Nat Genet. 2004 Aug;36(8):818-26 [15273686.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Oct 12;101(41):14794-9 [15459318.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Apr;85(7):2081-5 [3127824.001]
  • [Cites] Nature. 1989 Aug 31;340(6236):692-6 [2549426.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Oct;86(20):7900-3 [2554294.001]
  • [Cites] N Engl J Med. 1991 Dec 12;325(24):1688-95 [1944469.001]
  • [Cites] Endocrinology. 1992 Jan;130(1):167-78 [1370150.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jun 1;89(11):5152-6 [1594625.001]
  • [Cites] J Cell Biol. 1992 Dec;119(5):1297-307 [1280272.001]
  • [Cites] Cell. 1994 Jul 1;77(7):1063-70 [7912657.001]
  • [Cites] Nature. 1994 Dec 22-29;372(6508):804-9 [7997272.001]
  • [Cites] Mol Biol Cell. 1996 Aug;7(8):1225-33 [8856666.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8715-20 [9671744.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):10038-43 [9707596.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15475-80 [9860993.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3830-5 [10097123.001]
  • [Cites] Endocrinology. 2004 Dec;145(12):5459-64 [15331575.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 17;102(20):7386-91 [15883378.001]
  • [Cites] Eur J Hum Genet. 2005 Sep;13(9):1033-9 [15915160.001]
  • [Cites] Science. 2005 Sep 2;309(5740):1559-63 [16141072.001]
  • [Cites] Endocrinology. 2005 Nov;146(11):4697-709 [16099856.001]
  • [Cites] Endocrinology. 2006 May;147(5):2253-62 [16484323.001]
  • [Cites] J Clin Endocrinol Metab. 2006 May;91(5):1842-7 [16507630.001]
  • [Cites] J Biol Chem. 2006 Jul 14;281(28):18989-99 [16672216.001]
  • [Cites] J Urol. 2006 Sep;176(3):891-5 [16890646.001]
  • [Cites] Bone. 2007 May;40(5):1425-8 [17321228.001]
  • [Cites] Cell. 2007 May 18;129(4):823-37 [17512414.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Jun;92(6):2370-3 [17405843.001]
  • [Cites] Hum Mol Genet. 2007 Aug 15;16(16):1921-30 [17566083.001]
  • [Cites] Brain Res. 2008 May 1;1207:225-36 [18374906.001]
  • [Cites] Am J Med Genet A. 2008 Jul 15;146A(14):1788-96 [18553568.001]
  • [Cites] J Biol Chem. 2000 Jan 14;275(2):1327-36 [10625681.001]
  • [Cites] J Clin Invest. 2000 Mar;105(5):615-23 [10712433.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3342-6 [10716699.001]
  • [Cites] Hum Mol Genet. 2000 Mar 22;9(5):835-41 [10749992.001]
  • [Cites] Nature. 2000 May 25;405(6785):482-5 [10839546.001]
  • [Cites] Nature. 2000 May 25;405(6785):486-9 [10839547.001]
  • [Cites] Mol Cell Biol. 2000 Aug;20(16):5808-17 [10913164.001]
  • [Cites] J Biol Chem. 2000 Oct 27;275(43):33622-32 [10931823.001]
  • [Cites] J Biol Chem. 2000 Oct 27;275(43):33633-40 [10931851.001]
  • [Cites] J Bone Miner Res. 2000 Nov;15(11):2074-83 [11092390.001]
  • [Cites] J Bone Miner Res. 2000 Nov;15(11):2084-94 [11092391.001]
  • [Cites] J Clin Invest. 2001 Mar;107(6):R31-6 [11254676.001]
  • [Cites] Hum Mol Genet. 2001 Jun 1;10(12):1231-41 [11406605.001]
  • [Cites] N Engl J Med. 2002 Jan 10;346(2):99-106 [11784876.001]
  • [Cites] Biotechniques. 2002 Jun;32(6):1372-4, 1376, 1378-9 [12074169.001]
  • [Cites] Mol Endocrinol. 2002 Jul;16(7):1638-51 [12089357.001]
  • [Cites] Mol Endocrinol. 2002 Aug;16(8):1912-9 [12145344.001]
  • [Cites] Genomics. 2002 Oct;80(4):373-5 [12376090.001]
  • [Cites] Clin Exp Dermatol. 2004 Jan;29(1):77-80 [14723729.001]
  • (PMID = 19423757.001).
  • [ISSN] 1945-7170
  • [Journal-full-title] Endocrinology
  • [ISO-abbreviation] Endocrinology
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK073911; United States / NIA NIH HHS / AG / P30 AG013846; United States / NIDDK NIH HHS / DK / DK073911-01A2; United States / NIDDK NIH HHS / DK / R01 DK073911-01A2; United States / NIA NIH HHS / AG / P30AG13846; United States / NIDDK NIH HHS / DK / R01DK073911
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 5' Untranslated Regions; 0 / DNA, Complementary; 0 / RNA, Messenger; E0399OZS9N / Cyclic AMP; EC 3.6.5.1 / GTP-Binding Protein alpha Subunits, Gs
  • [Other-IDs] NLM/ PMC2717877
  •  go-up   go-down


55. Wang XL, Zhang HM, Chen SR, Pan HL: Altered synaptic input and GABAB receptor function in spinal superficial dorsal horn neurons in rats with diabetic neuropathy. J Physiol; 2007 Mar 15;579(Pt 3):849-61
Hazardous Substances Data Bank. GLYCINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hyperactivity of spinal dorsal horn neurons plays an important role in the development of diabetic neuropathic pain.
  • To determine the changes in synaptic input to dorsal horn neurons and the GABAB)receptor function in streptozotocin-induced diabetes, we performed whole-cell recording (GDP-beta-S included in the internal solution) on lamina II neurons in rat spinal cord slices.
  • On the other hand, the basal frequency and amplitude of GABAergic spontaneous IPSCs and mIPSCs and those of glycinergic spontaneous IPSCs and mIPSCs did not differ significantly between control and diabetic rats.

  • MedlinePlus Health Information. consumer health - Diabetic Nerve Problems.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GLUTAMIC ACID HYDROCHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pain. 1994 May;57(2):153-60 [8090511.001]
  • [Cites] J Neurosci. 2005 Jul 13;25(28):6658-66 [16014727.001]
  • [Cites] J Pain Symptom Manage. 1994 Nov;9(8):500-9 [7852758.001]
  • [Cites] J Physiol. 1995 Jan 1;482 ( Pt 1):29-38 [7730987.001]
  • [Cites] Brain Res. 1995 May 15;679(2):289-97 [7633890.001]
  • [Cites] J Pharmacol Exp Ther. 1995 Oct;275(1):219-27 [7562553.001]
  • [Cites] Pain. 1996 Nov;68(1):85-96 [9252003.001]
  • [Cites] Br J Pharmacol. 1997 Dec;122(7):1478-82 [9421298.001]
  • [Cites] Diabet Med. 1998 Jun;15(6):508-14 [9632127.001]
  • [Cites] Pain. 1998 May;76(1-2):151-7 [9696468.001]
  • [Cites] Pain. 2000 Apr;85(3):385-93 [10781911.001]
  • [Cites] Pain. 2000 Jun;86(3):273-82 [10812257.001]
  • [Cites] Eur J Neurosci. 2000 Sep;12(9):3201-10 [10998104.001]
  • [Cites] Neuroreport. 2000 Dec 18;11(18):4055-61 [11192628.001]
  • [Cites] Neuroscience. 2001;102(1):185-92 [11226682.001]
  • [Cites] J Neurophysiol. 2002 Apr;87(4):1938-47 [11929913.001]
  • [Cites] J Physiol. 2006 Mar 1;571(Pt 2):403-13 [16410279.001]
  • [Cites] Neuroscience. 2006;138(4):1277-87 [16427742.001]
  • [Cites] Neuron. 2006 May 18;50(4):589-601 [16701209.001]
  • [Cites] Mol Pharmacol. 2006 Oct;70(4):1246-54 [16868181.001]
  • [Cites] J Neurophysiol. 2002 Jun;87(6):2726-33 [12037174.001]
  • [Cites] J Neurosci. 2002 Aug 1;22(15):6724-31 [12151551.001]
  • [Cites] Neuroscience. 2002;114(2):291-9 [12204199.001]
  • [Cites] J Physiol. 2002 Sep 15;543(Pt 3):807-18 [12231640.001]
  • [Cites] Anesthesiology. 2002 Dec;97(6):1602-8 [12459691.001]
  • [Cites] Brain Res. 2003 Mar 7;965(1-2):67-74 [12591121.001]
  • [Cites] J Pharmacol Exp Ther. 2003 Nov;307(2):676-81 [12966147.001]
  • [Cites] Anesthesiology. 2003 Dec;99(6):1409-14 [14639157.001]
  • [Cites] Eur J Neurosci. 2004 Feb;19(4):871-83 [15009134.001]
  • [Cites] J Neurophysiol. 2004 Jun;91(6):2413-21 [14749303.001]
  • [Cites] Reg Anesth Pain Med. 2004 May-Jun;29(3):269-76 [15138913.001]
  • [Cites] J Neurosci. 2004 Jul 7;24(27):6086-97 [15240800.001]
  • [Cites] Brain. 1980 Dec;103(4):717-72 [7437888.001]
  • [Cites] Nature. 1984 Jan 5-11;307(5946):71-4 [6318120.001]
  • [Cites] Ann Neurol. 1984 Jan;15(1):2-12 [6370098.001]
  • [Cites] Diabetes. 1985 Nov;34(11):1210-3 [4043559.001]
  • [Cites] Synapse. 1987;1(6):530-8 [2843995.001]
  • [Cites] J Neurophysiol. 1989 Jul;62(1):96-108 [2754484.001]
  • [Cites] Neuroscience. 1990;34(2):341-57 [2159128.001]
  • [Cites] Neuroscience. 1990;39(2):361-85 [1965016.001]
  • [Cites] Neuroscience. 1993 Mar;53(2):519-26 [8098516.001]
  • [Cites] J Pharmacol Exp Ther. 1993 Sep;266(3):1490-6 [7690402.001]
  • [Cites] J Pharmacol Exp Ther. 2005 May;313(2):697-704 [15640398.001]
  • [Cites] Brain Res Mol Brain Res. 2005 May 20;136(1-2):275-81 [15893611.001]
  • [Cites] Neuropharmacology. 1994 Sep;33(9):1103-8 [7838323.001]
  • (PMID = 17218355.001).
  • [ISSN] 0022-3751
  • [Journal-full-title] The Journal of physiology
  • [ISO-abbreviation] J. Physiol. (Lond.)
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM064830; United States / NINDS NIH HHS / NS / R01 NS045602; United States / NIGMS NIH HHS / GM / GM64830; United States / NINDS NIH HHS / NS / NS45602
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / GABA Agonists; 0 / GABA Antagonists; 0 / Receptors, GABA-B; 3KX376GY7L / Glutamic Acid; H789N3FKE8 / Baclofen; TE7660XO1C / Glycine; Y37615DVKC / Bicuculline
  • [Other-IDs] NLM/ PMC2151355
  •  go-up   go-down


56. Joho RH, Street C, Matsushita S, Knöpfel T: Behavioral motor dysfunction in Kv3-type potassium channel-deficient mice. Genes Brain Behav; 2006 Aug;5(6):472-82
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The voltage-gated potassium channels Kv3.1 and Kv3.3 are expressed in several distinct neuronal subpopulations in brain areas known to be involved in motor control such as cortex, basal ganglia and cerebellum.
  • Depending on the lack of Kv3.1 or Kv3.3 channel subunits, mutant mice show different Kv3-null allele-dependent behavioral alterations that include constitutive hyperactivity, sleep loss, impaired motor performance and, in the case of the Kv3.1/Kv3.3 double mutant, also severe ataxia, tremor and myoclonus (Espinosa et al. 2001, J Neurosci 21, 6657-6665, Genes, Brain Behav 3, 90-100).
  • The lack of Kv3.1 channel subunits is mainly responsible for the constitutively increased locomotor activity and for sleep loss, whereas the absence of Kv3.3 subunits affects cerebellar function, in particular Purkinje cell discharges and olivocerebellar system properties (McMahon et al. 2004, Eur J Neurosci 19, 3317-3327).


57. Brandt C, Gastens AM, Sun Mz, Hausknecht M, Löscher W: Treatment with valproate after status epilepticus: effect on neuronal damage, epileptogenesis, and behavioral alterations in rats. Neuropharmacology; 2006 Sep;51(4):789-804
Hazardous Substances Data Bank. VALPROIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A self-sustaining SE was induced by prolonged electrical stimulation of the basal amygdala via a depth electrode.
  • However, treatment with VPA after SE prevented the hyperexcitability and locomotor hyperactivity observed in vehicle-treated epileptic rats.
  • [MeSH-minor] Animals. Body Weight / drug effects. Cell Death / drug effects. Disease Models, Animal. Dose-Response Relationship, Drug. Electric Stimulation / adverse effects. Electroencephalography / methods. Female. Functional Laterality. Hippocampus / drug effects. Hippocampus / pathology. Hyperkinesis / drug therapy. Hyperkinesis / etiology. Maze Learning / drug effects. Motor Activity / drug effects. Rats. Rats, Sprague-Dawley. Rotarod Performance Test / methods. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16806297.001).
  • [ISSN] 0028-3908
  • [Journal-full-title] Neuropharmacology
  • [ISO-abbreviation] Neuropharmacology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticonvulsants; 614OI1Z5WI / Valproic Acid
  •  go-up   go-down


58. Marcellino D, Carriba P, Filip M, Borgkvist A, Frankowska M, Bellido I, Tanganelli S, Müller CE, Fisone G, Lluis C, Agnati LF, Franco R, Fuxe K: Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 heteromers. A combined neurochemical and behavioral analysis. Neuropharmacology; 2008 Apr;54(5):815-23
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Antagonistic CB(1)/D(2) interactions were also discovered at the behavioral level through an analysis of quinpirole-induced locomotor hyperactivity in rats.
  • The CB(1) receptor agonist CP 55,940 at a dose that did not change basal locomotion was able to block quinpirole-induced increases in locomotor activity.
  • [MeSH-minor] Animals. Behavior, Animal. Cell Line, Transformed. Cyclohexanols / pharmacology. Dopamine / pharmacology. Dopamine Agonists. Drug Interactions. Fluorescence Resonance Energy Transfer / methods. Guanylyl Imidodiphosphate / pharmacology. Humans. Luminescent Proteins / metabolism. Male. Protein Binding / drug effects. Quinpirole / pharmacology. Radiography. Rats. Rats, Sprague-Dawley. Rats, Wistar. Receptors, Cannabinoid / metabolism. Transfection / methods

  • Hazardous Substances Data Bank. DOPAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18262573.001).
  • [ISSN] 0028-3908
  • [Journal-full-title] Neuropharmacology
  • [ISO-abbreviation] Neuropharmacology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cyclohexanols; 0 / Dopamine Agonists; 0 / Dopamine D2 Receptor Antagonists; 0 / Luminescent Proteins; 0 / Receptor, Cannabinoid, CB1; 0 / Receptors, Cannabinoid; 0 / Receptors, Dopamine D2; 20OP60125T / Quinpirole; 34273-04-6 / Guanylyl Imidodiphosphate; 83003-12-7 / 3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol; VTD58H1Z2X / Dopamine
  •  go-up   go-down


59. Matthies HJ, Moore JL, Saunders C, Matthies DS, Lapierre LA, Goldenring JR, Blakely RD, Galli A: Rab11 supports amphetamine-stimulated norepinephrine transporter trafficking. J Neurosci; 2010 Jun 9;30(23):7863-77
Hazardous Substances Data Bank. AMPHETAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • NET is also a major target for medications used for the treatment of depression, attention deficit/hyperactivity disorder, narcolepsy, and obesity.
  • In this study, we used a recently developed NET antibody and the presence of large presynaptic boutons in sympathetic neurons to examine basal and AMPH-modulated NET trafficking.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2009 Nov 20;284(47):32869-80 [19797056.001]
  • [Cites] J Cell Biol. 1996 Nov;135(4):913-24 [8922376.001]
  • [Cites] Mol Cell Biol. 1996 Dec;16(12):6879-86 [8943343.001]
  • [Cites] Annu Rev Cell Dev Biol. 1996;12:575-625 [8970738.001]
  • [Cites] J Neurosci. 1997 Feb 15;17(4):1217-25 [9006967.001]
  • [Cites] Physiol Rev. 1997 Jul;77(3):759-803 [9234965.001]
  • [Cites] Curr Opin Cell Biol. 1997 Aug;9(4):496-504 [9261061.001]
  • [Cites] J Neurosci. 1997 Nov 1;17(21):8451-8 [9334417.001]
  • [Cites] Anal Biochem. 1998 May 1;258(2):251-8 [9570838.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 May 26;95(11):6187-92 [9600939.001]
  • [Cites] J Pharmacol Exp Ther. 1998 Nov;287(2):733-43 [9808704.001]
  • [Cites] Mol Cell Biol. 2000 Jan;20(1):416-27 [10594043.001]
  • [Cites] Mol Cell Neurosci. 2003 Dec;24(4):1131-50 [14697674.001]
  • [Cites] J Biol Chem. 2004 Mar 19;279(12):11480-8 [14699104.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 16;101(11):3833-8 [15007177.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Feb;5(2):121-32 [15040445.001]
  • [Cites] J Neurosci. 2004 Apr 21;24(16):4070-81 [15102922.001]
  • [Cites] Mol Biol Cell. 2004 May;15(5):2456-69 [15004234.001]
  • [Cites] J Cell Sci. 2004 Sep 1;117(Pt 19):4365-75 [15304524.001]
  • [Cites] Circulation. 2004 Sep 7;110(10):1191-6 [15337696.001]
  • [Cites] J Biol Chem. 2004 Oct 8;279(41):43027-34 [15292201.001]
  • [Cites] Mol Biol Cell. 2004 Nov;15(11):4990-5000 [15331762.001]
  • [Cites] Br J Pharmacol. 1971 Apr;41(4):571-91 [4397129.001]
  • [Cites] N Engl J Med. 1990 Oct 18;323(16):1147-8 [2215590.001]
  • [Cites] Nature. 1991 Mar 28;350(6316):350-4 [2008212.001]
  • [Cites] J Cell Biol. 1991 Oct;115(1):151-64 [1918133.001]
  • [Cites] Cell. 1992 Sep 4;70(5):729-40 [1516131.001]
  • [Cites] J Biol Chem. 1993 Sep 5;268(25):18419-22 [8360141.001]
  • [Cites] Anal Biochem. 1994 Aug 1;220(2):360-6 [7978279.001]
  • [Cites] Anal Biochem. 1994 Aug 1;220(2):367-73 [7978280.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Dec 20;91(26):12750-4 [7809115.001]
  • [Cites] Cell. 1996 Jan 12;84(1):13-21 [8548817.001]
  • [Cites] Neuroreport. 1996 May 17;7(7):1297-300 [8817553.001]
  • [Cites] J Pharmacol Exp Ther. 1998 Nov;287(2):744-51 [9808705.001]
  • [Cites] Brain Res. 1998 Nov 2;809(2):155-64 [9853106.001]
  • [Cites] J Neurochem. 1999 Mar;72(3):1110-6 [10037482.001]
  • [Cites] J Cell Biol. 1999 Apr 5;145(1):123-39 [10189373.001]
  • [Cites] Nat Genet. 1999 Jul;22(3):239-47 [10391210.001]
  • [Cites] J Neurochem. 1999 Sep;73(3):1024-32 [10461891.001]
  • [Cites] Traffic. 2005 Feb;6(2):131-43 [15634213.001]
  • [Cites] J Biol Chem. 2005 Feb 18;280(7):5972-82 [15572359.001]
  • [Cites] Neurosci Lett. 2005 Jul 1-8;382(1-2):51-5 [15911120.001]
  • [Cites] Mol Pharmacol. 2005 Jul;68(1):102-9 [15795321.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Aug 5;333(3):671-8 [15963952.001]
  • [Cites] Mol Pharmacol. 2005 Aug;68(2):457-66 [15894713.001]
  • [Cites] Nat Struct Mol Biol. 2005 Oct;12(10):879-85 [16155582.001]
  • [Cites] Dev Cell. 2005 Sep;9(3):351-63 [16137928.001]
  • [Cites] Dev Cell. 2005 Sep;9(3):365-76 [16224820.001]
  • [Cites] Nat Genet. 2005 Nov;37(11):1270-3 [16227995.001]
  • [Cites] Traffic. 2005 Dec;6(12):1070-7 [16262719.001]
  • [Cites] J Neurosci. 2006 Feb 1;26(5):1571-8 [16452680.001]
  • [Cites] Curr Opin Cardiol. 2006 May;21(3):173-9 [16601453.001]
  • [Cites] J Neurochem. 2006 Apr;97(2):310-33 [16539676.001]
  • [Cites] Handb Exp Pharmacol. 2006;(175):485-524 [16722247.001]
  • [Cites] J Psychopharmacol. 2006 Jul;20(4 Suppl):60-6 [16785272.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 8;103(32):11821-7 [16882731.001]
  • [Cites] Curr Biol. 1999 Dec 2;9(23):1411-4 [10607569.001]
  • [Cites] J Cell Sci. 2000 Jan;113 Pt 2:183-92 [10633070.001]
  • [Cites] N Engl J Med. 2000 Feb 24;342(8):541-9 [10684912.001]
  • [Cites] J Comp Neurol. 2000 May 1;420(2):211-32 [10753308.001]
  • [Cites] Nat Neurosci. 2000 May;3(5):465-71 [10769386.001]
  • [Cites] J Cell Biol. 2000 May 15;149(4):901-14 [10811830.001]
  • [Cites] J Biol Chem. 2000 Sep 15;275(37):29138-46 [10869360.001]
  • [Cites] J Neurosci. 2000 Oct 15;20(20):7571-8 [11027216.001]
  • [Cites] Hypertension. 2000 Nov;36(5):824-9 [11082150.001]
  • [Cites] J Neurosci. 2000 Dec 15;20(24):9040-5 [11124980.001]
  • [Cites] Mol Cell. 2000 Dec;6(6):1437-48 [11163216.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Feb;2(2):107-17 [11252952.001]
  • [Cites] Mol Biol Cell. 2001 Apr;12(4):981-95 [11294901.001]
  • [Cites] EMBO J. 2001 May 1;20(9):2202-13 [11331586.001]
  • [Cites] Neuron. 2001 Apr;30(1):121-34 [11343649.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 May 8;98(10):5619-24 [11331757.001]
  • [Cites] Mol Biol Cell. 2001 Jun;12(6):1843-57 [11408590.001]
  • [Cites] J Biol Chem. 2001 Oct 19;276(42):39067-75 [11495908.001]
  • [Cites] Mol Biol Cell. 2002 Jan;13(1):169-82 [11809831.001]
  • [Cites] J Pharmacol Exp Ther. 2002 Apr;301(1):152-9 [11907169.001]
  • [Cites] Brain Res Bull. 2002 Jul;58(3):279-84 [12128153.001]
  • [Cites] J Biol Chem. 2002 Jul 26;277(30):27193-9 [11994279.001]
  • [Cites] Pharmacogenomics J. 2002;2(4):217-35 [12196911.001]
  • [Cites] J Biol Chem. 2002 Dec 13;277(50):48876-83 [12372835.001]
  • [Cites] J Biol Chem. 2002 Dec 27;277(52):50415-21 [12393859.001]
  • [Cites] J Neurosci. 2003 Mar 1;23(5):1697-709 [12629174.001]
  • [Cites] J Neurosci. 2003 Jun 1;23(11):4470-8 [12805287.001]
  • [Cites] J Comp Neurol. 2003 Nov 24;466(4):478-94 [14566944.001]
  • [Cites] Exp Cell Res. 2003 Nov 1;290(2):322-31 [14567990.001]
  • [Cites] J Neurosci. 2003 Nov 19;23(33):10531-9 [14627637.001]
  • [Cites] J Biol Chem. 2003 Dec 26;278(52):52747-54 [14527960.001]
  • [Cites] FEBS Lett. 2006 Oct 2;580(22):5241-6 [16962593.001]
  • [Cites] J Cell Biol. 2006 Nov 20;175(4):571-8 [17116749.001]
  • [Cites] Eur J Neurosci. 2006 Dec;24(11):3141-52 [17156375.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 12;103(50):19164-9 [17146058.001]
  • [Cites] Mol Pharmacol. 2007 Jan;71(1):230-9 [17032905.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Nov 9;363(1):119-25 [17854769.001]
  • [Cites] Mol Biol Cell. 2007 Oct;18(10):3978-92 [17686995.001]
  • [Cites] J Cell Sci. 2007 Dec 1;120(Pt 23):4197-208 [18003705.001]
  • [Cites] Curr Protoc Cell Biol. 2001 May;Chapter 3:Unit 3.9 [18228361.001]
  • [Cites] Neuropharmacology. 2008 Mar;54(3):605-12 [18164041.001]
  • [Cites] J Biol Chem. 2008 Apr 4;283(14):9388-98 [18227069.001]
  • [Cites] Genes Brain Behav. 2008 Jun;7(4):487-95 [18081710.001]
  • [Cites] Mol Cell Proteomics. 2008 Jul;7(7):1331-48 [18388127.001]
  • [Cites] Neurol Sci. 2008 Sep;29 Suppl 2:S269-70 [18690515.001]
  • [Cites] J Physiol. 2008 Oct 15;586(Pt 20):4793-813 [18755741.001]
  • [Cites] J Cell Sci. 2008 Nov 15;121(Pt 22):3824-33 [18957512.001]
  • [Cites] Cell Signal. 2009 Jan;21(1):1-6 [18647649.001]
  • [Cites] J Biol Chem. 2009 Jan 30;284(5):2844-53 [19029296.001]
  • [Cites] Mol Biol Cell. 2009 Apr;20(8):2337-50 [19244346.001]
  • [Cites] BMC Neurosci. 2009;10:65 [19545450.001]
  • [Cites] Am J Med Genet B Neuropsychiatr Genet. 2009 Oct 5;150B(7):1013-6 [19105200.001]
  • (PMID = 20534835.001).
  • [ISSN] 1529-2401
  • [Journal-full-title] The Journal of neuroscience : the official journal of the Society for Neuroscience
  • [ISO-abbreviation] J. Neurosci.
  • [Language] ENG
  • [Grant] United States / NIDA NIH HHS / DA / R01 DA013975-04; United States / NIDA NIH HHS / DA / DA13975; United States / NIDA NIH HHS / DA / R01 DA013975; United States / NIDA NIH HHS / DA / DA013975-04; United States / NIMH NIH HHS / MH / MH05892; United States / NIDA NIH HHS / DA / R56 DA013975
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenergic Agents; 0 / Carrier Proteins; 0 / Membrane Proteins; 0 / Norepinephrine Plasma Membrane Transport Proteins; 0 / Rab11-FIP2 protein, rat; CK833KGX7E / Amphetamine; EC 3.6.1.- / rab GTP-Binding Proteins; EC 3.6.1.- / rab11 protein; EC 3.6.5.2 / rab4 GTP-Binding Proteins
  • [Other-IDs] NLM/ NIHMS212070; NLM/ PMC2935280
  •  go-up   go-down






Advertisement